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ABSTRACT 
 
 
 Mechanical damage to bulk polymers typically begins as a microcrack, which 
can lead to eventual failure of the material if there is no method to 
inhibit crack growth.  In living systems, this damage automatically initiates a healing response.  
Following the example of nature, self-healing polymers are engineered with the unique ability to 
extend the lifetime of materials by preventing damage propagation using various chemical 
mechanisms that are triggered by crack formation. The initial chemistry for self-healing 
materials employed a room temperature ring-opening metathesis polymerization (ROMP) using 
encapsulated dicyclopentadiene (DCPD) and wax-protected Grubbs’ catalyst. However the 
limitations of this system, including catalyst availability, cost, environmental toxicity, stability, 
and materials processing, have motivated the search for a simpler approach to self-healing.   
 Many chemical reactions require the use of a solvent. When an organic solvent is 
introduced into polymer systems, the mobility of polymer chains increases as the localized glass 
transition temperature is depressed. Solvent-based self-healing involves wetting of the polymer 
surface and resultant swelling of the bulk material, leading to interlocking of the polymer chains 
across a damaged crack plane to recover virgin mechanical properties. To achieve this healing in 
an autonomic fashion, liquid-filled microcapsules were prepared with various core components 
and embedded within a bulk polymer during processing. By compartmentalizing reactive fluids 
containing a solvent into a bulk material, in situ reactions occur upon damage in the form of a 
crack. A crack propagating through the polymeric material ruptures the embedded 
microcapsules, thus releasing solvent-based mixtures into the crack plane.  
 The encapsulation of various solvents has been developed for use in self-healing 
polymers. Solvent-filled microcapsules were incorporated into thermoset matrices and 
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thermoplastic materials such as poly(methyl methacrylate), and the healing performance is 
discussed in great detail. A self-healing bone cement/dental resin system based on free-radical 
polymerization reactions has also been studied. The development of solvent-based microcapsules 
led to the encapsulation of conductive materials for the repair of mechanically damaged 
electronic devices. Finally, additional research was carried out to examine the use of solid and 
protected amines for high temperature self-healing systems. 
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CHAPTER 1 
 
INTRODUCTION 
†
 
 
 
1.1 Motivation 
 
The natural fate of engineered polymeric materials is a slow and steady degradation in 
performance throughout their service life.
1
 Degradation is often a complex mechanism involving 
many environmental factors that accelerates with time. These and other forms of damage (e.g., 
microcracking) reduce the mechanical properties of the polymeric materials, thus demanding 
frequent external repair and inspection over their lifetime. For a new class of self-healing 
materials, this unrelenting march towards eventual material failure is no longer a certainty. Self-
healing polymers possess the ability to be repaired and recover functional performance by using 
the resources inherently available to them.
2,3
 A more restrictive class of self-healing achieves 
functional recovery in an autonomic fashion, i.e. automatically and without human intervention. 
An alternative approach or school of thought in the field is to use some form of external 
activation (e.g., heat) to trigger this repair mechanism.  
Macroscopic response to damage in terms of self-healing must fill the voids created by 
the damage and rebond affected interfaces.
4
 This requires mechanisms triggered by mechanical 
processes to locally release healing agents that can be transported and polymerized at the site of 
damage. Although it seems counterintuitive to add liquid components to structural solid 
materials, it has been shown that liquid-filled compartments actually improve the mechanical 
properties of the matrix.
5
 This phenomenon of incorporating liquid-filled components into solid 
polymers which release upon damage marks a paradigm shift in designing polymeric materials. 
                                                 
†
 Some of the content presented in this chapter was published in White, S. R.; Caruso, M. M.; Moore, J. S. MRS 
Bull. 2008, 33, 766-769, Copyright 2008, Materials Research Society; and Caruso, M. M. et al. Chem. Rev. 2009, 
109, 5755-5798, Copyright 2009, American Chemical Society. 
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The transport of liquids to the site of damage spurs this nature-inspired process of self-healing 
studied by our laboratory.
3
 This chapter will provide an overview of self-healing materials, 
including various microcapsule-based systems and alternative chemistries for self-healing. 
1.2 Self-Healing Materials 
 
1.2.1 Concept of Autonomic Self-Healing 
 
The general concept of autonomic self-healing is depicted in Figure 1.1a. When damage 
occurs in the material, a crack forms and eventually propagates until it ruptures a microcapsule 
that contains a healing agent. The healing agent is then transported to the crack plane by 
capillary action and undergoes polymerization, rebonding the crack faces. The entire process is 
triggered by damage, and recovery occurs under ambient conditions requiring no external source 
of energy (such as heat). Many different types of materials systems have been developed, but all 
are predicated on the same underlying concepts of healing through compartmentalization of 
reactive phases. 
This motif of dispersing a microencapsulated healing agent has since been applied to 
multiple polymeric systems and proven to be a generic platform for achieving autonomic healing 
functionality. Three types of systems have been demonstrated (Figure 1.1b), all of which are 
triggered when damage occurs in the material and the stress singularity at the crack tip drives the 
crack forward until it ruptures a microcapsule. In the original autonomic self-healing system 
developed by White et al., the healing agent (monomer) was microencapsulated, and a solid 
catalyst was dispersed throughout the polymer matrix (Figure 1.1b, left).
2
 Alternatively, both 
phases can be encapsulated and dispersed (Figure 1.1b, center),
6
 or the healing agent can be 
phase-separated in the matrix (Figure 1.1b, right).
7
 The desired healing chemistry and polymer 
matrix in which the healing will occur dictate the specific type of system used. For example, if 
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chemical reactions are possible between the polymer matrix and either phase of the healing 
chemistry, the dual-capsule approach ensures that healing reactions occur only after the material 
incurs damage. 
Assessment of healing in structural materials is based on mechanical performance 
recovery (Figure 1.1c). The initial (virgin) and healed responses of a material are measured 
following experimental protocols that are specific to the performance metric of interest. For 
example, the tapered-double-cantilever beam (TDCB) sample geometry provides a crack-length-
independent measure of mode I fracture toughness (KIC) and the ratio of healed to virgin 
toughness is a common measure of healing efficiency (η).8 Other definitions of healing 
efficiency can be used that are related to various specific performance metrics (e.g., stiffness, 
ultimate strength). 
1.2.2 Brief History of Self-Healing Polymers 
Early work in this field defined ―healing‖ as the recovery of a material’s original 
mechanical properties after it incurs damage. Wool and coworkers discovered that thermoplastic 
materials could be healed after crack damage when fractured surfaces were rejoined to allow the 
polymer chains to re-entangle.
9
 However, most of the preliminary studies on crack healing 
involved the use of an external stimulus such as heat or solvents to promote chain entanglement 
across the damaged interface.
10
 Dry et al. proposed a structural thermoset material that contained 
liquid healing components within hollow millimeter-scale capillary tubes.
11
 These hollow tubes 
were filled with liquid monomers that were released upon mechanical damage to the composite 
in order to heal the cracks. A variety of chemically distinct liquid healing agents (two-part 
epoxy, polyesters, vinyl monomers) and fibers were explored with limited success.
10
 Hollow 
micron-scale fibers were later incorporated into polymer composites as reinforcing agents and as 
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carriers by which epoxy resin and hardener could be supplied to a damage site.
12
 Upon mixing of 
these two components, a thermoset network was formed and self-healing ability was 
demonstrated.
13-16
 The elegant approach of flowing a fluorescent dye through the fibers allowed 
for visual detection of crack damage in these composites.
13,14
 
 In 2001, it was discovered that the ring-opening metathesis polymerization (ROMP) of 
the olefin-based monomer dicyclopentadiene (DCPD) could be used as an effective chemical 
reaction to repair crack damage in an epoxy matrix using Grubbs’ first generation catalyst 
(Figure 1.2a).
2
 In the original paper on autonomic self-healing composites,
2
 the components of 
this reaction — Grubbs’ catalyst and polymer microcapsules containing the liquid DCPD as the 
core material — were both incorporated into an epoxy matrix. The microcapsules ruptured in 
response to mechanical damage in the form of a propagating crack through the epoxy composite 
(Figure 1.2c). Upon rupture, the liquid contents of the microcapsules wicked into the crack plane 
of the epoxy matrix through capillary action. When the DCPD and the embedded catalyst came 
into contact, the ROMP reaction occurred, resulting in polymer formation in the crack plane 
(Figure 1.2b). The fracture toughness of the epoxy composite was restored to up to 75–90% of 
the initial value.
2,8,17,18
 Significant fracture toughness was recovered within an hour at room 
temperature, but up to 12 h were required for complete restoration.
18,19
 Low temperature healing 
has been investigated with exo DCPD which remains liquid down to -78 °C and showed 
significantly faster polymerization kinetics compared to endo DCPD.
20
 Recently, self-healing 
and self-sealing of fiber-reinforced composites containing the components of the DCPD/Grubbs’ 
system have been reported by our laboratory.
21,22
 
The healing efficiency in this microcapsule-based self-healing system was dependent on 
several factors including: (1) monomer stability in the absence of catalyst (2) polymerization 
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kinetics, (3) adhesion of the new polymer to the surrounding matrix, and (4) chemical 
compatibility of the catalyst with the matrix. DCPD was selected as an appropriate monomer for 
the ROMP-based system because unlike vinyl monomers, it has good stability in the absence of a 
metathesis catalyst. The poly(DCPD) formed in the crack plane is a hydrocarbon (Figure 1.2a) 
and incompatible with the epoxy matrix, thus limiting the adhesion through intermolecular 
interactions with the polar epoxy matrix system. In order to improve the adhesion of the newly 
formed polymer to the epoxy matrix, more polar healing agents and matrices have been 
considered.
23
 The optimal catalyst is one that remains fully active when embedded in an epoxy 
matrix, but rapidly dissolves and reacts upon contact with released monomer from 
microcapsules. One approach is the protection of the catalyst in wax microspheres, which has 
been found to enhance its stability with the matrix.
6
 The following sections summarize the 
behavior of microcapsules containing liquid healing agents and secondary phases that are 
contained in a self-healing polymeric system. 
1.3 Microcapsule-Based Systems 
Polymeric, liquid-filled microcapsules are used in autonomic self-healing materials to 
compartmentalize the healing agents from the surrounding polymer matrix. Capsules are 
commonly prepared by an emulsification process whereby monomers polymerize to form a shell 
wall around suspended liquid droplets.
24
 Various techniques have been used to prepare 
microcapsules and microspheres; different types are shown in Figure 1.3 and more details on the 
types of capsules used in this work are provided in Chapter 3 of this dissertation.
25
 These 
microcapsules are incorporated into a polymer matrix, as shown in Figure 1.2c. The crack 
ruptures the embedded microcapsules, and the fluid is dispersed through capillary action, 
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covering the crack interface. The crack’s trajectory is attracted to the microcapsules due to the 
difference in compliance between the matrix and microcapsules.
2
 
 In situ encapsulation techniques produce a robust, dense, and brittle shell wall, which is 
often ideal for compartmentalizing a hydrophobic core material which will fracture in a polymer 
matrix (Figure 1.3a).
25,26
 The reaction of urea and formaldehyde (shown in Scheme 1.1) was 
used to form the polymeric shell wall of DCPD-filled microcapsules.
26
 The mechanical 
properties of the microcapsules ex situ were analyzed in terms of modulus and failure behavior 
by single capsule compression testing.
27
 For capsules to rupture in a reliable fashion, they must 
have an effective embedded modulus lower than that of the surrounding polymer matrix; which 
as previously mentioned, is important for guiding cracks trajectory to microcapsules.
2 
Overall 
however, microcapsules provide additional benefits as particulate fillers, such as improving the 
fracture toughness of a polymeric material.
5 
Conventional microencapsulation procedures have been modified to design more 
complex architectures with enhanced release capabilities. Microcapsules containing the 
monomer DCPD for use in self-healing materials were synthesized with urea-formaldehyde (UF) 
shell walls on the micro
26
 and nanoscale
28 
for use in self-healing materials. The UF capsule 
diameter size was controlled by the agitation rate of the emulsion, and nanocapsules were 
produced with the use of sonication and droplet stabilization techniques.
28 
By using smaller 
capsules containing dibutylphthalate (secondary liquid) as Pickering stabilizers, binary 
microcapsules were prepared in which the main core material was DCPD.
29
 This development 
allows for two liquids to be delivered from a single capsule architecture.   
An extensive study was conducted to determine how microcapsules of various sizes 
affected the self-healing performance of the materials.
30
 This work demonstrated that recovery of 
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fracture toughness could be optimized by varying the amount of healing agent released, the size 
of the damage, and volume fraction of microcapsules in the epoxy. The amount of healing agent 
released from the microcapsules scales with capsule diameter and with the percent loading of the 
microcapsules (wt%) in the epoxy matrix. The total mass of fluid healing agent delivered to the 
crack plane (MHealing Agent in mg·cm
-2
) is given by 
     MHealing Agent =  ρs φ Dc    (1) 
where ρs is the density of the matrix, φ is the mass fraction of microcapsules, and Dc is the mean 
diameter of the microcapsules.
30,31
 In an effort to reduce the total crack volume in a self-healing 
specimen, shape memory alloy wires were embedded into the epoxy matrix and activated to 
apply crack closure forces. This ROMP-based system gave higher healing efficiencies than the 
original system.
32
 
1.4 Fatigue Responses 
 
In the previous sections, the self-repairing polymer systems refer to monotonic fracture as 
the mechanical stimulus. However, fatigue response is perhaps more critical for extending the 
lifetime of structural materials. Fatigue-resistant materials are needed in a variety of structural 
applications, such as bio-implants, where it is neither safe nor practical to replace the implant 
after damage from repeated, cyclic loading. In structural applications, crack damage to 
unmodified epoxy thermosets is a major drawback, limiting widespread use in advanced 
composites.
33
 Their inherently brittle behavior has been improved with the addition of fillers 
such as inorganic particles
34,35
 and thermoplastics.
36
 In contrast to these physical approaches, the 
fracture toughness
5
 and fatigue life
37
 of the epoxy matrix has been improved using a   
chemically-based DCPD-filled microcapsule system.    
8 
 
Both the mechanical and chemical environments of a self-repairing system must be 
considered when analyzing the fatigue lifetime of a mechanically-responsive self-healing 
material (Figure 1.4). The relative rates of mechanical damage and healing compete to determine 
the fatigue lifetime. For example, the loading frequency (ω) and stress intensity interval (ΔKI) 
determine the rate at which damage occurs according to the Paris power law.
38
 When damage 
leads to crack growth in a self-healing system, the chemical response is activated by 
microcapsule rupture and release. The response or rate of repair is then determined by the 
chemical environment. For example, the rate at which healing occurs depends on the transport of 
monomer into the epoxy crack plane, dissolution of catalyst particles, and the rate of 
polymerization. Catalyst dissolution depends on solid-state phase and catalyst particle size and 
shape.
39,40
 The competition between the rate of damage and rate of repair ultimately defines the 
stability of a dynamically loaded materials system.
3 
 Using the TDCB geometry for fracture testing,
8
  Brown et al. studied the fatigue response 
of microcapsule-toughening epoxy by monitoring crack growth.
37,41
 The fatigue testing protocol 
was initially examined at various stress intensity loading conditions.
41
 Crack arrest was observed 
for self-healing samples containing DCPD microcapsules and embedded Grubbs’ catalyst 
provided that the rate of healing agent transport and corresponding DCPD polymerization was 
faster than the rate at which crack damage was imparted to the specimen. Conversely, when the 
rate of damage was greater than the rate of healing, the crack propagated quickly through the 
epoxy. Under these conditions, crack arrest was possible only when rest periods of 10 h were 
built into the fatigue cycle to allow for the DCPD polymerization to occur.
41
 Catalyst availability 
plays a critical role in the healing rate. For example, the fatigue behavior under higher stress 
intensities was explored in systems whereby Grubbs’ catalyst was present in different 
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morphologies and forms (recrystallized, freeze-dried, or protected in wax spheres).
39
 When wax 
microspheres containing the catalyst were embedded in the matrix, the healing kinetics improved 
from the system using embedded catalyst particles in the matrix,
41
 and the fatigue life 
dramatically increased. Kamphaus and coworkers also demonstrated crack arrest in an alternative 
catalyst/monomer system, using tungsten hexachloride and ethylidene norbornene/DCPD 
monomer mixtures.
42
 The fatigue response of the most recent solvent-based self-healing systems 
will be discussed in more detail in Chapter 5 of this dissertation. 
1.5 Alternative Self-Healing Chemistries 
From a practical point of view, there are several drawbacks to the initial Grubbs’/DCPD 
self-healing system including cost, toxicity, availability of Grubbs’ catalyst, and the 
compatibility of the catalyst with sample manufacturing. For example, the amine curing agent 
present in the epoxy (diethylenetriamine, DETA) reacts with and deactivates Grubbs’ catalyst, 
which decreases potential healing efficiencies.
8
 In order to overcome these problems, several 
modifications were studied: wax-protection of the catalyst,
6
 different catalyst morphologies,
40
 
alternative metathesis catalysts,
23,42,43 
and change in matrix to an epoxy vinyl ester.
7,44
 Ongoing 
research in this field continues to explore catalyst-free self-healing systems based on             
ring-opening reactions or solvent healing, with the goal of eliminating the dependence on the 
ROMP reaction of DCPD for recovery of damaged materials.
31,45,46
   
The synthesis of polydimethylsiloxane (PDMS) has also been exploited as a viable 
chemistry for self-healing materials. In one demonstration, the monomer components        
(PDMS and polydiethoxysiloxane or PDES) were phase-separated as droplets suspended in an 
epoxy vinyl ester matrix.  This matrix also contained microcapsules of the catalyst, dibutyltin 
dilaurate (DBTL), dissolved in chlorobenzene (Figure 1.5).
7
 Upon crack damage, the 
10 
 
microcapsules ruptured, releasing the catalyst into the crack plane, thus initiating the formation 
of PDMS. Later studies involved a two-capsule PDMS system in which a platinum-based 
catalyst was encapsulated with the PDMS precursor in one capsule and the hydrosiloxane 
copolymer initiator was encapsulated in another.
47
 When the contents of both capsules were 
transported into the crack plane upon mechanical damage, hydrosilation occurred, resulting in a 
cross-linked PDMS network. Healing efficiencies of 70–100% were reported, based on tear 
strength recovery 48 h after the initial damage had occurred.
47
 This chemistry was also used in a 
self-healing flexible laminate composite in which puncture holes were sealed upon the 
polymerization of the encapsulated PDMS and catalyst components.
48
 The effectiveness of this 
self-healing elastomer was defined by the ability to prevent gas leakage through a punctured 
composite using a pressure test cell. 
Other ring-opening reactions have been suggested for use in structural self-repairing 
materials. The reaction between epoxides and amines
33
 to create a thermoset has been considered 
given the advantage that the healing chemistry produces the same material as the surrounding 
matrix. There are, however, challenges to make this system effective for autonomic repair. In this 
type of envisioned system, a self-healing thermoset composite would contain both epoxy and 
amine-filled microcapsules. The released epoxy would be delivered to the damaged area and 
react with the released curing agent to produce a new cross-linked polymer. One challenge is to 
ensure mixing between the two components at stoichiometric ratios. Another challenge is to 
efficiently mix the two components in the crack plane. Numerous examples of microcapsules 
containing epoxy monomer core solutions have been reported.
49-54
 Due to the water solubility of 
aliphatic amine-based curing agents, in situ encapsulation techniques
26
 have proven difficult for 
use in preparing microcapsules with amine-functional core materials. Thus, a reverse-phase 
11 
 
emulsion was employed to stabilize a higher molecular weight reactive amine and synthesize 
microcapsules.
55
 Ongoing work in our laboratory seeks to explore the self-healing capability of 
these capsules in epoxy composites.  
Alternative curing agents such as imidazole derivatives have been microencapsulated and 
used in combination with epoxy microcapsules to evaluate self-healing capability.
56-58
 This 
system is non-autonomic, requiring external heat to promote the reaction of imidazole with 
epoxy, and the healing efficiencies over time (defined as the recovery rate of interlaminar 
fracture toughness in composites) initially decreased and then leveled off after storage times of 
up to 18 months.
59
 
Modifications have been made to the conventional two-part epoxy chemistry in an effort 
to overcome some of these presented challenges. In one case, a more robust, room temperature 
epoxy system was developed by encapsulating a polythiol curing agent, pentaerythritol 
tetrakis(3-mercaptopropionate).
60
 Self-healing was demonstrated in a thermoset with these 
mercaptan and epoxy microcapsules embedded in the matrix.
61
 High healing efficiencies were 
achieved at room temperature for samples containing a small amount of capsules and this system 
holds great promise for commercial applications. More recently, Rong et al. prepared 
microcapsules
62
 and sisal fibers
63
 containing boron trifluoride diethyl etherate ((C2H5)2O · BF3) 
as a curing agent to be used in place of the mercaptan-containing capsules. This cationic chain 
polymerization reaction between epoxy and (C2H5)2O · BF3 is non-stoichiometric and provided a 
faster cure for use in self-healing systems.
63,64
  
1.6 Overview of the Dissertation 
Solvent healing agents have also been explored for use in self-healing polymer 
composites and are the focus of this dissertation. When an organic solvent is introduced into a 
12 
 
polymer system, the mobility of polymer chains increases.
65,66
 Early work in this field employed 
solvents such as ethanol and methanol to heal crack damage in thermoplastic polymers          
(e.g., PMMA) after heat treatment.
67-72
 The healing mechanism proposed was the wetting of the 
polymer surface and resultant swelling of the bulk polymer material, which leads to reptation and 
interlocking of the chains across the crack plane to recover the original mechanical properties. 
 
Recently, it was discovered that when microcapsules with solvent cores were incorporated into 
an epoxy thermoset, the release of solvents upon damage promoted the mobility of residual 
functional groups to entangle and react across the crack plane to render the material self-
healing.
45
 Solvent-promoted self-healing is only effective when residual, unreacted epoxy and 
amine segments remain in the matrix. Chapter 2 will give mechanistic insights into this solvent 
healing phenomenon. Chapter 3 outlines the variety of solvent microcapsules that have been 
prepared and characterized. 
Full recovery of fracture toughness (100% healing efficiencies) was achieved for a 
thermoset matrix that incorporates microcapsules containing unreacted epoxy monomer 
dissolved in the solvent healing agents.
31
 Upon crack damage, the embedded capsules ruptured to 
release their components; the unreacted epoxy underwent a chemical reaction with the residual 
amines in the matrix, healing the matrix with up to 100% efficiencies. More environmentally-
friendly solvents (ethyl phenylacetate and phenylacetate) were employed as healing agents in this 
work, showing promise for a commercial system.
31
 The quasistatic and fatigue self-healing 
behavior of epoxy thermosets containing solvent- and epoxy-solvent-filled microcapsules will be 
discussed in Chapter 4 and 5, respectively.  
The limitation of solvent-based healing is that the epoxy matrix must be cured at a low 
temperature to leave unreacted functionality. However, most commercial epoxies undergo full 
13 
 
reaction at elevated temperatures where solvent healing agents are no longer effective. In 
Chapter 6, an alternative approach to healing in an epoxy thermoset is presented. Instead of 
depending on a two-capsule system with epoxy and amine-containing capsules, the amine would 
be masked with a protecting group or embedded in the matrix as a solid particle. Upon crack 
damage, embedded microcapsules would then release a deprotecting agent for the amine and 
excess epoxy to further react. 
Chapter 7 extends the concept of solvent healing to thermoplastics. The process of 
incorporating solvent-filled microcapsules into thermoplastics is not trivial, and the 
characterization of these samples will be presented in more detail. Attempts to use solvent 
healing agents to promote chain entanglement of incorporated thermoplastics as a secondary 
phase into high-temperature cured epoxies will also be discussed.  
 The ability to microencapsulate solvents has expanded the toolbox of new chemistries 
that can be compartmentalized for use in self-healing materials. In the development of a multi-
component self-healing system based on a free-radical polymerization, the initiator must be 
separated from the monomers and tertiary amine activators. Liquid monomers could easily be 
encapsulated, but the other components are commercially available as solids. Appropriate 
solvents were selected to dissolve the solid materials and prepare solutions that could then be 
microencapsulated. Chapter 8 covers the encapsulation of all the necessary components for the 
free-radical polymerization and the self-healing behavior of an epoxy vinyl ester matrix 
containing these capsules. 
To date, self-healing materials systems have largely focused on restoring functions such 
as mechanical properties of structural composites and barrier properties of protective coatings. 
The self-healing concept based on release of liquid content from microcapsules is a general one, 
14 
 
and could also be used to restore materials functionality such electrical conductivity in damaged 
electronics. For example, in order to overcome the cycle life and the safety issues that plague 
lithium-ion battery technology, new approaches are needed which can stabilize the electrode-
electrolyte interface and restore electrodes degraded by microcracks induced by charge-discharge 
recycling. To this end, new types of polymer nanocomposites in which precursor materials such 
as carbon nanotubes (CNTs) have been suspended in organic solvents encapsulated within 
polymer-based microcapsules and will be presented in Chapter 9. A more sophisticated system 
investigated was the formation of the conductive TTF-TCNQ (tetrathiafulvalene–
tetracyanoquinodimethane) charge-transfer salt via rupture of microencapsulated solutions of its 
individual components.
73
 Solutions of TTF and TCNQ in various solvents were separately 
incorporated into poly(urea-formaldehyde) core-shell microcapsules. This approach was the first 
microcapsule system for the autonomic restoration of mechanically damaged electronic devices 
in which the healing agent remains non-conductive until its release. 
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1.8 Figures 
 
 
Figure 1.1. Autonomic healing of polymers. (a) Underlying concept in which damage (a crack) 
triggers the healing response by rupturing embedded microcapsules containing a healing agent 
that polymerizes in the crack plane, rebonding crack faces. (b) Types of autonomic healing 
systems: (left) the healing agent (A) is encapsulated, and the catalyst (B) is dispersed in the 
polymer matrix; (center) both the healing agent and catalyst phases are microencapsulated and 
dispersed in the matrix; (right) the healing agent is phase-separated in the matrix, and the catalyst 
phase is microencapsulated. (c) Assessment of healing efficiency (η) is based on the recovery of 
mechanical properties of interest including fracture toughness, fracture energy, stiffness, ultimate 
strength, and tear strength. Reprinted with permission from Reference 3. Copyright 
2008, Materials Research Society. 
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Figure 1.2. (a) Reaction scheme of the monomer DCPD undergoing ring-opening metathesis 
polymerization to form poly(DCPD); (b) Optical micrograph of an in situ fatigue specimen 
showing poly(DCPD) formed in the crack plane behind the crack tip; (c) The autonomic self-
healing system showing crack initiation, rupture of microcapsules and the release of healing 
agent, and the resulting polymer formed in the crack plane. Reprinted with permission from 
Reference 4. Copyright 2009, American Chemical Society. 
 
 
Figure 1.3.  (a) Solvent-filled urea-formaldehyde (UF) capsules prepared by an in situ 
polymerization technique;  (b) Grubbs’ catalyst microspheres prepared by meltable dispersion 
technique; (c) Dibutylphthalate (DBP)-containing gelatin-gum acacia microcapsules prepared by 
coacervation technique; (d) DBP-containing polyurethane microcapsules produced using an 
interfacial polymerization technique.
25
 Reprinted with permission from Reference 4. Copyright 
2009, American Chemical Society. 
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Figure 1.4. Diagram showing the interconnection between the mechanical and chemical 
environments of self-healing materials and their influence on fatigue lifetime. Reprinted with 
permission from Reference 4. Copyright 2009, American Chemical Society. 
 
 
Figure 1.5. Schematic of phase-separated PDMS self-healing system and chemical structures of 
each component.
7
 Reprinted with permission from Reference 4. Copyright 2009, American 
Chemical Society. 
20 
 
Scheme 1.1. Polymerization of urea and formaldehyde to form short chain oligomers that make 
up the shell walls of microcapsules (reaction conditions = 4 h at 55 °C, pH 3-5).26 
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CHAPTER 2 
 
SCREENING OF ORGANIC SOLVENTS AS HEALING AGENTS 
 
 
2.1 Mechanistic Insights of Epoxy-Amine Reaction  
 
 The chemistry behind the reactions of epoxy thermosets is controlled by the kinetics of 
the involved epoxy-amine reactions,
1
 which depends on stoichiometry between the components 
and reaction temperature. Most commercial epoxy prepolymers are prepared by the step-reaction 
polymerization of bisphenol A and epoxide-containing compounds in the presence of a base (this 
process is known as „curing‟).2 The curing agents employed in epoxy resin preparation usually 
contain multitopic primary amines that react by nucleophilic addition to the terminal epoxide 
rings (curing) to form a three-dimensional cross-linked network (Scheme 2.1). The degree of 
curing is a function of reaction time and temperature; a fully-cured epoxy system is one wherein 
all reactive epoxide termini have been consumed. 
 The original autonomic self-healing polymer system developed by researchers at the 
University of Illinois consisted of an epoxy thermoset, made from the epoxy prepolymer EPON 
828 and curing agent diethylenetriamine (DETA) (Figure 2.1).
3
 This translucent, room 
temperature-cured epoxy can easily incorporate liquid-filled microcapsules by mixing in the 
solid materials by hand.
4
 The working time at room temperature (RT) is about 30 min before it 
begins to polymerize. As a result, subsequent publications on self-healing polymer systems from 
our laboratory
5-11
 have used the same components and curing conditions for their specific 
polymer matrix. The curing times and temperatures were determined based on the final 
mechanical properties of the epoxy (in terms of fracture toughness) after undergoing a cure cycle 
of 24 h at room temperature and a post-cure at 35 °C for 24 h.
4
 This cure cycle is referred to as 
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the „normal cure cycle‟ for the remainder of this dissertation. The resulting epoxy fracture 
specimens were brittle enough that upon crack propagation through the material, the embedded 
microcapsules successfully ruptured at the crack plane, yielding a self-healing epoxy polymer.
3,4
 
 This chapter studies the thermal behavior of the EPON 828:DETA polymer matrix and 
the effect of exposing this matrix to common organic solvents.
12
 Two contributing mechanisms 
of solvent-based self-healing in epoxy thermosets are proposed: (1) solvent penetration through 
the matrix swells the surrounding matrix, decreasing crack face separation to facilitate polymer 
chain entanglement (and thus “healing”); and (2) unreacted functional groups present in the 
matrix become mobile upon the introduction of solvent and can undergo further cross-linking 
reactions. These concepts are demonstrated in Figure 2.2. Spectroscopic evidence for continued 
cross-linking reactions in the presence of solvent supports this solvent healing concept and is 
presented in Section 2.1.2. The remainder of this chapter gives a summary of preliminary solvent 
screening experiments.   
2.1.1 Evidence for Incomplete Curing of Epoxy   
 The bulk polymerization of the epoxy-amine network throughout the previously-used 
curing process was first examined. The degree of cross-linking or curing for a specific thermoset 
depends on the stoichiometric ratio of the epoxy and amine functionalities as well as the thermal 
history or curing cycle.
13-15
 For the epoxy-amine matrix used in this work (Figure 2.1) – EPON 
828:DETA – it was found that after a cure cycle of 24 h at RT followed by 24 h at 35 °C,4 the 
stoichiometric (12 parts per hundred or pph relative to the epoxy) epoxy matrix was only 77–
80% cured as measured by DSC. Representative DSC thermograms for the matrix at each stage 
of the curing cycle are shown in Figure 2.3. Due to the low temperature curing cycle, the curves 
show an endothermic vitrification point (55–60 °C), which is the temperature where the two 
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liquid components become glassy and form a cross-linked network because the reaction kinetics 
have shifted from being kinetically-controlled to diffusion-controlled.
16
 As the temperature was 
ramped past the vitrification temperature (Tv), the exothermic transition observed in Figure 2.3 is 
indicative of the polymerization of residual reactive groups.
17-19
 This residual heat can be 
compared to the initial heat of reaction to determine degree of cure for the system as a resin and 
enthalpies from the DSC curves are reported in Table 2.1.
20
 A „fully cured‟ specimen required 
high temperature (T > 100 °C) curing for at least 1 h.
21
  
 The unreacted epoxy and amine groups in the thermoset are able to continue cross-
linking in the presence of solvent because the localized glass transition temperature (Tg) of the 
system has been lowered to permit these reactions to occur at RT.  Possart et al.
22,23
 suggested 
that the presence of a highly cross-linked region in a less cross-linked region was possible, which 
was observed in solvent healing epoxies presented in this work. Epoxy fracture specimens
4,11
 
were prepared of neat 828:DETA and healed by injecting ethyl phenylacetate (EPA) or 
chlorobenzene (PhCl) into the crack plane. After 24 h, the samples were re-fractured and small 
pieces of the healed interface were analyzed by dynamic DSC experiments. The thermal 
behavior for these bulk epoxy samples is reported in Table 2.1. The residual heat recorded for 
solvent-healed samples was lower than the control sample of bulk epoxy alone, meaning that 
additional cross-linking reactions had taken place in the presence of solvent. Furthermore, the Tg 
of the solvent healed samples measured upon in situ curing in the DSC was lower than the Tg of 
control bulk epoxy specimens.   
 In addition to DSC analysis of resins and bulk epoxy samples, dynamic mechanical 
analysis (DMA) has been used as a very sensitive technique to characterize thermal transitions in 
epoxy materials and was employed here.
24
 There are various ways to determine the Tg of cured 
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epoxies based on their viscoelastic response. Palmese et al.
25
 calculated the Tg as midpoint 
between the tangents (inflection point) of the storage modulus (E´), Vanlandingham et al.
26
 
documented the peak of the loss modulus (E˝), and Papanicolaou et al.27 recorded the peak of the 
tan(δ) transition. However, the dampening peak, tan(δ) represents the partial loosening of the 
polymeric structure so that chain segments have the ability to move is not always equivalent to 
the Tg of a material. This peak is generally 15–20 °C above the glass transition temperature.
28,29
 
Thus, the Tg for our epoxy matrix cured under the „normal cure cycle‟ conditions at various 
amine stoichiometries was reported using the E´, E˝, and tan(δ) values (Table 2.2). There was an 
excellent correlation between the midpoint of the E´and E˝, while the peak of tan(δ) was 
generally 10–13 °C higher. For the stoichoimetric ratio, where the amine content was 12 pph 
DETA, it was noted that there was a dual transition in the dampening curve, tan(δ), shown in 
Figure 2.4a. This dual peak has been attributed to heterogeneous networks in which microgel 
structures are found among macrogel or rigid structures in the thermoset.
28
 This phase separation 
was noted for those matrices consisting of 12–16 pph curing agent and the values of both peaks 
are given in Table 2.2. At the epoxy-rich and amine-rich extremes, only one dampening peak 
was observed, agreeing with similar experiments done with DGEBA and aliphatic amines where 
more homogeneous networks were formed.
30
 These observations corresponded well with the 
DSC results as further evidence that the epoxy was under-cured and contained residual 
functional groups.
31
 However, it is important to note that upon increasing the temperature above 
that of the first transition (ca. 60 °C) for samples that underwent the „normal cure cycle,‟ the 
matrix became fully cured, and the second peak represents the Tg of the fully cured polymer. To 
confirm this phenomenon, a separate experiment was conducted on the 100:12 828:DETA matrix 
where the temperature was cooled to RT after the first sweep (to 160 °C) and then ramped back 
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up to 160 °C. The resulting curves are shown in Figure 2.4b. For the second sweep, there was 
only one peak observed at ca. 135 °C, which correlated to the Tg observed by DSC for „fully-
cured‟ samples that was reported in Table 2.1. Thus, the viscoelastic response observed (dual 
peak) by DMA experiments was a result of the partially cured initial epoxy network.  
 As it was demonstrated in the previous section with DMA experiments, the stoichiometry 
of the epoxy-amine system affected the epoxy network structure and mechanical properties of 
the cross-linked thermoset.
15,32
 When the molar ratio of epoxy:amine (828:DETA) was varied off 
the stoichiometric point at 12 pph, the initial heats of reaction measured by DSC also varied and 
are listed in Table 2.3. The highest degree of reaction occurs at the stoichiometric point
25,33
 as 
well as for the Tg of the fully-cured material and is demonstrated in Figure 2.5. In networks with 
increasing amine content, the glass transition temperature was observed to be lower because of 
increased mobility of the polymer chains (the sol phase acts as a softener).
34
 When solvent 
healing was attempted with off-stoichiometric epoxy matrices (from 8–25 pph DETA) with PhCl 
as the solvent, reference tests showed an increase in healed peak load with increasing amine 
concentration as shown in Figure 2.6. Conversely, healing performance appeared to be inversely 
related to crosslink density (above the stoichiometric point). The highest crosslink density was 
observed at 12 pph DETA and agrees with previously published studies for this system.
35
 Thus, 
both the thermal curing conditions and stoichiometry of epoxy-amine matrices must be 
considered when discussing solvent healing effects for self-healing polymers.  
2.1.2 Spectroscopy of Epoxy Films with Solvent 
The role of solvents in a thermoset matrix is a complicated issue because one must 
consider not only the bulk properties of the polymeric material such as modulus and glass 
transition temperature, but also the chemical properties of each matrix component. The previous 
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section discussed the physical effects of solvent in epoxy, but the chemical effects must also be 
considered when discussing a solvent healing mechanism. The effect of additional cross-linking 
reactions was observed by thermal analysis in enthalpic terms, and spectroscopic evidence would 
lend more support to our mechanistic proposal by monitoring the epoxy and amine stretches in 
the presence of solvent by FTIR. Indeed, Figure 2.7a shows the disappearance of the epoxide IR 
peak at 917 cm
-1
 (terminal C–H stretch of the epoxide ring) over time when exposed to PhCl. By 
testing a variety of solvents for healing over a time period of 24 h, the epoxide peak disappeared 
as a function of time to indicate further cross-linking reactions were occurring. As a control, 
films with no added solvent did not have any spectral change due to the epoxide stretch after    
24 h. At various epoxy-amine stoichiometries, the hydroxyl peak at 3400 cm
-1
 was observed to 
increase as the amount of amine in the matrix increased (Figure 2.7b), indicating that there was 
more secondary alcohol formation when more amines were present in the matrix. The fully-cured 
sample at 100:12 ratio (post-cured at 140 °C for 1 h following the „normal cure cycle‟) had the 
greatest –OH peak at 3400 cm-1 since all the epoxide groups have reacted with the amine curing 
agent.   
The decrease in the epoxide peaks over time in the presence of solvent was also observed 
by near-IR spectroscopy as shown in Figure 2.8. In the near-IR region, the epoxide stretch had a 
greater initial intensity than that in the mid-IR region. Thus, experiments were conducted in both 
IR ranges to confirm the disappearance of the epoxide peak over time. A summary of the 
additional epoxide conversion by mid-IR and near-IR over 24 h is shown in Figure 2.9. The 
epoxide conversion term (X) was calculated using equation 1 for normalized IR spectra, where 
the peak heights at tf = 24 h were compared to the initial peak heights (t0).
36
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The conversion values are low (< 20%) because the initial epoxy film already had 80% of 
its epoxide groups reacted, confirmed by DSC experiments (vide infra). Therefore, Figure 2.9 
should be viewed as epoxide conversion (%) observed 24 h after the introduction of solvent. The 
highest amount of epoxide conversion after 24 h was demonstrated using NMP as the solvent. 
For control epoxy film samples, the epoxide peak was not visible for fully-cured films and the IR 
spectra did not change upon addition of chlorobenzene as a solvent. Furthermore, films without 
added solvent or films in which water was the added solvent did not exhibit spectral change in 
the epoxide stretch in mid-IR or near-IR after 24 h. Therefore, the correlation between additional 
epoxide conversion and healing reported for the chosen solvents indicated the amount of further 
cross-linking reactions that occur in the presence of solvent. The solvent screen conducted for 
healing of epoxy is discussed in more detail later in this chapter (Section 2.2.1). 
2.1.3 Swelling of Bulk Epoxy Specimens 
 The mobility of polymer chains in the presence of solvent has been discussed thus far in 
this chapter, and the degree of swelling (increase of free volume) for bulk samples had not 
specifically been mentioned to this point. Swelling experiments have been shown to be useful for 
determining the degree of cross-linking and network structure of epoxy matrices.
34,37
 
Additionally, the ability of solvents to swell cured epoxy at RT would be the first step in the 
proposed mechanism of solvent healing to decrease crack separation and bring the epoxy faces in 
close contact for chemical reactions across the interface to occur (Figure 2.2). When small, 
cylindrical 828:DETA samples after being cured under the „normal cure cycle‟ were immersed a 
variety of organic solvents for 24 h, the mass gained was determined and is shown in Figure 
2.10. The solvents are organized in terms of polarity from left to right; nonpolar solvents are on 
the far left of the graph and polar solvents are on the far right. When reference healing tests were 
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performed for these solvents (measure of fracture toughness), it was found that the mid-range 
polarity solvents exhibited the highest peak loads.
12
 Thus, the correlation between healing 
performance and degree of swelling for these solvents is shown in Figure 2.11. In general, the 
trend observed from the reference fracture tests corresponded to the degree of swelling observed 
after 24 h. This trend should apply to other solvents yet to be reported and these initial studies 
are by no means inclusive to show of all the possible solvents that possess healing abilities.    
2.1.4 Kinetics of Solvent Healing      
 Further evidence for the proposed solvent healing mechanism is that the rate at which 
mechanical properties are recovered (observed healing response) should correlate to the rate of 
chemical conversion that takes place during the healing event. Thus, the rate of healing observed 
was compared to the rate of epoxy-amine polymerization of the matrix by isothermal DSC 
experiments (Figure 2.12). The neat epoxy resin (EPON 828:DETA) data shows the degree of 
polymerization of only the polymer matrix, while the data from healed fracture experiments of 
samples containing PhCl-filled microcapsules is overlaid on the plot. As evidenced by the two 
curves, within the first 30 min of healing after crack propagation, healed peak loads showed the 
effect of chain mobility in the presence of solvent. It was found that healing increased with 
similar rates as the epoxy-amine reaction in the matrix, suggesting that the healing event begins 
to plateau 12 h after the initial fracture event. As a control for this study, epoxy samples were 
prepared in the same fashion but not exposed to solvent and kept at 50 °C for 10 h to simulate 
the extent of epoxy-amine reaction within the given time frame. The reported healed peak loads 
for five samples were 15 N, supporting the observation that any fracture toughness recovery 
greater than this value was a result of further cross-linking in the presence of solvent. 
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2.2 Solvent Screening in Epoxy Matrices 
 
2.2.1 Reference Testing 
 
 Organic solvents were screened for their healing ability by manually injecting solvent 
onto the crack plane of a fractured epoxy test specimen (EPON 828 and diethylenetriamine, 
DETA). These reference tests mimic the behavior of the autonomic mechanism of solvent 
delivery but avoid a multitude of extra variables associated with the fully in situ case. An 
extensive evaluation of common organic solvents shows a range of healing efficiencies that 
correlate with solvent polarity (Figure 2.13). Polarity of solvents was determined using an 
empirical solvent parameter (ET)
38
 and the polarities are plotted according to this value. On both 
extremes of the polarity spectrum, nonpolar solvents such as cyclohexane and hexanes, and polar 
solvents such as formamide and water show no indication of recovering mechanical integrity. 
This behavior is consistent with control experiments for our initial metathesis-based self-healing 
system which showed no healing in the absence of catalyst.
3
 The five solvents that exhibit the 
highest healing efficiencies are nitrobenzene, NMP, DMA, DMF, and DMSO. These polar 
aprotic solvents have dielectric constants ranging from 32–47, boiling points ranging from    
153–210 °C, and are theta solvents for the epoxy. The hydrogen bond acceptor ability of the five 
most efficient solvents is another possible explanation for healing performance, since the reacted 
epoxy contains a large amount of free hydroxyl groups which serve as hydrogen bond donors. 
The dipole-dipole interaction between hydrogen bond accepting solvents and free amines has 
been reported as having an influence on the epoxy-amine curing reaction.
39
 Additionally, the 
solubility of amines in more polar solvents (e.g., acetone where ET = 0.36),
38
 such as these 5 
most efficient solvents, contribute to the healing observed while the solubility of the epoxy resin 
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is higher in less polar solvents.
40
 This can help account for the dual healing peaks observed in 
Figure 2.13.  
2.2.2 Chlorobenzene as a Model Solvent 
 The autonomic system requires that the solvent is protected by encapsulation and that the 
capsules are dispersed throughout the epoxy matrix. Unfortunately, the five highly efficient 
solvents noted above have yet to be successfully encapsulated using the urea-formaldehyde (UF) 
in situ polymerization method
41
 due to their high degrees of polarity. Thus, chlorobenzene 
(PhCl) emerged as a potential solvent for our preliminary autonomic healing experiments since it 
was previously encapsulated.
42 
Chlorobenzene did not demonstrate the optimal recovery of 
fracture toughness when compared to the other solvents tested (refer to Figure 2.13), but it 
served as an adequate choice for initial demonstration of the solvent-based, autonomic healing 
concept. When the PhCl capsules were incorporated into the epoxy matrix and a crack 
propagated through the epoxy specimen, the solvent was released, wetting the crack plane 
surface upon cleavage of the capsules. Using short-groove tapered-double-cantilever beam 
(TDCB) specimens (25 mm in length with chlorobenzene capsules embedded in the crack-
directed groove),
11
 the healed peak load grew with increasing amounts of microcapsules in the 
system (Figure 2.14a). Since the TDCB geometry is a crack length independent measurement of 
fracture toughness,
3
 the healing efficiency can be determined based on the ratio of the healed 
peak load to the virgin peak load. Representative virgin and healed load-displacement curves for 
in situ fracture testing of a system with 20 wt% UF PhCl capsules are shown in Figure 2.14b. 
This sample represents ca. 82% healing efficiency.     
 Solvent healing is not only limited to our specific epoxy matrix (EPON 828:DETA). 
Chlorobenzene was also used as a healing solvent in two other RT epoxy systems – EPON 862 
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(Bisphenol F derivative):EPICURE 3274 (aliphatic amine) and EPON 
828:tetraethylenepentamine (TEPA).  Reference tests with manually injected chlorobenzene for 
these matrices show significant recovery of fracture toughness, with average healed peak loads 
of 80 N and 60 N, respectively, compared to the reported Phealed = 66 N for the EPON 828:DETA 
matrix. The virgin peak loads for neat epoxy ranged from 70–80 N. 
2.3 Experimental Section 
 
 Materials: Organic solvents, octadecyltrichorosilane, and other chemicals used in 
experiments were purchased from Sigma-Aldrich and used without purification unless otherwise 
noted. Solvents tested include cyclohexane, hexanes, xylenes, toluene, iodobenzene (PhI), hexyl 
acetate (HA), pentyl acetate, chlorobenzene (PhCl), ethyl phenylacetate (EPA), phenylacetate 
(PA), tetrahydrofuran (THF), dichlorobenzene (DCB), methylene chloride (CH2Cl2), 
nitrobenzene, N-methyl pyrrolidone (NMP), dimethyl acetamide (DMA), N,N-dimethyl 
formamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile (CH3CN), butanol, ethanol, 
formamide, and deionized water. Ethylene-maleic anhydride (EMA) copolymer (Zemac®-400) 
powder with an average molecular weight of 400 kDa was graciously donated by Vertellus and 
used as a 2.5 wt% aqueous solution. EPON 828 was purchased from Miller-Stephenson and 
diethylenetriamine (Ancamine DETA) curing agent was received from Air Products.  
 Instrumentation: Microcapsule diameters were determined through optical microscopy 
using a Leica DMR Optical Microscope at various magnifications (5X, 10X). ImageJ software 
was used to measure the diameters and an average of at least 100 capsules was used to determine 
the size distribution per batch. A Philips XL30 ESEM-FEG instrument was used to image 
samples with a 5 kV electron source after sputter-coating with a gold-palladium source. 
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  Thermal Analysis: Differential scanning calorimetry (DSC) was performed on a 
Mettler-Toledo DSC 821
e
 instrument, calibrated by indium, octane, and zinc standards. Unless 
otherwise indicated, the heating rate was 10 °C/min. For each analysis, the sample (ca. 20 mg) 
was accurately weighed into an aluminum pan, which was hermetically sealed. Routine DSC 
traces recorded heat flow during a heating and cooling cycle over the temperature range          
25–300 °C at a rate of 10 °C/min. The Tg was measured (reported as the midpoint temperature of 
the transition) on the second heating scan after a single cycle from 25–300 °C at a rate of          
10 °C/min. Vitrification temperatures (Tv) was measured as the peak of the endothermic 
transition (not the onset temperature). Isothermal DSC experiments were performed at 25 °C for 
120 min. The degree of cure (%, αt) was determined as a function of time using the following 
equation: 
                
T
t
t
Q
Q
100                                           (2) 
where Qt is the reaction heat during an isothermal scan at various times t, and QT is the total heat 
of polymerization taken from dynamic scans.
20,43
  
 Thermogravimetric analysis (TGA) was performed on a Mettler-Toledo TGA851
e 
instrument, calibrated by indium, aluminum, and zinc standards. The mass loss was recorded 
during a heating cycle over the temperature range of 25–650 °C at a constant rate of 10 °C/min 
in an atmosphere of N2. For each experiment, approximately 2–5 mg of sample was accurately 
weighed (± 0.02 mg) into an alumina crucible. 
 Epoxy Sample Preparation: The epoxy matrix used in this work was mixed at a 100:12 
ratio (by weight) unless otherwise stated of EPON 828:DETA, degassed, and poured into 
silicone molds and underwent a cure cycle of 24 h at RT and 24 h at 35 °C (referred to as the 
„normal cure cycle‟ in the text). Long-groove tapered-double-cantilever beam (TDCB) 
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specimens
4,11
 were prepared for DSC experiments of solvent healed fracture surfaces. After 
inserting a precrack with a sharp razor blade into the groove of the sample, the TDCB specimens 
were pin-loaded and tested to failure using an Instron load frame under displacement control at a 
rate of 5 μm/s. For reference tests, 25 μL of each solvent was injected onto the crack plane, the 
two sides were realigned, and allowed to heal for 24 h at RT. The healed TDCB samples were 
again loaded to failure and the load-displacement curve was recorded. All healed samples were 
tested after 24 h, unless otherwise stated. After testing healing of these samples, small pieces 
were cut from the healed fracture surface of the epoxy for DSC analysis. In situ healing was 
assessed in a similar manner as reference specimens, except that solvent was present in 
microcapsules (at 15 wt% of the matrix) dispersed throughout the central insert section of the 
short-groove TDCB samples (64 mm in length). Short-groove TDCB specimens were used for in 
situ healing because the average crack face separation is reduced from 26 μm (long-groove 
TDCB specimens) to 3 μm near the pin holes of the sample, allowing for intimate contact 
between the crack faces.
17
 Healing efficiencies were defined as the ratio between the healed and 
the virgin fracture toughness,
4 
represented as: 
    η = Phealed/Pvirgin    (3) 
where P and η represent the fracture peak loads of each sample and the healing efficiency, 
respectively.   
 Dynamic Mechanical Analysis: Modulus and Tg were determined from measurements 
collected on a dynamic mechanical analyzer (DMA, TA RSA 3). The samples of EPON 
828:DETA were prepared at stoichiometries of 8, 10, 12, 14, 16, 20% DETA (by weight) were 
cast in 75 mm x 25 mm x 2.5 mm silicone molds and underwent the „normal curing cycle‟ as 
stated above. The samples were cut with a band saw into 30 mm long x 3.5 mm wide x 4 mm 
34 
 
thick rods. Sample rods were loaded onto a 25 mm three-point bend fixture in the DMA and a 
dynamic ramp test was performed (25–220 °C at 5 °C/min) under 0.5% strain at a frequency of   
1 Hz unless otherwise indicated. Storage modulus (E´) at 30 °C, loss modulus (E˝), and tan(δ) 
were recorded for each sample. The crosslink density was calculated from the E´ at 140 °C, 
following previously reported procedures.
28
 
 FTIR: Microscope glass slides (Propper Manufacturing Co., Inc.; 3" x 1"; 1 mm thick) 
were coated in a 0.1 M solution of octadecyltrichorosilane in toluene to prevent adhesion of the 
films to the slides.
44
 The slides were rinsed with toluene, and a mixture of EPON 828:DETA was 
prepared and poured on the slides. Two slides were clamped with the resin in between, and the 
films underwent the „normal cure cycle‟ as cited above. After curing, two small pieces of film 
were placed in the IR sample chamber and a reference spectrum was acquired. Then, 5 μL of 
each solvent was injected between the two films and another spectrum was acquired. Each 
experiment was run in situ by keeping the films in the sample chamber of the instrument for 24 h 
and acquiring IR spectra at known time intervals. Spectra were collected on samples exposed to 
the following representative solvents: DMSO, DMF, NMP, water, nitrobenzene, DMA, and 
chlorobenzene. Films were also prepared using 100:20 and 100:25 stoichiometries (by wt%) of 
EPON 828:DETA and DMSO was used as the solvent for these experiments. A high 
temperature-cured 100:12 EPON 828:DETA film was also prepared by subjecting the sample to 
the „normal cure cycle,‟ followed by a post-cure at 140 °C for 1 h to create a „fully-cured‟ 
sample.
21
  Chlorobenzene was the chosen solvent for both mid-IR and near-IR experiments of 
the fully-cured films. Mid-IR absorbance spectra were acquired on a Nicolet Nexus 670 FT-IR 
spectrometer representing the sum of 32 individual scans at a resolution of 4 cm
-1
 from 800-4000 
cm
-1
. All mid-IR spectra were normalized to the aromatic –CH ring stretch at 830 cm-1.36     
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Near-IR spectra were also acquired of films prepared in the same manner as described above on 
a Varian Cary 500 Near-IR spectrometer at set time intervals from 3100-7000 cm
-1 
at a rate of 
100 wavenumbers per second. Near-IR spectra were collected on samples exposed to the 
following representative solvents: DMSO, DMF, NMP, nitrobenzene, hexanes, water, and 
chlorobenzene for epoxy films that underwent the „normal cure cycle.‟ Near-IR spectra were 
normalized to combination band at 4623 cm
-1
 of the aromatic –CH fundamental stretch on the 
epoxy.
36 
    
 Swelling Experiments: Cylindrical epoxy samples (15 mm x 7.5 mm, 0.850 ± 0.015 g) 
of 828:DETA were prepared and underwent the „normal cure cycle‟ as stated above. After 
removing from silicone molds, the samples were weighed and placed into separate 10 mL 
scintillation vials (one epoxy sample per vial). Exactly 2 mL of each solvent was delivered to 
each vial using a volumetric pipette to completely immerse the epoxy sample in solvent. The 
vials were capped and left at room temperature for 24 h.  Each sample was then wiped dry and 
re-weighed.   
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2.5 Figures and Tables 
 
 
Figure 2.1. Chemical structures of epoxy matrix components used. 
 
 
Figure 2.2. In the process of solvent-based self-healing in thermosets: (a) healing solvent (green) 
containing epoxide functionality is released from ruptured microcapsules into the crack plane of 
the matrix (beige), (b) the solvent swells the matrix and extracts unreacted amines that proceed to 
react with the capsule-delivered epoxide resin, (c) leading to newly formed epoxy resin material 
(purple) that heals the damage. [image courtesy – Eric Shoemaker (ITG)] 
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Figure 2.3. Dynamic DSC thermograms for stoichiometric EPON 828:DETA resin taken after 
various curing stages. The fully-cured trace corresponds to a cure cycle of 24 h RT, 24 h 35 °C, 
and 1 h 125 °C. 
 
 
(a)  (b)  
Figure 2.4. DMA curves from temperature sweep experiments of the 100:12 EPON 828:DETA 
epoxy matrix after being exposed to a „normal cure cycle.‟ 
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Figure 2.5. Glass transition temperatures measured for EPON 828:DETA resin at varying amine 
concentrations. The fully-cured trace corresponds to a cure cycle of 24 h RT, 24 h 35 °C, and 1 h 
125 °C. 
 
 
 
 
Figure 2.6. Healed peak loads and crosslink density versus amine content for „normal cured‟ 
EPON 828:DETA epoxy matrix. Samples were healed for 24 h after manually injecting 5 µL of 
PhCl onto the fracture plane. 
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 (a)  (b)  
Figure 2.7. Representative mid-IR spectra showing (a) a decrease in the peak at 917 cm
-1
 
attributed to the C–H stretch/bend of the epoxide group when exposed to chlorobenzene; and (b) 
neat epoxy thin films at different amine stoichiometries (with no solvent). 
 
 
 
 
Figure 2.8. Near-IR spectra over time of chlorobenzene in between two epoxy thin films. 
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Figure 2.9. Summary of additional epoxide conversion of EPON 828:DETA epoxy films for 
representative solvent systems after 24 h. 
 
 
 
 
Figure 2.10. Mass gained in swelling experiments after 24 h exposure to respective solvents. 
Error bars represent one standard deviation based on 2 samples tested per solvent. 
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Figure 2.11. Correlation plot of reference tests reporting healed peak loads and mass gained in 
swelling experiments after 24 h exposure to respective solvents.  Error bars represent one 
standard deviation based on 5-10 samples for healing results and two samples for the swelling 
tests. 
 
 
 
 
Figure 2.12. Kinetics of 828:DETA polymerization monitored by isothermal DSC experiments 
over 12 h and healing of in situ TDCB samples over a time period of 24 h. 
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Figure 2.13. Summary of reference tests for solvents of varying polarity. Healed peak fracture 
load is plotted as a function of polarity, defined by the experimental solvent parameter (ET).
14
 
Error bars represent standard deviation based on 5–10 samples.   
 
 
(a) (b)  
 
Figure 2.14. (a) In situ healing of samples containing UF chlorobenzene microcapsules as a 
function of capsule loading. Recovered peak loads were recorded 24 h after the initial fracture 
event. Error bars represent one standard deviation based on the indicated number of samples (in 
parentheses). The reference test point represents manually injected chlorobenzene (5 μL) in a 
short-groove TDCB specimen. (b) Representative load-displacement curves for short-groove 
specimens demonstrating in situ healing with 20 wt% chlorobenzene capsules. Reprinted with 
permission from Reference 12. Copyright 2007, American Chemical Society. 
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Table 2.1.  Thermal behavior of EPON 828:DETA epoxy resin and bulk polymer under different 
curing and healing conditions. Initial heats of reaction and vitrification temperatures were 
monitored by DSC. The degree of cure is based on the baseline resin heat of reaction. The 
reported Tg is taken from the second heat cycle.  
 
Epon 828:DETA (100:12) 
Vitrification T 
(°C) 
Heat of Rxn 
(J/g) 
Degree of Cure 
(%) 
Tg 
(°C) 
Baseline n/a 540 100 130 
24 h RT 53.2 140 74 - 
24 h RT, 24 h 35 °C 61.2 111 79 - 
bulk epoxy matrix after cure 64.6 122 77 126 
bulk epoxy healed with PhCl 49.1/65.6 103 81 120 
bulk epoxy healed with EPA 64.1 97 82 119 
 
 
Table 2.2.  Summary of DMA data for matrices of varying amine contents.  The averaged results 
and standard deviations are based on 3 samples. 
 
Amine E' at 30 °C Mid. Pt. of E' E" 
Peak of 
tan(δ) 
Peak of 
tan(δ) 
(pph) (GPa) (°C) (°C) (°C) (°C) 
8 3.7 ± 0.04 56.5 ± 0.68 56.4 ± 0.72 68.2 ± 0.44 - 
10 3.1 ± 0.26 57.6 ± 0.35 57.2 ± 0.65 67.7 ± 0.96 - 
12 3.4 ± 0.29 58.5 ± 0.07 58.5 ± 0.08 78.7 ± 0.66 126 ± 1.4 
14 2.8 ± 0.09 58.6 ± 0.47 59.0 ± 0.69 74.5 ± 1.69 123 ± 0.5 
16 3.0 ± 0.07 59.6 ± 0.36 59.2 ± 0.42 73.6 ± 0.35 117 ± 0.5 
20 3.1 ± 0.15 57.5 ± 0.26 57.5 ± 0.26 78.4 ± 1.32 - 
25 3.2 ± 0.10 55.0 ± 0.32 55.8 ± 0.27 65.3 ± 0.74 - 
 
 
Table 2.3.  Glass transition temperatures of fully-cured 828:DETA epoxy matrices at various 
stoichiometries and initial heats of reaction monitored by DSC. The results are averaged and one 
standard deviation is based on 2–3 experiments. 
 
Amine Content 
(pph) 
Amine:Epoxy 
(molar ratio) 
Tg 
(° C) 
Heat of 
Rxn (J/g) 
8 0.72 72.3 351 ± 25 
10 0.90 121 475 ± 35 
12 1.09 130 539 ± 0.8 
14 1.26 105 528 ± 29 
16 1.43 104 303 ± 34 
20 1.79 84.8 377 ± 22 
25 2.22 74.7 485 ± 19 
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Scheme 2.1. Cross-linking reaction between a primary amine curing agent and an epoxy 
prepolymer to form an epoxy thermoset.
29
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CHAPTER 3 
 
MICROCAPSULE PREPARATION AND CHARACTERIZATION 
‡
 
 
 
3.1 Introduction 
 
 Most of the mechanistic studies on solvent healing discussed in the Chapter 2 of this 
dissertation involved manually injecting solvent healing agents into the epoxy matrix. For an in 
situ self-healing system where the healing agents are contained within the bulk epoxy, solvent-
filled microcapsules must first be prepared and characterized. The solvents in this chapter were 
identified to be mostly nonpolar such that oil-in-water emulsion polymerization techniques
1,2
 
could be used for capsule preparation. Refer to Section 1.3 of this dissertation for more 
background on microencapsulation. A variety of encapsulation procedures were used in this 
chapter to prepare solvent-filled polymeric microcapsules depending on the shell-wall 
components and properties desired.  
3.2 Chlorobenzene Capsules 
 Chlorobenzene (PhCl) was initially identified as the model solvent in this work to 
demonstrate the concept of solvent-based self-healing.
3
 PhCl was previously used as a solvent to 
dissolve a tin catalyst for siloxane-based self-healing agents in an earlier system.
4
 The employed 
procedure for microcapsule preparation in this work was an interfacial polymerization of 
diisocyanates and polyfunctional alcohols to form polyurethane (PU) shell walled capsules.
4,5
 A 
scanning electron microscope (SEM) image of these capsules is shown in Figure 3.1a. The shell 
walls of these capsules had dented features (usually due to leaching of core material) when 
compared to other synthesized capsules, but the solvent was not observed to leach through the 
                                                          
‡
 Some of the content presented in this chapter was published in Blaiszik, B. J.; Caruso, M. M. et al. Polymer 2009, 
50, 990-997, Copyright 2009, Elsevier; and Caruso, M. M. et al. ACS Appl. Mater. Interfaces 2010, 2, 1195-1199, 
Copyright 2010, American Chemical Society. 
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shell walls during storage. This procedure was used to produce microcapsules at a variety of 
sizes by changing the emulsion stir rate, and this relationship is shown in Figure 3.1b.    
 Another procedure used to prepare PhCl-containing microcapsules was the urea-
formaldehyde (UF) in situ polymerization method.
1,2
 This procedure is experimentally simpler 
than that for the preparation of PU capsules and the resulting liquid-containing spheres had very 
smooth shell walls. An SEM of these capsules containing PhCl is shown in Figure 3.2a. Various 
batches of UF PhCl capsules were also prepared at different stir rates, such as what was done 
with the PU PhCl capsules (Figure 3.2b). Using a modified UF procedure that will be discussed 
later in Section 3.4, PU/UF PhCl capsules were prepared that demonstrated an increase in 
thermal stability when compared to the single-walled PhCl capsules.  
 A summary of the chlorobenzene capsules with three different shell walls is given in 
Table 3.1 and their thermal behavior was characterized by thermogravimetric analysis (TGA) 
(Figure 3.3). The PU PhCl capsules decomposed at the lowest temperature, while the UF PhCl 
capsules started to lose mass from the beginning of the temperature ramp. The observed spike, or 
increase in mass was observed for UF PhCl capsules and attributed to the explosive nature of 
PhCl solvent at higher temperatures. The double-walled PU/UF capsules showed the greatest 
degree of thermal stability of all the PhCl capsules produced. 
3.3 Urea-Formaldehyde Solvent Capsules 
 
 Other nonpolar solvents were  encapsulated using the UF in situ emulsion polymerization 
method with no further modifications to the procedure.
2
 These solvents included hexanes, 
xylenes, toluene, hexyl acetate, iodobenzene, ethyl phenylacetate (EPA), anisole, phenyl acetate 
(PA), and 1,2-dichlorobenzene (DCB). Representative stir rates and corresponding capsule 
diameter sizes for each of these capsules is given in Table 3.2. TGA curves for each type of 
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capsules prepared at the stir rates given in Table 3.2 are shown in Figure 3.4. The higher boiling 
point solvents are grouped in Figure 3.4b and demonstrate similar thermal stability. When 
smaller capsules of each solvent were prepared at higher stir rates, only PA capsules leached 
when stored at room temperature, suggesting incomplete shell wall formation. In order to 
stabilize PA capsules to prevent water absorption and leaching of the core material over time,     
5 wt% polystyrene (PS) beads were added to 60 mL PA and were allowed to dissolve overnight 
before encapsulation. The addition of the PS beads increased the viscosity of the PA solution, but 
did not affect any healing observed when using these solvent capsules in an epoxy system. 
3.4 Double-Walled PU/UF Capsules
6
 
 
 Previous sections have discussed capsule synthesis using an interfacial polymerization or 
an in situ emulsion polymerization technique to produce single-walled microcapsules. In an 
effort to increase the thermal stability of solvent-containing capsules, a multi-walled capsule was 
desired. Other methods for the preparation of multiwalled capsules
7,8
 involve three, discrete 
steps: 1) interfacial reaction between isocyanates and polyols to build the PU shell wall; 2) 
rinsing and filtration of prepared PU microcapsules; and 3) re-dispersion in aqueous medium and 
deposition of a UF shell wall. Secondary nucleation onto the microcapsule exterior allows the 
UF microcapsules to bond to the matrix for efficient rupture in a self-healing composite, which is 
a major problem with PU single-walled capsules.
5
 In this section, PU/UF microcapsules were 
prepared by a single-batch process and characterized in terms of shell morphology, thermal 
stability, and failure strength as a function of the PU prepolymer added.  EPA was selected as the 
core solvent due to its ability to dissolve the PU prepolymer and its successful healing ability in 
solvent-promoted self-healing polymers.
9,10
 The behavior of the PU/UF capsules is most 
accurately compared to that of UF microcapsules with the same core material. 
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 Following the modified encapsulation procedure shown in Figure 3.5, PU/UF EPA 
capsules of various sizes were produced by changing the stirring speed. Figure 3.6 reveals the 
size range of PU/UF EPA capsules produced with a constant amount of PU prepolymer. The 
capsule diameter was compared to UF EPA capsules for a range of stir rates.
2
 The addition of PU 
prepolymer does not significantly change the mean size of the resultant PU/UF EPA 
microcapsules from the sizes of the produced UF EPA capsules. 
 The addition of the PU prepolymer resulted in PU/UF microcapsules with thicker shell 
walls than UF capsules. Moreover, two distinct shell morphologies were observed when the PU 
prepolymer was added to the core. SEM imaging of the epoxy surfaces (Figure 3.7a) reveals an 
abrupt change in texture that suggests a distinct double-wall morphology. AFM imaging of a 
PU/UF EPA capsule prepared with the highest amount of PU used in this study (7.5 g) is 
presented in Figure 3.7b. A false-color map was created from raw AFM phase images, which 
displayed a difference in phase for the two regions. These regions were designated as different 
shell walls based on a series of images taken as the amount of PU was systematically increased. 
Based entirely on their location, the inner texture was assigned as the PU shell wall and the outer 
texture was assigned as the UF shell wall. The precise chemical composition of these textures is 
the subject of future studies. As a control, an AFM image of a UF EPA capsule showed only one 
phase with a uniform texture consistent with a single wall and a color map was also added to this 
image in order to make this concept more evident (Figure 3.7c). Capsule shell wall thicknesses 
are measured from a series of AFM phase images using ImageJ analysis software. The average 
thicknesses are presented in Figure 3.8 and show that as the amount of PU prepolymer added to 
the core increased, the size of the inner wall, which is presumably a PU layer formed by 
interfacial polymerization, also increased.  The outer wall was most likely a UF layer formed by 
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the in-situ polymerization reaction; the thickness of this outer wall did not change within 
observational scatter (Figure 3.8). In contrast, the UF EPA capsules showed only one capsule 
wall.  
 The thermal stability of PU/UF EPA capsules was analyzed by TGA. Onset temperatures 
of mass loss for these capsules in a dynamic experiment were higher than that of the UF EPA 
capsules (Figure 3.9). The fill content of microcapsules from dynamic TGA experiments can be 
determined, and assuming the mass of the shell wall is negligible (~1%), the mass loss for these 
capsules was > 90%. This behavior was consistent from batch to batch of UF EPA microcapsules 
and PU/UF EPA microcapsules. However, a dynamic TGA experiment does not provide data on 
the amount of core mass lost when the capsules are exposed to high temperatures for an extended 
period of time. Thus, the better experiment to simulate capsule stability during commercial 
polymer processing was an isothermal protocol in which the temperature was ramped from room 
temperature to 180 °C and then held constant at 180 °C for 2 h. Representative traces for EPA 
capsules are shown in Figure 3.10. UF capsules (made without the addition of PU) lost a 
significant amount of mass (ca. 60 %) during the 2 h isotherm, while the PU/UF capsules lost 
only ca. 10%.  
 The mechanical properties of capsule shell walls have been determined through single-
capsule compression experiments for polyurethane,
5,11
 melamine-formaldehyde,
12
 gelatin,
13
 and 
urea-formaldehyde microcapsules.
13,14
 Following the same procedure as described in Keller et 
al.,
14
 single microcapsules were compressed between parallel plates and the load versus 
displacement data was acquired until capsule rupture occurred. Representative plots for a UF 
EPA capsule (represented by the dashed line in the figure) and a PU/UF EPA capsule 
(represented by the solid line) are shown in Figure 3.11a. When capsules of similar diameter are 
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compared, the PU/UF EPA capsules had higher loads to failure than the UF capsules.  
Furthermore, as the amount of PU added to the EPA core increased and average capsule diameter 
was held constant, the failure strength also increased with respect to the total shell wall thickness 
(Figure 3.11b). The dashed line on the plot indicates the failure strength of UF DCPD capsules 
tested by Keller et al. at a similar capsule diameter.
14
  
3.5 Epoxy-Solvent Capsules 
 
 A modified UF encapsulation procedure was used for capsules containing epoxy-solvent 
solutions (Figure 3.12a).
9,15
 The encapsulation method was adapted from that of Brown et al.
2
 
Without modification, the method of Brown et al. produced capsules with a thick layer of porous 
UF on the surface (Figure 3.12b, inset). This thick layer of UF caused agglomerations in solution 
and after filtration when the core material was a solution of resin and solvent. The encapsulation 
shell wall materials and aqueous phase were then each decreased by half, as was the case with 
the PU/UF encapsulation procedure discussed in the previous section of this chapter (Section 
3.4). This proportional decrease maintained the concentrations of the shell wall forming 
materials in the aqueous solution while decreasing the overall mass of shell wall forming 
materials in the solution to form much smoother, free-flowing capsules. These capsule qualities 
are desirable for incorporation into bulk polymer materials. Properties of the epoxy-solvent 
capsules prepared in this study are in Table 3.3.    
 Control of microcapsule core composition is critical for self-healing applications.
10
 In 
particular, healing efficiency for solvent based systems is a function of both the epoxy and the 
solvent delivered to the crack plane and is discussed in more detail in Chapter 4 of this 
dissertation. The presence of both components within the microcapsules was confirmed through 
examination by DSC, and the relative amounts of epoxy and solvent in the liquid core of these 
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capsules were determined by TGA. Representative DSC and TGA scans of the extracted 
microcapsule core are shown in Figure 3.13. In the DSC experiments, two distinct transitions 
characteristic of the epoxy resin and the solvent were observed in the core of the microcapsules. 
The DSC plots contained an endothermic peak representing the evaporation of EPA (minimum 
ca. 240 °C) and an exothermic peak representing the homopolymerization of EPON 828 
(maximum ca. 370 °C).
16
 To confirm that the epoxy to solvent ratio remained constant once the 
solutions were encapsulated, the relative mass ratios of epoxy resin to solvent were characterized 
by TGA. A series of capsule batches at different resin-solvent ratios were prepared and analyzed 
(Figure 3.13b). Excellent agreement was obtained between the expected microcapsule core 
concentrations and the concentrations measured by TGA.   
 Thus, when preparing microcapsules with mixtures of core materials (e.g., solids, PU 
prepolymer, epoxy resin, etc.), the modified UF procedure must be used where the shell wall 
components are halved to produce free-flowing capsules.
9
 However, when pure solvent is the 
only core liquid of the desired microcapsules, the unmodified UF in situ emulsion 
polymerization method is appropriate. When the modified procedure was used for pure solvent 
capsules (a number of different solvents have been attempted), the resulting capsules were 
clumpy and contained residual water since the full shell wall did not properly form.  
3.6 Microcapsule Stability over Time 
 
 One of the main concerns of microencapsulated solvents is the boiling point of the core 
material. This property will greatly affect the thermal stability of microcapsules, which could be 
a limitation depending on the desired application. The stability of solvent microcapsules must be 
increased to survive the temperatures and pressures required for injection molding of the bulk 
thermoplastic material. In previous work,
3
 the average size of microcapsules used to show 
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solvent-based healing was ca. 200 μm in diameter, which is too large for processing of 
composites and other materials. By adjusting the stir rate at which the solvent is encapsulated in 
UF shell walls,
2
 capsules of PhCl, PA, and EPA were prepared with average diameters of         
ca. 50 μm. The thermal stability of these capsules was shown by tracking the mass loss of a 
microcapsule sample during a 2 h isotherm at a given temperature. Figure 3.14 shows that the 
smaller capsules exhibit a lower mass loss during a 2 h isotherm at designated temperatures than 
that for the larger capsules. Since PhCl is the lowest boiling point solvent selected (bp = 132 °C), 
a two-hour isotherm at the temperature of 150 °C is sufficient to show ca. 92% mass loss. 
However, when the same isotherm is repeated with smaller capsules, a mass loss of only 23% is 
observed. Small capsules with EPA as the core solvent were shown to be the most temperature-
stable, showing a mass loss of 40% during a two-hour isotherm at 180 °C.  
 Thermal stability of epoxy-solvent capsules was also investigated by tracking the mass 
loss of a microcapsule sample during a 2 h isotherm at a given temperature. All capsules 
contained a combination of 15 pph EPON 828 resin and a solvent. Figure 3.15 shows that 
capsules with PhCl as the core solvent (828-PhCl) exhibited a minimal mass loss during a 2 h 
isotherm at 100 °C, but lost over 40% of its core material during a 2 h isotherm at 150 °C. 
Capsules with PA as the core solvent (828-PA) were more temperature stable, showing a mass 
loss of less than 5% during a 2 h isotherm at 150 °C. The highest level of thermal stability for the 
resin-solvent combinations investigated was reported using capsules with EPA as the core 
solvent (828-EPA), showing a mass loss of less than 20% during a 2 h isotherm at 180 °C. Only 
during an isotherm at the elevated temperature of 210 °C was more than 50% of the core material 
lost for 828-EPA capsules. 
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 In order to demonstrate the long-term stability of double-walled PU/UF capsules at RT, 
UF EPA and PU/UF EPA capsules were tested after one year by TGA (Figure 3.16). Both 
capsules absorbed water as evidenced from the initial mass loss around 100 °C. The PU/UF EPA 
capsules are still more stable over time since the sharp drop in mass loss occurs at a temperature 
close to the boiling point of EPA, while the UF EPA capsules show a gradual mass loss at 
elevated temperatures. A similar analysis of capsule quality was performed on DCPD capsules in 
Blaiszik et al.
1
 
3.7 Experimental Section 
 Materials: Organic solvents and other chemicals used in experiments were purchased 
from Sigma-Aldrich and used without purification unless otherwise noted. Solvents tested 
include hexanes, xylenes, toluene, iodobenzene (PhI), hexyl acetate (HA), chlorobenzene (PhCl), 
ethyl phenylacetate (EPA), anisole, phenyl acetate (PA), and dichlorobenzene (DCB). Ethylene-
maleic anhydride (EMA) copolymer (Zemac®-400) powder with an average molecular weight of 
400 kDa was graciously donated by Vertellus and used as a 2.5 wt% aqueous solution. EPON 
828 was purchased from Miller-Stephenson. The commercial polyurethane (PU) prepolymer, 
Desmodur® L 75, was purchased from Bayer MaterialScience and used as received. Desmodur® 
L 75 is a prepolymer solution in ethyl acetate with a reported equivalent weight of 315 g and an 
isocyanate content of 13.3 ± 0.4 wt%. PS beads (120 kDa) were purchased from Polysciences, 
Inc. and used as received.  
 Instrumentation: Microcapsule diameters were determined through optical microscopy 
using a Leica DMR Optical Microscope at various magnifications (5X, 10X). ImageJ software 
was used to measure the diameters and an average of at least 100 capsules was used to determine 
the size distribution per batch. A Philips XL30 ESEM-FEG instrument was used to image 
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samples with a 5 kV electron source after sputter-coating with a gold-palladium source. The 
procedure to image capsule shell walls by AFM was based on examination of microtomed 
surfaces as follows: thin films of epoxy samples (EPON 828:DETA) containing 5 wt% 
microcapsules were ultramicrotomed into 300 nm slices and mounted onto glass slides for 
imaging. Atomic force microscopy (AFM) images were acquired on an Asylum Research    
MFP-3D AFM in tapping mode with BudgetSensors Tap300AL tips. Single capsule compression 
testing was performed on a series of microcapsule batches with ≥ 8 capsules from each batch 
tested at a displacement rate of 5 μm/s using a previously described setup and procedure.14 For 
each experiment, a dry microcapsule was compressed between flat parallel plates and imaged 
through a stereo microscope (Nikon SMZ-2T) during testing while the load vs. displacement 
behavior was recorded.   
  Thermal Analysis: Differential scanning calorimetry (DSC) was performed on a 
Mettler-Toledo DSC 821
e
 instrument, calibrated by indium, octane, and zinc standards. Unless 
otherwise indicated, the heating rate was 10 °C/min. For each analysis, the sample (ca. 20 mg) 
was accurately weighed into an aluminum pan, which was hermetically sealed. Routine DSC 
traces recorded heat flow during a heating and cooling cycle over the temperature range          
25–300 °C at a rate of 10 °C/min.   
 Thermogravimetric analysis (TGA) was performed on a Mettler-Toledo TGA851
e 
instrument, calibrated by indium, aluminum, and zinc standards. The mass loss was recorded 
during a heating cycle over the temperature range of 25–650 °C at a constant rate of 10 °C/min 
in an atmosphere of N2. For each experiment, approximately 2–5 mg of sample was accurately 
weighed (± 0.02 mg) into an alumina crucible. For microcapsule core analysis, dried and sieved 
capsules were placed in a syringe filter (Millipore Millex®GP) attached to the end of a syringe. 
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The syringe was depressed to crush the capsules, and the liquid contents of the microcapsules 
were collected in a vial and analyzed using TGA and DSC. To obtain thermal stability curves, a 
mass of dried microcapsules (mean diameter ca. 180 μm) was measured in an alumina crucible. 
The sample mass was recorded during a heating cycle over the temperature range of 25–600 °C, 
with a 2 h isotherm at one of the specified temperatures of 100, 150, 180, and 210 °C.  Sample 
mass loss was defined as the difference between the original mass of the sample and the mass 
after the isotherm. 
 Polyurethane Microcapsules: For the polyurethane encapsulation of PhCl, 30 mL of 
deionized water was added to a 150 mL beaker, which was placed in a heated water bath. To 
this, 7.5 g of 2.5 wt% EMA surfactant was added, and the solution was stirred at varying stir 
rates using a stir blade with a 40 mm diameter. Then, 3 g of the prepolymer synthesized using the 
procedure outlined by Cho et al.
4
 was added to 21.5 g of PhCl. Dissolution of the solid was 
increased by moderately heating the PhCl until a homogeneous solution was observed. This 
organic phase was added to the stirring aqueous solution, creating an oil-in-water emulsion. The 
water bath temperature was ramped to 70 °C at a rate of 6 °C/min. When the temperature of the 
solution reached 50 °C, 3 g of 1,4-butanediol was added directly to the solution, and the beaker 
was covered with aluminum foil to limit evaporation of the solution. After the addition of the 
1,4-butanediol, the encapsulation was left under constant agitation for 2 h. Microcapsules were 
collected by vacuum filtration and washed with two 100 mL aliquots of water. Capsules were left 
overnight to filter. 
 Urea-Formaldehyde Capsule Preparation: Pure solvent microcapsules were prepared 
follow previously reported procedures at various stir rates.
2
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 PU/UF Capsule Preparation: The procedure to yield polyurethane/poly(urea-
formaldehyde) (PU/UF) microcapsules incorporates both shell components in a single batch 
process. In contrast to producing UF microcapsules,
2,9
 the modified procedure combines in-situ 
poly(urea-formaldehyde) microencapsulation with an interfacial microencapsulation
5,17,18
 using a 
commercially available PU prepolymer (Desmodur® L 75) following the procedure outlined in 
Figure 3.5. The amount of Desmodur® L 75, denoted as “X” g in Figure 3.5, was varied in this 
work from 0–8 g. The prepolymer was dissolved into the desired core liquid (60 mL EPA) before 
adding to the stirred emulsion. In preparing PU/UF EPA capsules, the Desmodur® L 75 easily 
dissolved into the solvent. 
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3.9 Figures and Tables 
 
(a)  (b)  
 
Figure 3.1. (a) SEM of synthesized PU PhCl microcapsules; and (b) log-log plot of capsule 
diameter as a function of stir rate for PU PhCl microcapsules. 
 
(a)   
 (b)   
 
Figure 3.2. (a) SEM of synthesized UF PhCl microcapsules; and (b) log-log plot of capsule 
diameter as a function of stir rate for UF PhCl microcapsules. 
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Figure 3.3. Overlaid TGA curves of PhCl capsules with different shell wall materials. 
 
(a)  (b)  
 
Figure 3.4. Representative TGA curves for UF solvent microcapsules.  
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Figure 3.5. Microencapsulation protocol for the preparation of PU/UF capsules. The amount of 
Desmodur® L 75 prepolymer solution (“X”) varied from 0–8 g. Reprinted with permission from 
Reference 6. Copyright 2010, American Chemical Society. 
 
 
 
Figure 3.6. Log-log plot of capsule diameter as a function of stir rate for UF and PU/UF (with 
1.5 g PU) microcapsules containing EPA. Reprinted with permission from Reference 
6. Copyright 2010, American Chemical Society.  
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Figure 3.7. (a) SEM image of an epoxy sample showing the double wall morphology for a 
PU/UF EPA capsule with core material containing 7.5 g PU; AFM phase images with a 3D-
representation of a microtomed epoxy sample showing the capsule shell wall morphology of a 
(b) PU/UF EPA capsule with 7.5 g PU and (c) UF EPA capsule. Reprinted with permission from 
Reference 6. Copyright 2010, American Chemical Society. 
(a)  
 
(b)  (c)  
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Figure 3.8. Average thicknesses of PU/UF EPA capsule shell wall components and total shell 
thickness as a function of the amount of PU added to the EPA core material. At least 30 
measurements using ImageJ were taken using one AFM phase image per data set for the average 
thickness and error bars show one standard deviation of the measurements for one image. 
Reprinted with permission from Reference 6. Copyright 2010, American Chemical Society. 
 
 
  
 
Figure 3.9. Dynamic TGA curves of UF (dashed line) and PU/UF (solid line) EPA capsules 
(average diameter size = 150 μm).  
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Figure 3.10. Representative isothermal TGA curves for UF EPA capsules (dashed line) and 
PU/UF EPA capsules (solid line) plotted versus the temperature profile (25–180 °C at               
10 °C/min), held at 180 °C for 2 h, then heated from 180-600 °C at 10 °C/min). The average 
diameter of the capsules tested was 150 μm and 1.5 g PU was added to the PU/UF capsules. 
Reprinted with permission from Reference 6. Copyright 2010, American Chemical Society. 
 
(a) (b)  
 
Figure 3.11. (a) Representative load-displacement curves for single capsule compression testing 
of EPA capsules. The average capsule diameter size was 125 ± 15 μm and the EPA with PU 
contained 1.5 g of PU. (b) Normalized failure strength of EPA capsules as a function of the 
amount of PU added to the core material. The average capsule diameter size was 57 ± 3 μm for 
the results shown. Reprinted with permission from Reference 6. Copyright 2010, American 
Chemical Society. 
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Figure 3.12. Optical micrographs of capsules immersed in mineral oil showing (a) 828-PhCl 
capsules prepared at 400 RPM and (b) 828-EPA capsules prepared at 275 RPM using improved 
solvent encapsulation method. The inset shows 828-EPA capsules with a thick layer of porous 
UF on the surface prepared at 275 RPM using standard UF encapsulation method.
2
 Reprinted 
with permission from Reference 9. Copyright 2009, Elsevier. 
 
 
 
 
Figure 3.13. (a) Representative DSC and TGA curves for (15 pph 828)-EPA extracted 
microcapsule core solution. (b) TGA determination of EPA and 828 concentrations in 
microcapsules as a function of expected concentrations. Reprinted with permission from 
Reference 9. Copyright 2009, Elsevier.   
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Figure 3.14. Mass loss reported for solvent microcapsules during isothermal TGA experiments 
at the specified temperatures. The mass loss percentages were recorded at the end of a two-hour 
isotherm. 
 
 
 
 
Figure 3.15. Mass loss reported for solvent-based microcapsules (average diameter = 180 μm) 
during isothermal TGA experiments at the specified temperatures. The percentages were 
recorded at the end of a 2 h isotherm at each temperature. Data for pure solvent capsules is 
circled in black on the plot. 
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Figure 3.16. Dynamic TGA curves of UF (dashed line) and PU/UF (solid line) EPA capsules 
(average diameter size = 150 μm) after a year at room temperature. 
 
 
Table 3.1. Representative stir rates and diameter sizes of PhCl microcapsules. 
 
Shell Wall Stir Rate Capsule Diameter
PU 850 150 ± 30 μm
UF 350 153 ± 24 μm
PU/UF (1.5 g PU) 900 51 ± 13 μm  
 
 
Table 3.2. Representative stir rates and diameter sizes of UF solvent microcapsules. 
 
Core Solvent Stir Rate (RPM) Capsule Diameter Boiling Point (°C)
Hexanes 350 236 ± 38 μm 69
Xylenes 500 122 ± 28 μm 138
Toluene 400 123 ± 33 μm 110
Hexyl Acetate 350 171 ± 30 μm 168
Iodobenzene 550 99 ± 39 μm 188
EPA 375 156 ± 53 μm 229
Anisole 550 139 ± 22 μm 154
PA 450 143 ± 24 μm 196
1,2-Dichlorobenzene 400 181 ± 36 μm 180  
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Table 3.3. Representative stir rates of UF microcapsules containing epoxy-solvent solutions. 
 
Core Solvent Stir Rate (RPM) Capsule Diameter
828-PhCl 300 177 ± 61 μm
828-PA 300 161 ± 76 μm
828-EPA 300 143 ± 82 μm  
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CHAPTER 4 
 
AUTONOMIC SOLVENT-BASED HEALING OF EPOXY THERMOSETS
 §
 
 
 
4.1 Introduction 
 
 Epoxy is one of the most common matrix components of polymer composites used in an 
array of applications such as wind turbine blades, aircraft structures, sporting goods, and 
protective coatings.
1,2
 Most epoxy thermosets consist of a two-part system that when cured or 
reacted, creates a glassy polymer network with advantageous mechanical properties such as 
strength and stiffness. However, epoxy matrix composites are inherently brittle and prone to 
matrix microcracking under service loading conditions. Microcracks are often contained deep 
within a structural component making them difficult to detect or repair. Microcrack propagation 
throughout a polymer composite can eventually lead to overall mechanical failure of the 
material. The ability to autonomically repair cracks within a composite is necessary to retain 
structural integrity and extend the lifetime of the material.
3,4
 One of the earliest reports of crack 
healing in an epoxy resin required high temperature conditions greater than 250 °F (121 °C).
5
 
After fracture of the virgin material and subsequent heating of the material above its glass 
transition temperature (Tg), healing was observed due to molecular diffusion and reaction of 
residual functionality.
6-8
 A second example of crack healing at elevated temperatures was 
observed in a matrix consisting of EPON 828 with triethylenetetramine (TETA) where partial 
recovery (ca. 50%) of Izod impact strength was reported.
9
 An extension to promote healing is the 
addition of a solvent to a polymer matrix. Recent research has explored the effects of the solvent 
tetrahydrofuran (THF) in epoxy-amine polymerizations.
10-12
 Palmese et al. found that solvent 
                                                          
§
 Some of the content presented in this chapter was published in Caruso, M. M. et al. Macromolecules 2007, 40, 
8830-8832, Copyright 2007, American Chemical Society; and Caruso, M. M. et al. Adv. Funct. Mater. 2008, 18, 
1898-1904, Copyright 2008, Wiley InterScience. 
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molecules can influence the epoxy-amine reaction chemistry, leading to inhomogeneous 
thermosetting networks.
12
 Additionally, the presence of THF increased the free volume in the 
matrix. Furthermore, the Palmese group reported the healing capability of an epoxy-amine 
thermoset at temperatures above the Tg of the material
10
 and at room temperature (RT) based on 
a Diels-Alder reaction.
13
 
 In this chapter, we describe the first use of solvents to heal cracks in thermoset materials 
at RT in an autonomic fashion.
14
 Our objective was to demonstrate that cracks formed in epoxy-
based thermoset materials can autonomically be healed with encapsulated organic solvents, 
preventing further crack propagation, while recovering the material’s original mechanical 
integrity (Figure 4.1). This chapter presents the fracture data for a variety of organic solvents 
used as inexpensive healing agents, and an improved self-healing system with epoxy-solvent 
microcapsules.  
4.2 Solvent In Situ Testing 
 
 To date, nine organic solvents have been successfully encapsulated with the in situ 
emulsion polymerization method
17
 and these capsules were discussed previously in Chapter 3 of 
this dissertation. Each of these capsules was incorporated into short-groove TDCB specimens to 
determine the degree of healing possible from the solvents. It was expected that they would 
follow the trend shown in Figure 2.13 for the reference tests discussed in Chapter 2 of this 
dissertation. As shown in Table 4.1, the in situ results (within error) generally mimic the healing 
trend of the solvent reference tests from Figure 2.13.  
 The exceptions would be the lower in situ healing efficiencies reported for anisole and 
toluene, and a higher in situ efficiency for xylenes when compared to their respective reference 
test results. The reason for these discrepancies is a result of the microcapsule quality for each 
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solvent. In order to be consistent throughout these experiments, the average capsule size and 
loading (wt%) was held constant for each set of samples prepared with solvent microcapsules. 
The anisole capsules were observed to lose core material over time at RT, thus were not as full as 
other solvent microcapsules which led to the lower observed healing efficiency for this solvent. 
Stability of these capsules was discussed in detail in Section 3.6 of this dissertation. Toluene 
capsules have a lower density since the core material, the primary capsule component by volume, 
has a lower density than the other solvents. Therefore, when these capsules were incorporated 
into the TDCB samples (by wt%), the amount of capsules per volume was much larger than the 
other samples. Due to the increased amount of capsules in these samples, the matrix volume 
available for swelling and further cross-linking (solvent-promoted healing) was decreased and a 
lower healing efficiency was reported. The reason for increased healing observed for samples 
containing xylenes microcapsules is currently unknown. When these capsules were embedded in 
an epoxy matrix, they released more solvent compared to other solvent capsules. One can refer to 
Chapter 3 of this dissertation for complete characterization of all the solvent microcapsules used 
in this study. 
4.3 Self-Healing with Epoxy-Solvent Microcapsules 
 
4.3.1 Full Recovery of Fracture Toughness 
 
 It was discovered that a way to further improve the healing ability of the solvent-based 
system was to use an epoxy monomer co-encapsulated with solvents (Figure 4.2). Several groups 
have reported the success and ease of making microcapsules containing epoxy resins.
20-23
 We 
selected the epoxide functionality as a coencapsulant to test our mechanistic hypothesis that 
solvents swell the epoxy matrix and transport the residual amines in the matrix sol phase (where 
solids are present in the discontinuous phase), making them available for further curing reactions 
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in the crack plane. As reported below, an improvement in the healing efficiencies (ca. 100%) is 
observed for samples containing epoxy-solvent microcapsules when compared to healing 
efficiencies (ca. 82%) for the system that consisted of microcapsules containing solvent only.
14
 
The section demonstrates that additional reactive thermosetting material is deposited in the crack 
plane from the embedded microcapsules, which presumably is the reason for the improved 
healing response. 
 Given our proposed mechanism that sol-extracted residual amine functionality present in 
a partially cured epoxy matrix is the dominant contributor to the chemistry of solvent-based self-
healing systems (Chapter 2), it was reasoned that the delivery of excess epoxide functionality to 
the matrix might facilitate the repair process. In an effort to test this hypothesis, microcapsules 
were initially prepared containing varying amounts of epoxy monomer (EPON 828) dissolved in 
PhCl. A first attempt incorporated a solution of 20 wt% epoxy in PhCl into UF microcapsules. 
Healing efficiency was measured in an EPON 828:DETA matrix using short-groove TDCB 
specimens.
14,17,19
 A lower healing efficiency was measured compared to prior samples containing 
pure solvent capsules (η20% epoxy = 0.30 vs. ηchlorobenzene = 0.82).
14
 From these initial studies, it was 
further reasoned that the decreased healing behavior may have resulted from excess epoxy 
compared to the amount of residual amines in the sol phase and matrix.  Indeed, by increasing 
the amine content of the matrix (20 pph instead of the stoichiometric 12 pph) and incorporating 
these same microcapsules, improved healing was observed (η = 0.81 ± 0.13) relative to the prior 
results (η20% epoxy = 0.30). Likewise, it was expected that decreasing the amount of epoxy 
monomer in the microcapsules might also provide more desirable results for the epoxy matrix 
fixed at the original stoichiometry. UF microcapsules (average diameter = 200 μm) were 
prepared containing a core solution of 5 wt% epoxy-PhCl.
24
 In situ fracture testing with short-
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groove TDCB specimens embedded with 5–20 wt% loadings of the epoxy-containing 
microcapsules demonstrated healing efficiencies up to 100% (Figure 4.3). As shown in this 
figure, the healing efficiency increased proportionately with capsule loading. Complete recovery 
of fracture toughness was obtained at 15 wt% capsule loadings and above. A low 5 wt% loading 
of these epoxy-PhCl capsules exhibited healing efficiencies of ca. 80%. In comparison, this same 
degree of healing was previously achieved with a much higher loading (20 wt%) of pure PhCl 
capsules.
14  
 
Full recovery of fracture toughness can be explained within the context of the postulated 
mechanism for solvent healing previously discussed in this dissertation (Chapter 2). When the 
microcapsules are ruptured by an incoming crack, the solvent locally swells the matrix, allowing 
accessibility of residual amines and further crosslinking with residual epoxide functionality. 
However, the additional epoxy delivered to the crack plane from the ruptured capsules increases 
the availability of reactive functional groups to undergo additional crosslinking reactions and 
helps bond new thermoset material to the original matrix interface. This newly formed polymer 
was identified by scanning electron microscopy (SEM) on the crack plane surface of healed 
samples (Figure 4.4), and was not previously observed on the crack faces of samples containing 
pure solvent capsules.
14 
Since this new thermoset consists of the same epoxy material as the 
matrix, it was difficult to distinguish between the original matrix and the new thermoset material.  
 Thus, surface characterization techniques were used to confirm that the healed film 
formed in the crack plane of fracture specimens was attributed to the encapsulated epoxy curing 
on the surface. Specifically, a brominated epoxy (EPON 1163) shown in Scheme 4.1 was 
encapsulated in the solvent PhCl using the UF in situ polymerization method at a concentration 
of 0.447 M (epoxide molar ratio equivalent to 13% by weight of EPON 828). Short-groove 
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TDCB fracture samples were prepared with 15 wt% capsules and demonstrated comparable 
healing efficiencies to the EPON 828-PhCl system (η = 0.81 ± 0.21). The fracture surfaces were 
analyzed by SEM to reveal the healed film (Figure 4.5a). Previously, this film was 
indistinguishable from the matrix, but by using the brominated epoxy in microcapsules, the film 
is clearly visible by energy dispersive x-ray spectroscopy (EDS) mapping of the fracture surface 
(Figure 4.5b). Additionally, time-of-flight secondary ion mass spectrometry (TOF-SIMS) was 
used to confirm the presence of a bromine-containing epoxy film on the fracture surface. This 
technique has previously been used on epoxy-amine surfaces to characterize the chemical 
components.
25
 Results produced from the spectrometer indicate a high degree of bromine 
isotopes (m/z = 79 and 81) on the entire surface (Figure 4.6), confirming release of the 
brominated epoxy monomer from the microcapsules leading to formation of a new film on the 
surface. 
4.3.2 Alternative Healing Solvents  
Given the preliminary success of the epoxy-chlorobenzene system, we sought to expand 
the scope of solvents for self-healing materials, particularly to less-toxic solvents. Aromatic 
esters emerged as possible, environmentally-friendly solvent alternatives to chlorobenzene. 
Microcapsules containing mixtures of esters have been prepared previously for application in the 
fragrance industry.
26,27
 Phenylacetate (PA, dielectric constant εr = 6.9) and ethyl phenylacetate 
(EPA, εr = 5.4) were identified as candidates for solvent-based healing in an epoxy material since 
their polarities are similar to that of chlorobenzene (εr = 5.6).
28
 Reference tests in which the 
acetate solvents were manually injected into crack plane of TDCB long-groove specimens
29
 were 
performed and exhibited healed peak loads similar to that of chlorobenzene (Table 4.2). 
Microcapsules were then prepared with PA and EPA cores
30
 and embedded in short-groove 
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TDCB specimens. Mechanical testing of these samples showed significant fracture toughness 
recoveries 24 h after the initial fracture event when compared to the healing performance of 
chlorobenzene. Furthermore, epoxy monomer was co-encapsulated with these acetate solvents in 
the same manner as PhCl and the healed peak loads for reference and in situ tests are reported in 
Table 4.2. EPA being the less toxic solvent,
31
 was selected to coencapsulate with epoxy 
monomer for further investigation. As an additional note, since EPA has a higher boiling point, it 
forms better quality microcapsules than PA and is a more reliable solvent to use for preparing 
robust microcapsules. 
4.3.3 Multiple Healing Events  
Interestingly, it was found through experimental evaluation that samples containing 
epoxy-solvent microcapsules could undergo multiple repair events. After the first healing event, 
samples were retested after 7 days or longer and reported high healed peak loads (Figure 4.7). 
Due to the RT curing of this epoxy matrix being complete after 7 days at RT,
32
 one week was the 
set time frame to let the sample heal before re-testing. Repeated testing of these samples showed 
a decrease in the healed peak load with each subsequent healing cycle. A maximum of 3–5 
rehealing events were observed over a series of experiments for both solvent systems. A possible 
explanation for this repeated healing is that when re-damaging a specimen, there was evidence of 
crack branching as shown in Figure 4.8. Deviated cracks through the sample ruptured additional 
microcapsules and released more healing agent into the new crack plane. Similar behavior had 
been reported for a self-healing elastomeric system where 100% healing efficiencies were also 
reported 24 h after the initial virgin tear.
33
 The release of each solvent from the embedded 
microcapsules during the fracture event was detected by their characteristic smell, which was a 
way to confirm new capsule rupture when testing the same sample multiple times.  
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However, healing efficiency decreased with increasing number of healing cycles. A 
systematic study was conducted using EPA and Epoxy-EPA microcapsules (Figure 4.9) 
embedded in the epoxy matrix. After the initial fracture/healing cycle of the TDCBs, the 
specimens were allowed to heal at RT, and then tested again to determine how many healing 
events would occur and how the healing efficiencies were affected over time for these two 
systems (Figure 4.10). The goal was to achieve multiple releases (at least two) of healing 
compounds from the same area. The TDCB specimens were tested at various time intervals, from 
30 min to 24 h (i.e. maximum healing efficiency). Both types of capsules demonstrated the 
ability to heal the epoxy matrix multiple times, with the epoxy-EPA generally providing a higher 
retention of healing efficiency. For shorter time frames (30 min and 4.5 h), the additional healing 
events were attributed to the fact that EPA was still present, (i.e. did not have a chance to 
evaporate from the crack plane) thus making it available for localized swelling of the epoxy and 
subsequent cross-linking reactions. At longer time intervals (12 and 24 h), the released solvent 
was not evident on the epoxy crack plane because it had completely evaporated after almost 
completely healing the sample. Thus, the further healing events occurred due to slight deviation 
of subsequent cracks from the virgin crack, provoking the rupture of previously unbroken 
capsules. As expected, the healing efficiencies decreased with increasing number of cycles, the 
result of local depletion of healing agent and reduction in residual amines available for cross-
linking. Even after three healing cycles every 24 h, the sample of epoxy-EPA capsules still 
retained close to 100% healing efficiencies. 
4.3.4 Optimization of Epoxy Delivered and Crack Separation for Self-Healing 
 Given the important role of stoichiometry for epoxy-amine reactions, the healing 
response as a function of mass of epoxy delivered was determined, while keeping the amount of 
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solvent constant. The total mass of fluid healing agent delivered to the crack plane (MHealing Agent) 
was calculated according to the derivation of Rule et al.
19
 as 
 MHealing Agent =  ρs φ Dc  (1) 
where ρs is the density of the matrix, φ is the mass fraction of microcapsules, and Dc is the mean 
diameter of the microcapsules. Equation (1) was modified to separate the mass of healing agent 
delivered (mg·cm
-2
) into the two components used in our capsules, 
 MEpoxy = ρs φ Dc ξ      (2) 
 MSolvent = ρs φ Dc (1 - ξ)  (3) 
where the quantity ξ represents the weight fraction of epoxy resin in the capsules. These 
equations are used with capsules of varying ξ values to maintain a constant delivery of epoxy or 
solvent. In our experiments, different amounts of PhCl capsules and epoxy-PhCl capsules were 
used to make fracture specimens and the results are shown in Figure 4.11a. Twenty-four hours 
after the initial virgin fracture (first healing event), the samples were tested for restoration of 
fracture toughness and healing efficiencies were calculated. The healing efficiencies begin to 
plateau when the epoxy delivered is about 0.1 mg·cm
-2
 then decrease at higher epoxy values, 
demonstrating that only a small amount of epoxy is required to react with residual amine 
functionality in the matrix. This amount of epoxy (0.1 mg·cm
-2
) was defined as the optimized 
system used in later studies presented in this chapter. In an effort to quantify the healing response 
of the epoxy-EPA microcapsule system, the mass of epoxy delivered was varied while keeping 
the amount of EPA solvent constant (Figure 4.11b). As observed with PhCl and previously 
mentioned in Section 4.3.3, subsequent repair events are shown for the system containing epoxy-
EPA microcapsules. These results demonstrate that alternative solvents (e.g., EPA and others) 
can be used to replace PhCl in future self-healing products. 
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Control experiments for the epoxy-solvent microcapsule mixtures were conducted using 
other solvent combinations. Hexyl acetate (εr = 4.4)
27
 was identified as a solvent that could be 
encapsulated using the UF in situ polymerization method but was too nonpolar to demonstrate a 
solvent healing effect in an epoxy matrix. Hexyl acetate did not demonstrate any degree of 
healing from reference tests or from in situ testing with prepared UF hexyl acetate capsules 
(η = 0). Thus, microcapsules containing 13% epoxy-hexyl acetate were prepared, incorporated 
into fracture specimens, and exhibited only a minimal amount of fracture toughness recovery            
(η = 0.20 ± 0.14). This result is most likely due to the epoxy released from the capsules 
reactiving with surface amine groups. At the opposite extreme, microcapsules containing 80% 
epoxy-hexyl acetate ruptured upon crack damage, but released too much epoxy into the crack 
plane to provide any recovery of fracture toughness (η = 0) as shown in Figure 4.12. These 
control experiments elucidated the contribution of both the appropriate solvent and optimal 
amount of epoxy to yield high healing efficiencies. 
 As discussed above, Rule et al. conducted a systematic study to determine the necessary 
amount of required healing agent in samples based on microcapsule size, amount, and crack 
volume.
19
 Crack separations were measured to be about 26 μm for long-groove TDCBs samples, 
and about 3 μm for short-groove TDCBs.19 Since intimate contact between the crack faces is 
necessary for optimal solvent-based healing, mostly short-groove specimens have been used for 
the studies presented in this chapter. However, there is no reported study on crack separations 
distances between the short and long groove (3–26 μm) specimens.  Therefore, a study was 
carried out to examine this variable and how it affected both healing efficiency and potential for 
multiple healing events with only epoxy-EPA microcapsules as the supplied healing agent 
(Figure 4.13). It should be noted that EPA was not selected for this study because it has lower 
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healing efficiencies than the epoxy-EPA system, and no secondary healing event. Short-groove 
TDCB specimens were employed in this study, but the crack propagated all the way through the 
specimen (breaking it in half) and then the two halves were realigned to heal at RT. After 
healing, the crack separation for each sample was measured by optical microscopy. The data 
shows that crack separations greater than 15 μm resulted in poor healing efficiencies while 
distances less than 15 μm resulted in higher healing efficiencies. In general, if the crack 
separation is less than 15 μm and the initial healing efficiency is at least 50%, then one could 
expect to observe multiple healing events occur with this self-healing system. This concept can 
be extended to composites when predicting the degree of healing for an epoxy-EPA system 
depending on the crack damage volume.  
4.4 Factors affecting Self-Healing: Time and Temperature  
 
 The time scale and environmental stability of self-healing are important factors to 
determine when developing solvent-based systems. Self-healing results presented up to this point 
of the dissertation have been consistently reported for samples tested 24 h after the initial virgin 
fracture at RT. The kinetics of the epoxy-amine reaction were presented in Chapter 2 of this 
dissertation, and indicated that the highest degree of polymerization is reached between 10–12 h 
reaction time. Thus, it is expected that the time scale of solvent-based healing should reach a 
maximum before 24 h. In order to empirically prove this concept, multiple sets of short-groove 
TDCB specimens with EPA and epoxy-EPA capsules were prepared. The amount of solvent 
delivered to the specimen crack plane was held constant at 3.15 mg·cm
-2
 and the amount of 
epoxy delivered was held constant at 0.1 mg·cm
-2
 (optimized system) – these values were 
selected based on the highest healing efficiencies reported at this data point (Figure 4.11b). 
Samples were tested for healing response at various times and the results are shown in Figure 
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4.14. Both systems show a significant increase in healing efficiency within the first hour            
(η = 0.40), followed by a steady increase until the healing plateaus at 24 h. The epoxy-EPA 
system is more effective than EPA alone in the first 24 h of healing, especially beyond 8 h. This 
recovery of fracture toughness can be explained within the context of the postulated mechanism 
for solvent healing.
24
 When the microcapsules are ruptured by an incoming crack, the EPA 
solvent locally swells the matrix, allowing accessibility of residual amines and further cross-
linking with residual epoxy functionality. However, when additional epoxy is delivered with the 
EPA solvent, this improves the likelihood for additional cross-linking reactions and helps bond 
new thermoset material to the original matrix interface, resulting in increased healing 
efficiencies.   
 Given the successful results after 24 h of healing for the epoxy-solvent system, it was 
important to test its stability over time through aging studies. Short-groove TDCB specimens 
were prepared with 15 wt% microcapsules of epoxy-PhCl, epoxy-PA, and epoxy-EPA 
(undamaged) and exposed to ambient conditions for varying time periods (25 °C, 40% relative 
humidity). After specified time periods, the samples were precracked and fractured. The degree 
of healing measured 24 h after the initial fracture event was reported in terms of healing 
efficiencies (Figure 4.15). Within experimental scatter, the healing efficiencies decrease only 
slightly over the time period of a month. This behavior was most likely a result of less available 
residual epoxide and amine groups in the epoxy matrix. 
 When considering long-term performance of this system, the two contributing factors of 
time and exposure temperature will affect the self-healing behavior. Short-groove TDCB 
samples were prepared with only epoxy-EPA capsules to predict stability at RT and the results of 
these experiments is shown in Figure 4.16. Additional samples were prepared with epoxy-PhCl 
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and epoxy-EPA capsules and exposed to elevated temperatures over a month time period        
(35, 50 °C) and tested at various time intervals (Figure 4.17). The decrease in healing over time 
indicates a limitation of this self-healing chemistry. The cross-linking reactions between the 
epoxy and amine components that continue over time and at higher temperatures decrease 
residual functional groups available for latent reactivity in the presence of solvent. Although the 
capsules still release 1.5 years after the initial preparation of the self-healing epoxy, the released 
healing agents no longer react with the residual matrix components to demonstrate recovery of 
mechanical properties. An alternative, more elegant approach to solvent-based self-healing that 
can be applied to fully-reacted epoxy materials is presented in Chapter 6 of this dissertation. 
4.5 Experimental Section 
 
 Materials: Organic solvents for the reference tests and encapsulation experiments were 
purchased from Fisher Chemicals and used without purification. Solvents tested included 
cyclohexane, hexanes, xylenes, toluene, iodobenzene, chlorobenzene (PhCl), ethyl phenylacetate 
(EPA), anisole, phenylacetate (PA), tetrahydrofuran (THF), o-dichlorobenzene (DCB), 
methylene chloride (CH2Cl2), nitrobenzene, N-methyl pyrrolidone (NMP), dimethyl acetamide 
(DMA), dimethyl formamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile (CH3CN), 
butanol, ethanol, formamide, and deionized water. EPON® 828, EPON® 862, EPON® 1163, 
EPICURE 3046 and EPICURE 3274 were purchased from Miller-Stephenson, and 
diethylenetriamine (Ancamine DETA) and tetraethylenepentamine (Ancamine TEPA) curing 
agents were received from Air Products.   
 Preparation of Hollow UF Capsules: 27.5 g of formalin (37 w/v% formaldehyde) was 
added to a 150 mL beaker and triethylamine was added drop-wise until the pH of the solution 
reached pH 8.0. Then the solution was heated at 70 °C in a water bath and 10.25 g urea was 
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stirred into the solution until all solids dissolved. The mixture was then heated for 1 h at 70 °C. 
At a separate hotplate set to ramp to 35 °C, 50 mL water and 12.55 mL 2.5% EMA surfactant 
were added to a 400 mL beaker. The heated prepolymer mixture was quickly added to this 
emulsion and agitated with a mechanical stirrer at the desired RPM (at least 1000 RPM). When 
the bath reached 30 °C, the pH was adjusted to 2.5 with formic acid. When the bath reached 34 
°C, 25 mL of warm deionized water was added to the stirring mixture and 4x15 mL of deionized 
water was added to the beaker at 15 min increments over the first hour. The beaker was covered 
with foil and mixture was left for an additional 4 h at 35 °C for capsules to form. Solid UF 
particles settled to the bottom while hollow capsules floated on the top of the water. These 
hollow capsules were then filtered and washed with water. 
Mechanical Testing: Fracture testing followed previously reported protocols
19,29
 using 
tapered double-cantilever beam (TDCB) samples prepared at the following epoxy:amine ratios 
(by weight) and poured into silicone rubber molds: 100:12 parts per hundred (pph) mixture of 
EPON 828:DETA, 100:50 pph mixture of EPON 862:EPICURE 3274, and 100:16 pph mixture 
of EPON 828:TEPA. The resins underwent the same cure cycle of 24 h at RT, followed by 24 h 
at 35 °C. Other than short-groove reference tests with 5 μL of PhCl manually injected into the 
crack plane of the EPON 862:EPICURE 3274 and EPON 828:TEPA matrices, EPON 828:DETA 
was used as the matrix for all experiments. After inserting a precrack with a sharp razor blade 
into the groove of the sample, the TDCB specimens were pin-loaded and tested to failure using 
an Instron load frame under displacement control at a rate of 5 μm/s. Long-groove TDCB 
specimens contained a 47 mm long molded groove, while the short-groove TDCB specimens had 
a 25 mm long molded groove.
19
 For the long-groove TDCB reference tests, 25 μL of each 
solvent was injected onto the crack plane, the two sides were realigned, and allowed to heal for 
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24 h at RT. The healed TDCB samples were again loaded to failure and the load-displacement 
curve was recorded. All healed samples were tested after 24 h, unless otherwise stated. In situ 
healing was assessed in a similar manner as reference specimens, except that solvent was present 
in microcapsules (at 15 wt% of the matrix) dispersed throughout the central insert section of the 
short-groove TDCB samples (64 mm in length). Short-groove TDCB specimens were used for  
in situ healing because the average crack face separation is reduced from 26 μm (long-groove 
TDCB specimens) to 3 μm near the pin holes of the sample, allowing for intimate contact 
between the crack faces.
19
 Healing efficiencies were defined as the ratio between the healed and 
the virgin fracture toughness,
4 
which simplifies to: 
    η = Phealed/Pvirgin            (4) 
where P and η represent the fracture peak loads of each sample and the healing efficiency, 
respectively.   
 Temperature Study: Short-groove TDCB specimens comprised of EPON 828:DETA at 
100:12 pph with 15 wt% microcapsules of 13 wt% EPON 828-solvent solution (average 
diameter  = 180 μm) were prepared and underwent a curing cycle of 24 h at RT (22 °C) and 24 h 
at 35 °C. The samples were put into a MicroClimate
®
 Environmental Chamber (Cincinnati Sub-
Zero Products) at 40% relative humidity and various temperatures (25 °C, 37 °C, 50 °C) for the 
following time periods: 7, 15, and 30 days. Following this time, the samples were precracked and 
virgin peak loads were recorded. The samples were healed at RT and re-tested 24 h after the 
initial fracture event. Healing efficiencies were measured to compare the virgin peak loads to the 
healed peak loads. 
 Aging Study: Short-groove TDCB specimens comprised of EPON 828:DETA at 100:12 
pph with 15 wt% microcapsules of 13 wt% EPON 828-solvent solution (average diameter  =  
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180 μm) were prepared and underwent a curing cycle of 24 h at RT and 24 h at 35 °C.  Solvents 
tested were PhCl, EPA, and PA. The samples were left at RT (relative humidity ca. 40%) for the 
following time periods: 7, 15, and 30 days. Following this time, the samples were precracked and 
virgin peak loads were recorded. The samples were re-tested 24 h after the initial fracture event 
and healing efficiencies were measured to compare the virgin peak loads to the healed peak 
loads. 
 Materials Characterization: Environmental scanning electron microscopy (ESEM) 
images of the fracture surfaces were taken on a Philips XL30 ESEM-FEG instrument after a 
sputter-coating treatment with a gold-palladium source. Elemental mapping was conducted on 
the surface by EDS (attached to the SEM) with a 20 kV electron source and spot size of 2.6 nm. 
Two mm thick samples of the fracture plane were sputtered coated (Au/Pd) and introduced into 
the TOF-SIMS (Physical Electronics TRIFT III) sample chamber. The instrument is equipped 
with a triple-focusing time-of-flight mass spectrometer and a pulsed 22kV Au metal ion source 
(average current 2 nA). Static SIMS conditions were employed using a pulsed Au
+
 primary ion 
beam rastered over an area of 500 x 500 μm2 at a bunched mode with the contrast diaphragm in 
and charge compensation enabled. SIMS spectra were acquired over a mass range of 1–2000 Da 
in the negative mode for 10 min. The mass calibration of negative ions was internally performed 
by using H
-
, O
-
, Cl
-
, Br
-
, Au
-
. 
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4.7 Figures and Tables 
 
 
 
Figure 4.1. Simplified self-healing polymer system containing microencapsulated solvent.  Upon 
crack damage, the microcapsules release their liquid core material into the crack plane and heal 
the crack.
13
 Reprinted with permission from Reference 14. Copyright 2007, American Chemical 
Society. 
 
 
 
Figure 4.2. 3D representation of polymeric microcapsule rupturing to release the healing agent.  
The liquid is comprised of an epoxy monomer, EPON 828, whose chemical structure is shown in 
the inset and solvent (depicted as the purple liquid) into a damaged fracture plane. Reprinted 
with permission from Reference 24. Copyright 2008, Wiley InterScience. 
 
 
 
Figure 4.3. Healing efficiency for epoxy-chlorobenzene microcapsules as a function of 
microcapsule loading (by wt%).  The reference test point is for a manually injected solution of   
5 wt% epoxy-PhCl (5 μL) and error bars indicate one standard deviation based on 5 samples. 
Reprinted with permission from Reference 24. Copyright 2008, Wiley InterScience. 
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Figure 4.4. SEM image of the healed film on the fracture surface of an EPON 828:DETA 
specimen containing 5% epoxy-PhCl microcapsules (10 wt% capsule loading). Reprinted with 
permission from Reference 24. Copyright 2008, Wiley InterScience. 
 
(a)  (b)  
 
Figure 4.5. (a) SEM image of the fracture surface showing new film formed on the healed crack 
plane. (b) SEM image with an elemental map of the same area (from EDS) showing oxygen in 
red and bromine in yellow. Reprinted with permission from Reference 24. Copyright 2008, 
Wiley InterScience. 
 
 
 
Figure 4.6. Mass spectra of the healed fracture surface of an epoxy sample with a 500 x 500 μm2 
area scanned during a TOF-SIMS experiment. 
87 
 
(a) (b)  
 
Figure 4.7. Representative load-displacement curves for short-groove TDCB specimens 
containing 15 wt% (a) epoxy-PhCl and (b) epoxy-EPA microcapsules showing multiple healing 
events 24 h (first heal) and 7 days (second heal) after initial crack damage. Reprinted with 
permission from Reference 24. Copyright 2008, Wiley InterScience. 
 
 
 
Figure 4.8. Short-groove TDCB specimen with epoxy-PhCl capsules and inset shows an SEM 
image of the virgin crack through the material and subsequent cracking through healed material. 
Reprinted with permission from Reference 24. Copyright 2008, Wiley InterScience. 
 
(a)  (b)  
 
Figure 4.9. Representative optical micrographs of (a) pure EPA capsules and (b) 3 wt% EPON 
828 in EPA capsules used for testing of multiple healing events and the time study. 
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(a)  (b)  
 
Figure 4.10. Self-healing results for multiple healing events at various time intervals for (a) EPA 
and (b) Epoxy-EPA microcapsules. The amount of solvent delivered to the damage site was held 
constant at 3.15 mg·cm
-2
 and the error bars indicated one standard deviation based on at least 
three TDCB specimens for each data point. 
 
 
(a) (b)  
 
Figure 4.11. Healing efficiencies reported for in situ short-groove TDCB specimens with varied 
amounts of epoxy delivered to the crack plane with the amount of (a) PhCl  and (b) EPA solvent 
held constant at 3.15 mg·cm
-2
. Recovery of fracture toughness after the first healing cycle was 
measured 24 h after the initial fracture. Subsequently, samples were allowed to heal for 7 days 
for the second healing cycle and then retested for fracture toughness recovery. Error bars 
represent one standard deviation based on 5–10 samples. Reprinted with permission from 
Reference 24. Copyright 2008, Wiley InterScience.  
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Figure 4.12. SEM image of healed crack plane from an in situ sample with 80% EPON         
828-hexyl acetate capsules (15 wt% loading). The microcapsules have ruptured to produce an 
excessively thick epoxy film on the surface (shown in the inset) that prevents the crack faces 
from joining to heal the epoxy. Reprinted with permission from Reference 24. Copyright 2008, 
Wiley InterScience. 
 
 
 
Figure 4.13. Variation in healing efficiency versus crack face separation for short-groove TDCB 
samples containing EPON 828:EPA microcapsules. The amount of solvent delivered to the 
damage site was held constant at 3.15 mg·cm
-2
 while the amount of epoxy delivered was held 
constant at 0.1 mg·cm
-2
. Samples were retested for healing 24 h after the initial fracture.   
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Figure 4.14. Healing efficiency of EPA and EPON 828-EPA microcapsules over the first 24 h 
after initial fracture. The amount of solvent delivered to the damage site was held constant at 
3.15 mg·cm
-2
 while the amount of epoxy delivered was held constant at 0.1 mg·cm
-2
. The error 
bars indicate one standard deviation based on 3 samples. 
 
 
 
Figure 4.15. Stability of EPON 828-solvent capsule systems (15 wt% loading) shown over time 
for samples exposed to ambient conditions before fracturing. Healing data was acquired after    
24 h from fracture event and error bars represent standard deviation based on 5 short-groove 
TDCB specimens. Reprinted with permission from Reference 24. Copyright 2008, Wiley 
InterScience. 
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Figure 4.16. Long-term self-healing results of epoxy-EPA capsule system (15 wt% loading) 
shown for over 1.5 years when samples were exposed to ambient conditions before fracturing. 
Healing data was acquired after 24 h from fracture event and error bars represent standard 
deviation based on 5 short-groove TDCB specimens. The best-fit line shows the exponential 
decay (equation given).  
 
 
(a)  (b)  
 
Figure 4.17. Stability of (a) epoxy-PhCl and (b) epoxy-EPA capsule systems (15 wt% loading) 
shown over time for samples exposed to various temperatures (40% relative humidity) before 
fracturing. Healing tests were conducted at RT and data was acquired after 24 h from fracture 
event. Error bars represent one standard deviation based on 5 short-groove TDCB specimens. 
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Table 4.1. Summary of healed fracture peak loads (in Newtons) observed for in situ samples 
embedded with solvent-filled capsules. Average peak loads and one standard deviation based on 
4-6 samples are given for each data set. Short groove TDCB specimens were used for these 
experiments. 
 
Solvent Healed Peak Load [N]
[a]
 
Hexanes 0 
Xylenes 
Toluene 
Iodobenzene 
38.2 ± 17.8 
12.2 ± 3.5 
103.5 ± 14.6 
EPA 100.9 ± 4.7 
PhCl 82.6 ± 8.2 
Anisole 55.7 ± 10.8 
PA 103.1 ± 10.8 
DCB 70.4 ± 7.7 
Air (hollow) 0 
[a]
 The in situ data shows healing based on 15 wt% capsule loading in an 828:DETA matrix of pure 
solvent capsules. 
 
Table 4.2. Summary of healed fracture peak loads (in Newtons) observed for PhCl, PA and EPA 
solvents. Reprinted with permission from Reference 24. Copyright 2008, Wiley InterScience. 
 
Solvent Long-groove 
TDCB [N]
[a]
 
Solvent 
In situ [N]
[b]
 
Epoxy-solvent 
Reference [N]
[c]
 
Epoxy-solvent 
In situ [N]
[d]
 
Chlorobenzene 66.4 ± 13.9 78.5 ± 12.3 55.7 ± 6.2 99.3 ± 14.9 
Phenyl Acetate 66.9 ± 11.7 103.1 ± 10.8 69.5 ± 11.0 83.8 ± 6.6 
Ethyl Phenylacetate 70.2 ± 10.4 48.2 ± 5.8 70.3 ± 5.0 83.8 ± 9.2 
Average peak loads and one standard deviation based on five 828:DETA epoxy samples are given for 
each data set. 
[a]
 The solvent reference test with manually injected (25 μL) solvent using long-groove 
TDCBs, while all other tests were done using short-groove TDCBs. 
[b]
 The in situ data based on 15 wt% 
pure solvent capsules (average diameter = 180 μm). [c] The epoxy-solvent reference test using 5 μL 
injected solution of 13% 828-solvent. 
[d]
 In situ tests with 13% 828-solvent capsules                       
(average diameter = 180 μm).  
 
 
 
 
Scheme 4.1. Chemical structure of brominated epoxy (Miller-Stephenson) used in this study. 
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CHAPTER 5 
 
FATIGUE PERFORMANCE OF SOLVENT-BASED HEALING AGENTS 
*
 
 
 
5.1 Motivation 
 
 Dynamic healing under cyclic fatigue is an important example of self-healing polymeric 
materials that highlights the interplay between the kinetic processes that are operative during the 
healing process.
1,2
 During fatigue, the crack tip propagates at a kinetic rate that is largely dictated 
by the mechanical environment (frequency, stress amplitude, etc.). In opposition to this, healing 
occurs at some other kinetic rate that accounts for characteristic times needed for rupture of the 
microcapsules, transport of the healing agent, mixing with the catalyst, and initiation and 
polymerization of the healing agent. 
 Of these healing processes, the polymerization stage is largely dominant under normal 
conditions. When mechanical kinetics dominate, damage propagates so quickly that there is not 
sufficient time for healing to occur, and degradation of the material proceeds largely unimpeded. 
Conversely, when healing kinetics dominate, the damage proceeds so slowly that it is 
immediately suppressed and fatigue cracks can be permanently arrested, thereby imparting what 
appears to be a fatigue threshold in self-healing epoxy.
3
 The ultimate challenge is to engineer 
systems in which the rate of damage accumulation is exactly balanced by the rate of healing so 
that the material systems remain in a stable configuration. 
 Our laboratory has extensively studied the fatigue performance of the DCPD-based self-
healing system under a number of conditions.
3-7
 The first demonstration of in situ self-healing of 
fatigue damage was conducted at both low-cycle fatigue (high applied stress intensity) and   
high-cycle fatigue (low applied stress intensity).
4
 A constant frequency of 5 Hz and load ratio of 
                                                          
*
 Some of the content presented in this chapter was published in White, S. R.; Caruso, M. M.; Moore, J. S. MRS 
Bull. 2008, 33, 766-769, Copyright 2008, Materials Research Society. 
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0.1 (where R = Kmin/Kmax) was used for all studies and the most impressive result was that 
complete crack arrest was achieved at the lower values of applied stress intensity. At the 
moderate applied stress intensities, fatigue life-extension values ranged from 89–213%, while 
under rapid growth conditions, the fatigue life could only be extended when the sample rested at 
the maximum intensity for 10 h. In a subsequent publication, Brown et al. proved that the 
concentration of microcapsules embedded in the epoxy matrix attributed for toughening of the 
matrix under fatigue loading conditions due to crack pinning and deflection.
5
 As a starting point, 
15 wt% capsules with an average capsule diameter of 180 μm were used in this work. 
 In this dissertation, all the mechanical fracture experiments presented to this point on 
solvent-based self-healing epoxies have been under quasi-static loading, in which the sample was 
loaded monotonically, not in a cyclic fashion. However, long-term performance under cyclic 
loading (fatigue) of a self-healing system is imperative to the application of this technology. To 
date, no work has been reported on the fatigue behavior of an autonomic solvent-based system 
and thus, this chapter presents data to help understand the healing performance under a variety of 
circumstances and environments.  
5.2 Selection of Testing Parameters 
 
 When performing fatigue experiments, previously reported protocols for the           
tapered-double-cantilever beam (TDCB) specimens were used to prepare epoxy specimens.
4,6-8
 
The same epoxy matrix composed of EPON 828:DETA was used as presented in previous 
chapters of this dissertation (Chapters 2 and 4). The four systems studied were neat epoxy (no 
microcapsules), in situ samples containing hexyl acetate microcapsules (a non-healing solvent 
that serves as a control), and two separate self-healing systems containing ethyl phenylacetate 
(EPA) microcapsules and epoxy-EPA microcapsules.
9
 The chemical structures of these healing 
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agents are shown in Figure 5.1. Testing was initiated at the Army Research Laboratory and then 
completed at the University of Illinois and Figure 5.2 shows the experimental setups at each 
location. 
 In an attempt to compare the performance of the solvent-based healing system to that of 
the DCPD/Grubbs’ self-healing system,1,3-6 a frequency of 5 Hz was used for all experiments 
presented in this chapter. These previous studies
1,3-6
 had not mentioned any increase in localized 
temperature of the samples at this frequency; thus, the fluctuation in room temperature was the 
only external factor of testing. A chart of ∆K values and their corresponding amplitudes and peak 
loads (N) had been developed specifically for the TDCB geometry
10
 and was applied to all the 
studies presented in this work (Table 5.1). The initial stress intensity factor (∆K) for testing was 
selected as 0.472 MPa·m
1/2
 as a mid-range stress. At ∆K = 0.472 MPa·m1/2, neat epoxy TDCB 
specimens were tested and the crack length was optically monitored during testing as the 
calibration test (Figure 5.3). The best-fit line in Figure 5.3a was used to calibrate all following 
experiments so that crack growth could be plotted versus the number of cycles. A representative 
fatigue test on neat epoxy at ∆K = 0.472 MPa·m1/2 is shown in Figure 5.4. From this plot, the 
best fit line to the data was defined as the crack growth rate (da/dN) within the constant K region 
according to the Paris law equation.
11
 For later tests, higher ∆K values were used until all 
samples tested were fatigued until complete failure. 
5.3 Results and Discussion 
 
 The fatigue behavior under investigation is for the systems consisting of purely EPA 
solvent microcapsules and epoxy-EPA capsules. Based on monotonic fracture testing presented 
in Chapters 2 and 4 of this dissertation,
9
 it was predicted that these systems would demonstrate 
crack arrest and fatigue life extension. For controls, crack propagation through neat epoxy is 
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used as the reference point at various stress intensity factors and epoxy samples containing a 
non-healing solvent (hexyl acetate) are used to investigate the fatigue response for capsule-filled 
epoxy specimens. A summary of the fatigue results for all four systems tested at a constant stress 
intensity of ∆K = 0.472 MPa·m1/2 is given in Table 5.2 and representative curves are plotted in 
Figure 5.5. As predicted, the neat epoxy sample failed first, followed by the specimens 
containing hexyl acetate microcapsules, since this solvent did not promote self-healing 
behavior.
9
 Both the samples containing EPA and epoxy-EPA microcapsules had very slow crack 
growth rates, and did not fail after 2.5 million cycles of testing. All specimens were removed 
from load frame and broken to image the fracture surfaces by scanning electron microscopy 
(SEM). A diagram is shown in Figure 5.6 for the location on each sample where it was imaged 
by SEM. Representative images are shown in Figure 5.7 for each system tested at this stress 
intensity factor. The striations on the surfaces were evidence from fatigue cycling of the samples. 
The fracture surface of samples containing epoxy-EPA capsules that demonstrated crack arrest 
was covered in a thin film (Figure 5.8), indicating that new polymer material had formed in the 
crack plane during the healing process.
9
 
 The stress intensity factor was then systematically increased for all four systems from  
∆K = 0.495 MPa·m1/2 to ∆K = 0.540 MPa·m1/2 by increasing the amplitude of testing (refer to 
Table 5.1). At ∆K = 0.495 MPa·m1/2, self-healing samples containing EPA capsules failed while 
the epoxy-EPA system did not after 1.5 million cycles. Table 5.3 summarizes the crack growth 
rates and number of cycles for each sample tested at this stress intensity factor. Additionally, 
SEM images of the tested fracture planes are shown in Figure 5.9. The river markings on the neat 
surface were also observed in previous fatigue experiments.
5
 At ∆K = 0.518 MPa·m1/2, self-
healing samples containing epoxy-EPA capsules still did not during the testing time period, 
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while the other three types of samples did fail within a shorter time frame because of the 
increased amplitude of cyclic loading. Table 5.4 shows a summary of results at this stress 
intensity factor and Figure 5.10 displays SEMs of tested specimens. Finally, by using the stress 
intensity factor ∆K = 0.540 MPa·m1/2, the epoxy-EPA self-healing specimens failed during 
testing. This selected amplitude was too high for efficient healing reactions to occur in the crack 
plane of these self-healing specimens. The crack growth rates and number of cycles to failure for 
all four systems is summarized in Table 5.5 and SEMs are shown in Figure 5.11. At this stress 
intensity range, the neat specimens were observed to fail immediately after the cyclic loading 
began; thus, SEM images of the fracture planes are not shown for neat specimens because they 
were smooth and did not show any characteristic features of fatigue.                 
 Since the self-healing performance observed for samples containing EPA and epoxy-EPA 
healing agents under quasi-static fracture appeared to reach steady-state values after the first 10 h 
of healing (Chapter 4 of this dissertation), representative curves for each system (with the 
exception of the neat epoxy specimens) were plotted during this time frame (Figure 5.12). As the 
∆K was increased, the crack growth rate increased and number of cycles to failure decreased for 
the hexyl acetate and EPA systems. The epoxy-EPA system was the best-performing self-healing 
chemistry tested under fatigue, displaying crack arrest for samples where ∆K < 0.540 MPa·m1/2. 
When the crack growth rate (da/dN) was plotted versus the applied stress intensity range (∆K) in 
Figure 5.13 for the four systems under investigation, the samples did not necessarily follow the 
Paris power law as had been observed for previous self-healing systems since they are generally 
non-linear.
5
 However, it is important to note that the hexyl acetate system overlays well with the 
neat epoxy system when ∆K > 0.472 MPa·m1/2, meaning that it is an effective solvent healing 
control. The crack growth rates observed for the EPA system slowly approach that for the control 
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systems at ∆K = 0.518 MPa·m1/2, and then dramatically increases for the last tested ∆K value. 
This behavior is uncharacteristic of samples within the constant K range, indicating that this ∆K 
was too high for any healing promoted by EPA to occur. Lastly, the epoxy-EPA system 
displayed the slowest crack growth rate for all the tested systems and finally approached the data 
points for control systems at ∆K = 0.540 MPa·m1/2. Thus, when the solvent-based self-healing 
systems were tested under fatigue conditions, the epoxy-EPA system shows the most promise for 
use in real world applications (within a certain stress intensity range). Future studies could 
include observing the fatigue behavior as a function of frequency used and microcapsule 
concentration since these factors were held constant in this study. 
5.4 Experimental Section 
 Materials: Ethyl phenylacetate (EPA) and hexyl acetate were purchased from        
Sigma-Aldrich and used as received. EPON® 828 was purchased from Miller-Stephenson, and 
diethylenetriamine (Ancamine DETA) curing agent was received from Air Products.           
Long-groove TDCB specimens
8,12
 were prepared by mixing, degassing, and pouring a 
stoichoimetric (100:12) EPON 828:DETA mixture into PDMS silicone molds. In situ TDCB 
specimens contained 15 wt% microcapsules dispersed throughout the insert section of the 
samples. All epoxy samples were cured at room temperature for 24 h, 35 °C for 24 h, followed 
by an additional post-cure of 6–8 days at room temperature. Procedures for preparing solvent and 
epoxy-solvent microcapsules were reported in Chapter 3 of this dissertation. The capsules used 
in this study were urea-formaldehyde (UF) hexyl acetate capsules prepared at a stir rate of      
350 RPM,
13
 UF EPA capsules prepared at a stir rate of 375 RPM,
13
 and UF 15 pph 828 in EPA 
(7.6 g in 60 mL EPA core solution) capsules prepared at a stir rate of 350 RPM using a modified 
UF procedure.
14
 The average capsule diameter ranged from 150–200 μm.    
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 Fatigue Testing: After the samples were cured, a precrack (9–15 mm in length) was 
inserted with a sharp razor blade into the groove of the sample. The samples were then           
pin-loaded and two rubber bands are attached to keep the sample fixed in place on an Instron 
8871 with a 1 kN load cell (Army Research Laboratory, Aberdeen, MD) and a Instron 
DynoMight 8841 with a 250 N load cell (University of Illinois at Urbana-Champaign, Urbana, 
IL). The load frames were run in load control and the R ratio was held constant at 0.1 for all 
tests. The frequency was held constant at 5 Hz and the ΔK varied between 0.47 and 0.54 
MPa·m
1/2
. All tests were conducted at room temperature. 
 Characterization: Capsule diameters were determined through optical microscopy using 
a Leica DMR Optical Microscope at various magnifications. ImageJ was used to measure the 
diameters and an average of at least 100 capsules was used to determine the size distribution for 
each capsule batch. Environmental scanning electron microscopy (ESEM) images of the fracture 
surfaces were taken on a Philips XL30 ESEM-FEG instrument with a 5 kV electron source after 
sputter-coating the sample with a gold-palladium source. 
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5.6 Figures and Tables 
 
 
 
Figure 5.1. Chemical structures of microcapsule core components – Bisphenol A Epoxy (EPON 
828) and solvents. 
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(a)  
 
(b)  
 
Figure 5.2. Testing setup on the load frames showing in situ long-groove samples at (a) the 
Army Research Laboratory and (b) the University of Illinois. The blue marking indicates the 
length of the precrack introduced into the EPA sample before loading. *The yellow TDCB on the 
frame in the large scale image is not the specific system used in this testing, but the inset shows a 
sample from the solvent system.  
 
102 
 
(a)  (b)  
 
Figure 5.3. Plot of fatigue behavior for a neat epoxy specimen tested at 5 Hz, R = 0.1, and       
∆K = 0.472 MPa·m1/2 showing (a) optical tracing of crack length during fatigue testing and the 
corresponding displacement where the best-fit line is shown above the graph and was used to 
calibrate all fatigue data to determine crack growth for individual specimens; and (b) crack 
length vs. compliance. 
 
 
 
Figure 5.4. Representative curve showing crack growth as a function of fatigue cycles at a 
frequency of 5 Hz, R = 0.1, and ∆K = 0.472 MPa·m1/2. 
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Figure 5.5. Representative fatigue curves for all four systems showing crack length as a function 
of fatigue cycles at a frequency of 5 Hz, R = 0.1, and ∆K = 0.472 MPa·m1/2. 
 
 
 
Figure 5.6. Schematic of in situ long-groove TDCB specimen indicating the region of the 
fracture surfaces that was imaged post-testing. 
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(a)  (b)  
 
(c)  
 
Figure 5.7. SEM of healed fracture surfaces for (a) neat epoxy with arrows pointing to the 
striations; (b) hexyl acetate capsules; and (c) EPA capsules after testing at ∆K = 0.472 MPa·m1/2. 
 
 
 
Figure 5.8. SEM of healed fracture surface containing epoxy-EPA capsules after testing at      
∆K = 0.472 MPa·m1/2.  
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(a)  (b)  
 
(c)  (d)  
 
Figure 5.9. SEM of healed fracture surfaces for (a) neat epoxy; (b) hexyl acetate capsules;       
(c) EPA capsules; and (d) epoxy-EPA capsules after testing at ∆K = 0.495 MPa·m1/2. 
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(a)  (b)  
 
(c)  (d)  
 
Figure 5.10. SEM of healed fracture surfaces for (a) neat epoxy; (b) hexyl acetate capsules;     
(c) EPA capsules; and (d) epoxy-EPA capsules after testing at ∆K = 0.518 MPa·m1/2. 
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(a)  (b)  
 
(c)  
 
Figure 5.11. SEM of healed fracture surfaces for (a) hexyl acetate capsules; (b) EPA capsules; 
and (c) epoxy-EPA capsules after testing at ∆K = 0.540 MPa·m1/2. 
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(a)  (b)  
 
(c)  
 
Figure 5.12. Overlaid curves of fatigue behavior vs. number of cycles at increasing stress 
intensity factors (values shown in the legends) for samples containing (a) hexyl acetate capsules; 
(b) EPA capsules; and (c) epoxy-EPA capsules for the first 10 h of testing. 
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Figure 5.13. Log-log plot of fatigue crack growth rate as a function of stress intensity factor for 
all four systems tested. 
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Table 5.1. Fatigue testing parameters for long-groove TDCB specimens.
15
 The specific ΔK 
values used in this work are shaded. 
 
ΔK ΔN (2*Amplitude) N mean (Avg Load) Kmax Nmax
0.000 0 0 0.000 0
0.023 2 1.2 0.025 2.2
0.045 4 2.4 0.050 4.4
0.068 6 3.7 0.075 6.7
0.090 8 4.9 0.100 8.9
0.113 10 6.1 0.125 11.1
0.135 12 7.3 0.150 13.3
0.158 14 8.6 0.175 15.6
0.180 16 9.8 0.200 17.8
0.203 18 11 0.225 20
0.225 20 12.2 0.250 22.2
0.248 22 13.4 0.275 24.4
0.270 24 14.7 0.300 26.7
0.293 26 15.9 0.325 28.9
0.315 28 17.1 0.350 31.1
0.338 30 18.3 0.375 33.3
0.360 32 19.6 0.400 35.6
0.383 34 20.8 0.425 37.8
0.405 36 22 0.450 40
0.428 38 23.2 0.475 42.2
0.450 40 24.4 0.500 44.4
0.473 42 25.7 0.525 46.7
0.495 44 26.9 0.551 48.9
0.518 46 28.1 0.576 51.1
0.541 48 29.3 0.601 53.3
0.563 50 30.6 0.626 55.6
0.586 52 31.8 0.651 57.8
0.608 54 33 0.676 60
0.631 56 34.2 0.701 62.2
0.653 58 35.4 0.726 64.4
0.676 60 36.7 0.751 66.7
0.698 62 37.9 0.776 68.9
0.721 64 39.1 0.801 71.1
0.743 66 40.3 0.826 73.3
0.766 68 41.6 0.851 75.6
0.788 70 42.8 0.876 77.8
0.811 72 44 0.901 80
0.833 74 45.2 0.926 82.2
0.856 76 46.4 0.951 84.4
0.878 78 47.7 0.976 86.7
0.901 80 48.9 1.001 88.9
0.923 82 50.1 1.026 91.1
0.946 84 51.3 1.051 93.3
0.968 86 52.6 1.076 95.6
0.991 88 53.8 1.101 97.8
1.013 90 55 1.126 100
1.036 92 56.2 1.151 102.2
1.058 94 57.4 1.176 104.4  
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Table 5.2. Summary of fatigue results for samples tested at 5 Hz, R = 0.1, and ∆K = 0.472 
MPa·m
1/2
. 
 
# of ΔK Total # of Cycles Crack Growth Rate Specimen
Sample Contents Samples (MPa·m
1/2
) (mm/cycle)
Neat Epoxy 4 0.472 5.1e4 ± 2.4e4 2.4e-4 ± 1.0e-4 CONTROL
Hexyl Acetate 4 0.472 3.1e5 ± 2.2e5 3.8e-5 ± 2.5e-5 Solvent Control
EPA* 6 0.472 2.5e6 ± 1.6e6 2.1e-6 ± 9.4e-7 Self-Healing
Epoxy-EPA* 4 0.472 3.4e6 ± 1.8e6 1.4e-6 ± 5.8e-7 Self-Healing
* = samples not cycled to failure  
 
Table 5.3. Summary of fatigue results for samples tested at 5 Hz, R = 0.1, and ∆K = 0.495 
MPa·m
1/2
. 
 
# of ΔK Total # of Cycles Crack Growth Rate Specimen
Sample Contents Samples (MPa·m
1/2
) (mm/cycle)
Neat Epoxy 3 0.495 6.4e4 ± 2.1e4 1.8e-4 ± 2.3e-5 CONTROL
Hexyl Acetate 3 0.495 7.2e4 ± 4.7e4 2.0e-4 ± 1.2e-4 Solvent Control
EPA 7 0.495 2.0e5 ± 1.8e5 4.6e-5 ± 2.6e-5 Self-Healing
Epoxy-EPA* 3 0.495 1.5e6 ± 4.6e5  1.9e-6 ± 9.8e-8 Self-Healing
* = samples not cycled to failure  
 
Table 5.4. Summary of fatigue results for samples tested at 5 Hz, R = 0.1, and ∆K = 0.518 
MPa·m
1/2
. 
 
# of ΔK Total # of Cycles Crack Growth Rate Specimen
Sample Contents Samples (MPa·m
1/2
) (mm/cycle)
Neat Epoxy 3 0.518 5.8e4 ± 4.1e4 2.3e-4 ± 1.4e-4 CONTROL
Hexyl Acetate 4 0.518 7.4e4 ± 4.6e4 2.4e-4 ± 2.3e-4 Solvent Control
EPA 5 0.518 6.7e4 ± 2.9e4 1.4e-4 ± 1.3e-4 Self-Healing
Epoxy-EPA* 3 0.518 7.4e5± 6.2e5 3.0e-5 ± 4.8e-5 Self-Healing
* = samples not cycled to failure  
 
Table 5.5. Summary of fatigue results for samples tested at 5 Hz, R = 0.1, and ∆K = 0.540 
MPa·m
1/2
. 
 
# of ΔK Cycles to Failure Crack Growth Rate Specimen
Sample Contents Samples (MPa·m
1/2
) (mm/cycle)
Neat Epoxy 3 0.540 1 immediate CONTROL
Hexyl Acetate 4 0.540 8.6e3 ± 5.5e3 1.5e-3 ± 1.4e-3 Solvent Control
EPA 3 0.540 7.6e2 ± 1.2e3 3.6e-2 ± 3.8e-2 Self-Healing
Epoxy-EPA 5 0.540 2.6e4 ± 1.1e4 5.8e-4 ± 4.2e-4 Self-Healing  
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CHAPTER 6 
 
MASKING REACTIVE AMINES IN EPOXY MATRICES 
 
 
6.1 Introduction 
 
 Although a simpler, more economical self-healing system using epoxy-solvent 
microcapsules has been developed with 100% recovery of fracture toughness,
1
 there are certain 
limitations preventing use of this technology in industrial polymeric matrix composites. The low 
temperature cycle (24 h RT, 24 h at 35 °C) used to cure the epoxy matrix leads to vitrification, or 
premature formation of a three-dimensional (3D) network structure, evident in differential 
scanning calorimetry (DSC) traces which show a reduced glass transition temperature of          
ca. 60 °C followed by an exothermal peak.
2
 As a result, unreacted functional groups present in 
the matrix become mobile upon the introduction of solvent and can undergo further             
cross-linking, leading to a healing response. However, if the epoxy matrix is cured above its 
glass transition temperature (Tg), the network becomes fully cross-linked, and solvent no longer 
has an effect on the epoxy due to its inability to extract residual functional groups. Since most      
epoxy-based structural composites are cured at temperatures of 100 °C or above,
3
 a practical 
self-healing system requires a new type of structural material that can be cured to a metastable 
state, while maintaining latent chemical reactivity for use in damage repair. The incorporated 
latent materials could be masked and distributed throughout the epoxy or protected in a 
polymeric capsule until damage is incurred. This new system could be used in tandem with the 
epoxy-solvent microcapsules, including an unmasking agent if necessary, to repair damaged 
regions upon crack propagation and allow for further cross-linking reactions to occur. In the 
ideal case, reactive functionality would be uniformly distributed and compartmentalized on the 
micron or nanoscale as solid amine particles (Section 6.2) and amines used in rubbers as 
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antioxidative agents (Section 6.3). Other approaches to latent reactivity involve standard amine-
based protecting group schemes and other covalent chemical modifications as discussed in 
Section 6.4. 
6.2 Solid Amines 
6.2.1 Preliminary Screening  
 A number of solid amines were screened for the following characteristics: (1) melting 
point temperature; (2) reactivity at room temperature with epoxy; and (3) dissolution/solubility in 
nonpolar solvents that can be encapsulated (discussed in Chapter 3 of this dissertation). Melting 
point was one consideration because the amine should be a solid at room temperature             
(RT, 21–24 °C), but also have a high melting point which would be preferable for high 
temperature curing in an epoxy matrix. Ideally, the solid amine should remain as an unreacted, 
secondary phase in the bulk epoxy material. For self-healing to occur in an autonomic fashion, 
the healing reaction should take place at RT with no external heat or intervention.
4
 Thus, when 
an epoxy-solvent mixture is released into the crack plane, the solid amine will be dissolved, 
leading to further cross-linking reactions at RT to produce a healed polymer. 
 Table 6.1 outlines the amines screened in this study. The first four amines listed in   
Table 6.1 were investigated due to their low melting points; their chemical structures are shown 
in Figure 6.1. With the exception of imidazole, they are primary amines, which are more 
nucleophilic at RT than secondary or tertiary amines.
5
 Unlike some liquid amine curing agents 
used for epoxies which typically react rapidly at RT, these amines have a longer pot-life at RT 
and usually react with epoxy at elevated temperatures. When these solid curing agents were 
mixed at their respective stoichiometric ratios with epoxy (bifunctional DGEBA resin, EPON 
828), mPDA and imidazole formed hard polymers after 48 h at RT while Ancamine 2337S and 
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P100 did not harden even at longer times than 48 h at RT. Three of these amines (mPDA, 
Ancamine 2337S, P100) also exhibited solubilities in different nonpolar solvents tested, but 
imidazole was only soluble in polar solvents; thus, it was no longer considered for this type of 
self-healing system. Solubility of all the amines is reported in Table 6.1 and the solvents 
screened were chlorobenzene (PhCl), ethyl phenylacetate (EPA), phenyl acetate (PA), hexyl 
acetate (HA), xylenes, and anisole. 
 The last three amines (DDS, DICY, Curezol 2MZ) listed in Table 6.1 have much higher 
melting points (175–250 °C). This ensures that upon high temperature curing of the epoxy 
matrix, the amine would remain in its solid form in contrast to the previous lower melting point 
compounds. However, the greatest limitations in using these solids are their limited solubility 
and reactivity with epoxy at room temperature. DICY and Curezol 2MZ were observed to gel at 
RT when mixed with EPON 828, while DDS was soluble in PA but did not produce any hard 
polymer when added to epoxy. Nevertheless, additional experiments were carried out to analyze 
the dissolution of these six solid amines when they were embedded in a cross-linked epoxy 
network. 
 Out of the amines screened, Ancamine 2337S, P100, and Curezol 2MZ curing agents 
were studied to a lesser extent in the bulk phase due to their lower solubility in nonpolar solvents 
and inability to react with epoxy at RT. The 2337S particles were optically measured to be       
ca. 14 μm based on cross-sectional diameters (Figure 6.2a). They clumped together in aggregates 
when embedded in a cylindrical epoxy samples (at 6.5 wt% loading), as shown by scanning 
electron microscopy (SEM) in Figure 6.2b. These epoxy samples of EPON 828:DETA with 
2337S were cured for 24 h at RT, followed by 24 h at 35 °C.  The samples were then fractured 
into two halves with a razor blade and various epoxy-solvent solutions were injected into the 
115 
 
fracture plane. The halves were clamped together to heal at RT for 24 h. This sample preparation 
and healing protocol was used for subsequent screening experiments in this chapter (unless 
otherwise noted). Only slight healing at RT was reported during this qualitative experiment by 
injecting 828-PhCl and 828-HA solutions onto the crack plane. Since the epoxy was cured at low 
temperatures, it was expected that the PhCl alone would have had a more pronounced solvent 
healing effect, suggesting that the 2337S accelerated the matrix cure leaving a lower amount of 
available reactants in the system.  
 The solid amine P100 was added to a different epoxy matrix – EPON 862:Epikure 3274 – 
because its optical clarity would be ideal to view the dispersed red solid amine embedded in the 
cured matrix. The thermal behavior of the epoxy with P100 was studied by DSC (Figure 6.3). 
The presence of P100 in this epoxy matrix was observed by the shoulder on the exothermic 
transition during the first DSC scan (black solid line in Figure 6.3). Upon a second heating cycle 
of this material, the Tg was observed for the system to be ca. 55 °C. When compared to the 
thermal behavior during the cure cycle of the 862:3274 matrix only (Table 6.2), the epoxy 
system with P100 is 90% cured. The Tg is very low for these systems (both with and without 
P100), meaning that solvent healing would lead to a positive healing result. Thus, when bulk 
epoxy samples (862:3274 with P100) were prepared and solvent alone was injected into the 
fracture plane, they yielded a very good healing response. Images of healed surfaces with EPA as 
the healing agent and a control are shown in Figure 6.4. This healing result can be attributed to 
the solvent healing phenomenon from residual functional groups being present in the epoxy. To 
confirm this behavior, a control experiment was conducted with 862:3274 bulk samples and PA, 
EPA, and PhCl (good healing solvents as discussed in Chapter 4 of this dissertation) were all 
sufficient to heal these samples. When this epoxy with P100 was cured at higher temperatures, 
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no healing was reported for solvent or epoxy-solvent healing agents. The same result was 
observed with 862:W epoxy samples containing P100 that were cured at higher temperatures. 
The 862:W is widely used for high temperature aerospace-grade composites
6
 and would be 
advantageous to use in the design of fully-cured self-healing materials. 
 Due to its high melting point (250 °C), Curezol 2MZ was incorporated into the high 
temperature 862:W matrix. At 5 wt% loading of Curezol 2MZ, some of the solid material settled 
to the bottom during a 24 h cure at 70 °C. After this curing step, the matrix was ca. 92% cured 
(refer to Section 6.5 for data analysis). However, enough exposed amine was present on the 
fracture surfaces of the samples to heal at RT when solvent (PA, EPA, PhCl) and 828-solvent 
solutions were injected in between the crack planes and clamped. When the epoxy samples 
underwent a post-curing step at 121 °C for 1 h and the same healing agent solutions injected in 
the fracture plane, no healing was observed. Therefore, the three amines in this section were not 
studied further due to their inability to heal when embedded in a high temperature epoxy matrix, 
which was a main goal for the designed self-healing system.  
6.2.2 mPDA 
 We hypothesized that the reaction between solid amines and epoxy depends on the 
particle size of the amines. mPDA was the first amine to be extensively studied for this project 
because its use as a healing agent for fully-cured epoxies has been previously reported.
7
 The    
as-received mPDA solid was ground with a mortar and pestle, and two particle sizes were sieved: 
75–180 µm (small mPDA) and >180 µm (large mPDA). These particles were then added to 
EPON 828 at a stoichiometric ratio and the thermal reaction was studied by conducting dynamic 
DSC experiments. Representative scans are shown in Figure 6.5a. Although the onset 
temperature of polymerization is the same for both size scales, the larger particles agglomerated 
117 
 
in the matrix to form a vitrified network, as evidenced by the sharp endothermic transition        
ca. 65 °C. The smaller mPDA particles dissolved more evenly into the epoxy matrix, leading to a 
higher heat of polymerization and percent conversion (Figure 6.5a).  
 When small mPDA particles were introduced into the 828:DETA epoxy matrix at       
14.5 wt% loading, the onset temperature of polymerization (58 °C) is significantly lower than 
that for small mPDA in 828 only (123 °C) and those curves are shown in Figure 6.5b. We 
selected this amount of mPDA because we expected it would stoichiometrically react with the 
amount of delivered epoxy from embedded microcapsules (13 wt% 828 in solvent) in the 
envisioned, fully in situ system. The quantitative data is summarized in Table 6.3. When the 
epoxy resin was cooled to RT after the first ramp in the DSC, and then the temperature ramped 
up to 300 °C a second time, only one Tg was observed for the polymer. Since there was no 
distinct melting point in this trace (not shown), the amount of solid amine available for further 
reaction was unable to be determined for this specific experiment. However, when looking at the 
dynamic scans, there was only a slight difference between onset temperatures of polymerization 
when this data (black dashed curve in Figure 6.5b) was compared to the onset temperature of the 
828:DETA matrix alone (blue curve in Figure 6.5b). When the total heats of polymerization 
(ΔH) are compared (termed „residual heat of rxn‟ in Table 6.3), there is a lower amount of heat 
released for the mPDA in 828:DETA system than the 828:DETA alone or 828:mPDA. Thus,  
12–18% of the amine reactivity in the composite has been “masked” by embedding solid mPDA 
in the matrix. The reactivity of this epoxy system with additional embedded reactivity (mPDA) 
was further studied under isothermal conditions at RT (25 °C) and is reported in Table 6.3. 
Polymerization appeared complete after 12 h at RT, with 93% cure, while the mPDA with 828 
only reported 19% conversion after 12 h and 28% cure after 24 h at RT.  
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 Bulk epoxy samples containing mPDA solid particles were then prepared to screen for 
the best healing agent combination of epoxy and solvent. Cylindrical epoxy samples                
(15 mm x 7.6 mm) of EPON 828:DETA with 2.2 wt% (14.5 pph) mPDA were cured for 24 h at 
RT, followed by 24 h at 35 °C.  The samples were then fractured into two halves and solutions of 
13 wt% 828 in solvent (PhCl or PA) were injected into the fracture plane and the halves were 
clamped together to heal at RT for 24 h. Both samples displayed the ability to heal (evidenced by 
the qualitative level of difficulty in pulling them apart). However, the healing could be attributed 
to solvent healing alone, since the epoxy was cured at low temperatures and thus contained 
unreacted functional groups. Partial dissolution of the amine and some film formation was 
observed by SEM on the healed fracture surfaces (Figure 6.6).  
 The next set of samples prepared comprised of EPON 828:DETA with 3.8 wt% (25 pph) 
mPDA were cured for 24 h at RT, 24 h at 35 °C, and followed by a 100 °C post-cure for 1 h. The 
matrix was previously shown to be fully-reacted at the higher temperature cure step, so the 
solvent healing mechanism would no longer be a contributing factor to healing. Unfortunately, 
EPA and 828-EPA solutions injected into the crack planes of these samples demonstrated no 
healing ability (they did not hold together after they were unclamped). However, the healed 
samples did appear to have a film present on the surfaces by SEM (not shown) suggesting that 
some dissolution of the amine had occurred and formed a new polymer. Control epoxy samples 
with no mPDA present did not show any healing response when EPA and 828-EPA solutions 
were used as healing agents. In the case of the sample with mPDA healed with the 828-EPA 
solution, perhaps too much epoxy was delivered to the surface thus there was not enough amine 
present to react.
1
 This phenomenon was evident in fully in situ tapered-double-cantilever beam 
(TDCB) samples prepared with 0.5 wt% mPDA and 3.5 wt% microcapsules containing a core 
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solution of 50% 828 in EPA (average diameter = 145 ± 38 μm). After 24 h of RT healing, these 
samples had a healing efficiency of 0%. An SEM image of the healing fracture plane indicates 
capsule rupture and film formation, potentially due to an excess of epoxy on the surface    
(Figure 6.7). The amount of mPDA and capsules were varied in an attempt to obtain any sign of 
healing. Additionally, the time and temperature of healing was increased to 1–2 days at          
RT–35 °C and a summary of these results are shown in Table 6.4. Future studies with this amine 
would benefit from investigating the effects of increasing the amount of amine embedded in the 
epoxy matrix and minimizing the crack face separation distance to optimize the healing behavior.    
6.2.3 DDS and DICY 
 The next amines studied in depth were DDS and DICY. In order to confirm the thermal 
stability of DDS and DICY within the processing temperature ranges, these solid amines were 
analyzed by TGA and DSC (Figure 6.8). Both amines did not melt nor decompose until 
temperatures higher than 190–200 °C, which indicates they will remain solid during high 
temperature epoxy processing. The first epoxy system used was 828:DETA, but fully cured at 
higher temperatures to eliminate any solvent healing effect. Epoxy samples were prepared 
containing 3 wt% of DDS, reacted under the „standard curing conditions‟ as defined in the 
experimental section, and post-cured at 95 °C for 1 h. However, no healing was reported when 
solvent (PA, EPA) and 828-solvent mixtures were injected into the crack plane. By examining 
the fracture surfaces with SEM, it appeared that some of the embedded amine was dissolved and 
partially reacted with the healing agents (Figure 6.9). Similar results with no healing were noted 
when two sets of samples were prepared with DICY (3.8 wt%) and post-cured at 70 °C for 1 h 
and 95 °C for 1 h. Since both DDS and DICY are commonly used as latent curing agents, they 
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would not react with epoxy at RT for at least 50 days or until temperatures greater than 100 °C 
are reached.
8
 
 In order to increase the mobility (and reactivity) of the embedded amines, healing 
experiments at elevated temperatures were performed. The healing agents used in this study were 
PA, EPA as pure solvents, and 828 in PA and EPA (at 13 and 50 wt% concentrations). The 
epoxy matrix (828:DETA) was „fully cured‟ using a post-cure step at 100 °C for 2 h (as 
described in the experimental section). Samples with DDS (3 wt% loading) demonstrated zero 
healing ability with PA and 50% 828-PA solutions when healed for 1 h at 50, 75, and 100 °C. 
Likewise, samples with DICY (3.8 wt% loading) demonstrated zero healing ability with EPA 
and 50% 828-EPA solutions when healed for 1 h at 50, 75, and 100 °C. In the next set of 
experiments, the epoxy matrix (828:DETA) was post-cured at 121 °C for 1 h, and 200 °C for 2 h 
to ensure complete reaction of the epoxide and amine groups. Partial healing was observed for 
samples containing 3 wt% DDS with 50% 828-solvent healed at 125 °C for 1 h. An increased 
amount of healing was also noted for samples containing 3.8 wt% DICY with 13% 828-solvent 
healed at 125 °C for 1 h (Figure 6.10). These preliminary results suggest that: (1) elevated 
temperatures show promise for healing microcrack damage; and (2) there are possible 
applications during high temperature processing of composites. 
6.2.4 Amine Incorporation into a High Temperature Epoxy System  
 Due to limited success in lower temperature epoxy systems (828:DETA and 862:3274) 
studied in the previous sections, an alternative matrix was explored. A common high temperature 
epoxy thermoset used in advanced composites and resin transfer molding is composed of EPON 
862 (bifunctional DGEBF resin) and curing agent W (diethyltoluene diamine), whose chemical 
structures are shown in Figure 6.11. This matrix has a long pot life (22 h at 25 °C) and low 
121 
 
viscosity (21–23 cP at 25 °C),6 which allows for further modifications/fillers to be added to the 
system before curing reactions take place. The degree of cure for this system was monitored by 
DSC to show a glass transition temperature of ca. 100 °C after the first stage of curing at 70 °C 
for 24 h (Figure 6.12). A summary of DSC experiments investigating the curing properties of 
this matrix is given in Table 6.5. The 3D network formed from these components is presumably 
more cross-linked because the chemical structure of the curing agent is more rigid than the 
previously studied aliphatic DETA and thus, does not allow solvent to permeate the denser 
network. As a control, when the solvents EPA, PA, and PhCl were introduced into the crack 
plane of cylindrical epoxy samples, no healing was observed. Thus, any healing reported from 
epoxy samples containing solid amines can be attributed to the amines being present in the 
matrix.  
 The amines DDS and DICY were chosen for use in the EPON 862:W matrix and cured at 
70 °C for 24 h (3 wt% loadings). At this point, solvents and solutions of unreacted epoxy-solvent 
were injected into the crack plane of cylindrical samples which demonstrated significant healing. 
Next, the matrix was post-cured at 95 °C for 1 h and only partial healing was observed for 
samples containing both DDS and DICY. The healing agent solutions used were PA, EPA,       
13 wt% 828-PA, and 13 wt% 828-EPA. Representative SEM images of the healed surfaces are 
shown in Figure 6.13 for DICY-containing samples. However, with subsequent post-curing steps 
at higher temperatures (120 °C for 1 h, and 177 °C for 1 h), no healing was observed. Thus, a 
temperature threshold was determined to be 95 °C for this matrix where beyond this value, no 
healing would be observed. Above this temperature, there is a limited mobility of healing agents 
through the epoxy network to dissolve the embedded amine particles, resulting in no healing 
response. The future scope of this project is not only limited to the amines mentioned above, but 
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functionalized nanoparticles could also have promise as nanofillers to improve the mechanical 
properties and serve as carriers of chemical functionality. To summarize this section, the use of 
solid amines in epoxy matrices as “masked curing agents” or unreacted functionality is only 
effective in low-temperature cured systems where a solvent allows for mobility of residual 
functional groups.
9
 These systems also hold promise when heat can be applied to initiate the 
healing process. 
6.3 Secondary Amines with Antioxidative Properties 
 When screening a number of solid amines in the previous section, it was found that some 
solid amine rubber particles also possess multifunctional capability, such as providing protection 
against fatigue degradation (both dynamic and quasi-static) and functioning as antioxidants and 
antiozonants for elastomeric materials. Their potential for use as multifunctional healing agents 
is described in this section. The use of a secondary phase of rubber particles in epoxy adhesives 
has been shown to improve the toughness of these thermoset materials.
10
 These particles have 
secondary amines in their chemical structures (see Figure 6.14), which can allow for covalent 
bonding to an epoxy matrix and also prevent fatigue degradation. p-phenylenediamine 
compounds are one class of these materials which can quench radical intermediates during the 
degradation process.
11,12
 Other groups have reported the microencapsulation of antioxidants;
13-16
 
thus, one goal of this work was to prepare and characterize microcapsules containing solutions of 
these amines. If a sufficient amount of amine could be encapsulated, then potential reactivity of 
the amines with epoxy healing agents could be further explored. 
 Important physical properties for the two selected amines are listed in Table 6.6. The 
solubility of these amines was first studied using the nonpolar solvents for encapsulating (as 
discussed in Chapter 3 of this dissertation). Santoflex 6PPD was not soluble in water, which 
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showed great promise for encapsulation using the urea-formaldehyde (UF) in situ emulsion 
polymerization procedure.
17
 Hexyl acetate was chosen as the solvent to dissolve 6PPD for a 
couple reasons. The deep red/purple color was preserved in hexyl acetate, but the solution turned 
brown when solid Santoflex was dissolved in EPA and PA due to amine degradation. 
Additionally, hexyl acetate does not demonstrate any solvent healing effect when microcapsules 
containing this solvent are embedded into an 828:DETA epoxy matrix.
1
  
 DPG is a white, powdery solid that was not soluble in water or xylenes, but very soluble 
in EPA, PA, PhCl, and HA. In order to understand the reactivity of these amines with epoxy, 
DPG with EPON 828 (at a stoichiometric ratio) was studied by DSC (Figure 6.15a) and the two 
exothermic peaks indicated heterogeneous mixing/polymerization of the two materials. 
Furthermore, IR spectra were acquired on the DPG solid alone showing the secondary amine 
peaks (1655 cm
-1
) present in the structure. To study any reaction between EPON 828 and DPG, 
IR scans of the mixture were acquired initially and after 24 h. The reaction vessel was kept inside 
the instrument for in situ data collection over the 24 h time period and representative spectra are 
shown in Figure 6.15b. The absorbance after 24 h was significantly lower than the initial scan, 
making the data analysis more difficult, and it appears that the epoxide peak (917 cm
-1
) decreases 
in magnitude. After removing the mixture from the instrument, it had not formed a hard polymer, 
but rather gelled the epoxy. Therefore, further studies with this amine were not continued; 
however, its excellent solubility in nonpolar solvents shows promise for encapsulation of 
antioxidative materials which could be of interest for future investigations. 
 In a similar set of experiments, EPON 828 was added to a stoichiometric amount of 
Santoflex 6PPD and a dynamic DSC temperature sweep was performed (Figure 6.16). Almost no 
thermal transition occurred, as evidenced by only a slight exotherm in the solid black line. Upon 
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cooling, the sample was heated for a second scan (red dashed line) and showed no glass 
transition temperature or decomposition peak, indicating that the amine had not reacted with the 
epoxy resin. Based on previous experiments, the epoxy alone does not decompose until 
temperatures greater than 300 °C are reached. As further confirmation, in situ FTIR experiments 
were performed on Santoflex in EPON 828 mixed between NaCl salt plates and their reaction 
was monitored over a 24 h time period. Selected spectra are plotted in Figure 6.17. The N–H 
stretches (1601 cm
-1
 and 3418 cm
-1
) are not as prominent in the 828/Santoflex spectrum, but 
since there is minimal change after 24 h in the spectra. It appears that the secondary amines 
present in the Santoflex are not nucleophilic enough to react with epoxides at room temperature. 
Qualitatively, the 828/Santoflex mixture after 24 h of reacting at RT did not form a hard 
polymer, but rather gelled. 
 Although the reactivity of Santoflex in epoxy matrices could not be utilized in our 
system, its promise as an antioxidative healing agent (preventing against fatigue degradation and 
oxidation at higher temperatures) was further explored. UF microcapsules
17
 were prepared 
containing various concentrations of Santoflex dissolved in HA (0.03, 0.05, 0.1 M). Since the 
solid Santoflex is a UV-active structure (λmax = 475 nm), we sought to characterize the 
concentrations of the microcapsule core solutions before and after encapsulation. Using         
UV-visible spectroscopy, five solutions of known concentrations of Santoflex in HA were 
prepared and their corresponding absorbance recorded (Figure 6.18). A linear regression was 
performed using these five data points which resulted in a calibration curve used to quantify the 
concentration of Santoflex in prepared microcapsules. The experimental data for extracted core 
solutions of the microcapsules correlated well to the expected absorbance, confirming that the 
core concentration remains constant upon encapsulation. This technique can be expanded to 
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characterize various microcapsules prepared with UV-active core materials. Further 
characterization of these microcapsules was conducted by TGA and DSC showing the thermal 
stability of the capsules and their core contents (Figure 6.19). The thermograms in Figure 6.19b 
confirm encapsulation of the Santoflex/HA solution since the thermal transitions overlaps for 
both the solution and capsules.   
6.4 Protection Schemes for Reactive Amines 
 
 This section outlines the efforts to produce metastable epoxy systems with incorporated 
latent materials that are protected and distributed throughout the epoxy or present in a polymeric 
sphere. Deprotection of these reactive groups would occur upon release of an encapsulatable 
base, acid, or solvent upon crack damage to the matrix. Our first efforts were to wax-protect 
solid amines via meltable dispersion, similar to the process employed for first generation 
Grubbs‟ catalyst in the original self-healing polymeric system.18 The second section discusses 
efforts to protect amine curing agents with acids and N-Boc (tert-butyl carbamate) groups. The 
last section summarizes a screening study to determine appropriate bases that can deprotect 
acidic protecting groups and survive in situ encapsulation conditions.
17
 
6.4.1 Wax-Protected Solid Amines 
 
Using a previously developed procedure for making wax spheres via meltable 
dispersions,
18
 the solid amine mPDA was melted in paraffin wax at two different concentrations 
(40 and 50%). A representative optical image of these spheres is shown in Figure 6.20a and they 
had average diameters of 126 ± 33 μm. During the microsphere preparation, all of the amine did 
not melt into the wax before addition to the emulsion, so it was difficult to guarantee how much 
of the amine would be encased in the wax spheres. DSC scans of the two wax sphere batches are 
shown in Figure 6.21a. When compared to the thermal behavior of wax only, the transitions are 
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almost identical except for a slight shoulder at 68 °C for the 50% mPDA in wax. This shoulder 
corresponds to the melting point of mPDA solid (indicated by an arrow in Figure 6.21a). As 
another comparison, a DSC of Grubbs‟ catalyst in wax is overlaid with wax only in Figure 6.21b 
and only differs in the magnitude of the endothermic peak at 60 °C. Thus, DSC is an inadequate 
method for determining if these solid compounds are embedded inside of wax spheres since the 
thermal transitions are at similar temperatures to the wax alone. Elemental analysis would be a 
more appropriate technique to characterize the nitrogen content of these spheres. 
An indirect method for determining if any solid was present in the wax spheres was to 
embed the spheres (8 wt% loading) into a standard-cured epoxy matrix (828:DETA) and inject 
solvent and epoxy-solvent mixtures into the crack planes to observe any healing response. Hexyl 
acetate (HA) was chosen as the solvent for this system because it demonstrated no solvent 
healing effect in standard-cured epoxies.
1
 Slight healing was observed when 13% 828 in HA was 
used as the healing solution, while HA alone demonstrated no healing response. SEM images of 
these fracture surfaces after healing are shown in Figure 6.22. Figure 6.22b shows partial 
dissolution of the embedded sphere while the control surface does not show any of these features 
(Figure 6.22a). Unfortunately, not enough amine was present in the spheres to react with the 
delivered epoxy and produce a polymer film on the surface.   
Other candidate amines worth investigating are aliphatic amines that can readily cure 
epoxy at room temperature; e.g., hexanediamine (HDA). Due to its reactivity in water, it cannot 
be encapsulated using the standard UF in situ emulsion polymerization method.
19
 However, by 
encasing this solid in a polymeric sphere or wax,
18
 the amine is protected from reacting with the 
matrix components until the sphere is either dissolved or ruptured. Optical images of prepared 
wax spheres containing HDA (6.25%) are shown in Figure 6.20b. Cylindrical epoxy specimens 
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were then prepared with spheres (2.5 wt% loading) and HA and epoxy-HA solutions were 
injected as healing agent. After 24 h, no samples demonstrated any degree of healing. Since the 
solvent may have been insufficient for wax dissolution, xylenes, petroleum ether, and n-heptane 
were also used as potential healing agents, but none of them proved successful. Thus, the 
inability to identify a nonpolar solvent that can both dissolve wax and epoxy was the major 
drawback in this amine protection strategy and was not pursued further. 
6.4.2 Encapsulation of a Boc-Protected Amine 
 
 A major challenge in developing a two-part epoxy-amine self-healing thermoset is the 
encapsulation of a reactive amine. Preliminary efforts in our lab have demonstrated this is 
feasible by preparing microcapsules via an interfacial polymerization containing an amine 
reaction adduct of EPON 828 and DETA.
20
 Another pathway would be to mask the reactivity of 
an amine by a protecting group, then it could survive the conditions for microencapsulation.
19
 
The N-Boc (tert-butyl carbamate) group is commonly used for protection-deprotection schemes, 
especially amine protection for peptide synthesis.
21
 For simple amines, the Boc group is 
normally cleaved with a strong acid or heat. To demonstrate this concept, a first approach was to 
encapsulate a commercially available Boc-protected amine and characterize the produced 
capsules to confirm its presence in the capsule core. Next, the Boc group would be removed with 
acid or heat, leaving a reactive primary amine in the core of a capsule.  
 For this study, N-Boc propargyl amine was selected as a small protected amine for 
encapsulation due to its water immiscibility (Scheme 6.1). After screening numerous nonpolar 
solvents, the amine solid was most soluble in xylenes at low concentrations (0.22 M), and this 
solution was encapsulated using the standard urea-formaldehyde procedure.
19
 An optical image 
of these capsules is shown in Figure 6.23a and their average diameter size was 178 ± 22 μm. The 
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capsules were characterized by TGA and compared to pure xylenes capsules (Figure 6.23b). In 
order to confirm that the protected amine was present in the core of the microcapsules, DSC 
scans of the initial solution and the capsules were taken and are shown in Figure 6.24a. The 
solution displayed two main endothermic transitions – the solid melts at 40–44 °C and the    
heat-triggered Boc removal occurs between 180–200 °C. Neither of these transitions was present 
for the capsules (red solid line) containing this solution. When the thermal behavior of these 
capsules was compared to that of xylenes capsules, the onset of decomposition occurs earlier in 
both the TGA and DSC curves. This shift occurs because the Boc deprotection at elevated 
temperatures leads to subsequent capsule rupture, pure xylenes in the capsule core decomposes at 
the same temperature the UF shell walls degrade (ca. 250 °C). FTIR was used to chemically 
characterize the contents of the N-Boc capsules and xylenes was used as a control since it was 
the chosen solvent for the amine (Figure 6.24b). The main stretches are the same for the solution 
as well as the crushed microcapsules, these are highlighted on the spectra at 1245 cm
-1
 (C–N), 
1725 cm
-1
 (C=O), and 3422 cm
-1
 (N–H).   
 In an attempt to remove the Boc group with heat, dry capsules containing the N-Boc 
amine were added to EPA and slightly stirred while heating in an oil bath at 185 °C for 30 min. 
During this process, the solution turned from clear to yellow/orange in color. The capsules were 
cooled and filtered to remove the excess solvent. Optical imaging showed that not all the 
capsules were spherically intact and most had ruptured at the elevated temperatures           
(Figure 6.25a). Upon further analysis by TGA, it was evident that EPA had soaked into the cores 
of the microcapsules (Figure 6.25b). EPA was chosen as the medium to conduct this high 
temperature experiment because of its high boiling point (229 °C), but it could not be sufficiently 
removed from the capsules, as evidenced by post-heat characterization methods                  
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(TGA, DSC, FTIR all showed the presence of EPA). Another drawback of this study was that the 
boiling point of the deprotected amine (propargyl amine) was 85–88 °C, which was too low to 
identify using our thermal analysis techniques. As a control experiment, when the solvent-free 
capsules were heated, the Boc group was not removed after thermal treatment as evidenced by 
DSC (not shown). The use of a vacuum in conjunction with heating the capsules may be a 
plausible method for the Boc removal in future studies. In the next section, several protected 
amines were synthesized and methods for deprotection such as using heat or a strong base were 
explored.  
6.4.3 Protected Amine Compounds 
 Diethylenetriamine (DETA) is used as a curing agent for epoxies in our laboratory.
22,23
 It 
possesses two primary amines that can be protected to mask its reactivity. The central secondary 
amine is not as reactive and thus, was not protected in this approach. The Boc group was selected 
since Boc-protected amines had been studied in the previous section (4.4.2). Using a solvent-free 
procedure and di-tert-butyldicarbonate or (Boc)2O,
24
 Boc-DETA was formed as a white insoluble 
polymer (Scheme 6.2). At 30 °C with stirring, the components did not dissolve, making it 
difficult to separate and purify. Thus, the next amine evaluated was triethylenetetramine (TETA), 
which is one ethylene unit larger than DETA. Following the same procedure for its preparation, 
Boc-TETA was formed upon addition of (Boc)2O and stirring for 1.25 h at RT (Scheme 6.3). 
The product was filtered, washed with water, and dried under vacuum. When this product was 
compared to the liquid TETA via DSC (Figure 6.26a), it was evident that the synthesis was 
successful – the Boc decomposition occurred at 180–185 °C while the boiling of TETA was 
observed at 260 °C. FTIR also confirmed the protection of TETA with the presence of the C=O 
at 1680 cm
-1
 and the N–H stretch became more pronounced at 3360 cm-1 (Figure 6.26b). Based 
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on DSC, the temperature selected for heat treatment to remove the Boc group from TETA was 
190 °C for 2 h. When this product was cooled, the DSC scan looked identical to the red dashed 
line in Figure 6.26a, indicating that the Boc groups had not been removed with elevated 
temperatures. Thus, due to the difficulty in being able to remove the Boc protecting group, we 
moved to a different strategy for these amine compounds. Future efforts for this aspect of the 
project could explore the capability for Boc removal by acid groups instead of heat treatment 
alone. However, the limitation for acids as deprotecting agents is that they would have to be 
encapsulated, meaning that they would have to be water immiscible. Potential candidates for this 
system to be investigated would be polymers with branched chains having terminal acid groups. 
 A simpler protecting group to use for aliphatic, multifunctional amines (DETA and 
TETA) is a proton. Upon the addition of an acid to DETA, the salt crashed out of solution 
(Scheme 6.4). The DETA and TETA salts were formed following a previously reported 
procedure in ethanol.
25
 Good crystals were formed when ethanol was used as the solvent, but 
when either THF or hexanes were used, crystal formation took a much longer time (at least         
2 weeks). These salts could be incorporated into the epoxy matrix as a secondary solid phase and 
then an encapsulated base would be released upon crack damage to remove the protons, and 
allow for further reaction between excess epoxy and the generated primary amines. As a first test 
of feasibility, cylindrical epoxy samples were prepared in which HCl was first added to DETA 
and then mixed into EPON 828 to generate the DETA salt in situ during the epoxy curing 
process. Samples underwent the standard cure cycle and separate samples were post-cured at  
100 °C for 2 h. Triethylamine (TEA) was used as the base to inject into the fracture plane of the 
samples, which were clamped and tested for healing after 24 h at RT. Partial healing for both 
types of samples were noted, while the control samples of 828:DETA with TEA showed no 
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healing response. Images of the healed fracture surfaces are shown in Figure 6.27. No epoxy was 
delivered as a healing agent, so any healing would have resulted from the deprotected amine 
reacting with residual epoxide groups in the matrix. The interesting features on the surfaces 
(Figure 6.27) indicate that some kind of acid-base chemistry was taking place during the healing 
process, lending promise for further study. 
 Since the amine salts could be easily synthesized, the other component for this system 
(the base) had to be identified. More specifically, we sought a base that had the potential to be 
encapsulated. A „pseudo-encapsulation‟ procedure was developed to mimic the emulsion 
conditions used to prepare UF microcapsules.
17
 Since many amines are water-soluble, this screen 
was performed to identify amine bases that remained in the organic phase (chlorobenzene) 
during „encapsulation.‟ The bases that were screened are as follows and their chemical structures 
are shown in Figure 6.28: 1,4-diazabicyclo[2.2.2]octane (DABCO), tetramethyl piperidine 
(TMP), 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), N,N-Dicyclohexylmethylamine (MDCA), 
N,N-diisopropylethylamine (DIPEA), quinoline, 2,4,6-collidine, and 4-dimethylaminopyridine 
(DMAP). By analyzing the contents of the organic layer by NMR after the reaction was 
complete, the amines DABCO, 2,4,6-collidine, quinoline, and DMAP were present. Thus, at 
small amine concentrations (0.1 M) in PhCl, large-scale encapsulations were attempted with 
these four amines. Unfortunately, none of these solutions formed microcapsules, presumably 
because the amines interfered with formation of the UF shell wall. Nevertheless, this small 
screening study was limited due to lack of time and resources, and future studies could explore 
additional bases for use in this system. 
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6.5 Experimental Section 
 
 Materials: Chlorobenzene (PhCl), ethyl phenylacetate (EPA), phenylacetate (PA), 
anisole, xylenes, hexyl acetate (HA), urea, ammonium chloride, formaldehyde solution            
(37 wt/vol%), resorcinol, imidazole, N-Boc propargyl amine, diethylenetriamine (DETA),        
di-tert-butylcarbonate, triethylamine (TEA), and sulfamic acid were used as received from 
Sigma-Aldrich, while m-phenylenediamine (mPDA), 4,4'-diaminodiphenyl sulfone (DDS), and 
dicyandiamine (DICY) were purchased from Sigma-Aldrich and ground with a mortar and pestle 
to make finer solid particles, as mentioned in the text. Triethylenetetramine (TETA, tech-grade, 
60%) was received from Sigma-Aldrich and boiled to remove the water before use. Ethylene-
maleic anhydride (EMA) copolymer (Zemac-400) powder of average molecular weight          
(Mw = 400,000 g/mol) was provided by Zeeland Chemicals. As-received EMA powder was 
mixed overnight with deionized water in a warm bath to obtain a 2.5% (wt/vol) aqueous 
surfactant solution. Poly(vinyl alcohol) or PVA (87–89% hydrolyzed,                                        
Mn = 85,000–124,000 g/mol) was purchased from Sigma-Aldrich and used in a 1 wt% solution 
in water as a surfactant. Hexanediamine (HDA) was purchased from Sigma-Aldrich and    
freeze-dried in water for 3 days before use. Curezol 2MZ-Azine UNGD Curing Agent (Curezol 
2MZ), diethylenetriamine (Ancamine DETA) Curing Agent, and Ancamine 2337S Curing Agent 
(2337S) were received from Air Products and the solids were ground with a mortar and pestle 
before use. Epikure P-100 Curing Agent (P100) was purchased from Hexion as red pellets, and 
ground into a fine powder before use. Curing Agent W (diethyltoluene diamine) was purchased 
and used as received from Hexion. EPON 828, EPON 862, and Epikure 3274 were purchased 
from Miller-Stephenson and used as received.  
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N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine (Santoflex 6PPD) was received from 
Flexsys in pellet form and ground with a mortar and pestle before use, while N,N'-
diphenylguanidine (Perkacit DPG) was used as-received from Flexsys as a white solid.  
 Epoxy Sample Preparation: Cylindrical epoxy samples (15 mm x 7.5 mm,                
0.85 g ± 0.01 g) were prepared at a 100:12 parts per hundred (pph) mixture of EPON 828:DETA, 
a 100:50 pph mixture of EPON 862:Epikure 3274, and a 100:26.4 pph mixture of EPON 862:W. 
The resins were degassed for 10–20 min under vacuum then sat at RT for 20 min before stirring 
in solid amine particles and pouring the resins into PDMS silicone rubber molds. The samples 
(828:DETA and 862:3274) underwent a cure cycle of 24 h at room temperature, followed by    
24 h at 35 °C, referred to in the text as the „standard curing conditions.‟ Epoxy samples 
composed of an 862:W matrix underwent higher temperature cures, with a „full cure procedure‟ 
designated as 24 h at 70 °C, 1 h at 121 °C, and 2.5 h at 177 °C.
6
                                            
 Short-groove tapered-double-cantilever beam (TDCB) samples
26
 were prepared with the 
same epoxy matrix (828:DETA) with mPDA and microcapsules in the central insert region. 
After creating a precrack with a sharp razor blade into the groove of the sample, the TDCB 
specimens were pin-loaded and tested to failure using an Instron load frame under displacement 
control at a rate of 5 μm/s.22,26 The healed TDCB samples were again loaded to failure and the 
load-displacement curve was recorded. All healed samples were tested after 24 h RT healing, 
unless otherwise stated. 
 Preparation of Microcapsules: Epoxy-solvent microcapsules (13 wt% 828/862 or       
50 wt% 828/862 in EPA/PA) were prepared following a previously reported procedure.
17
 Prior to 
encapsulation, 828/862 was dissolved in the solvent and thoroughly mixed to decrease the 
viscosity of the core mixture. In preparing the capsules containing the N-Boc protected amine,    
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1 g N-Boc propargyl amine was dissolved in 30 mL xylenes and stirred overnight. A half-batch 
of microcapsules were prepared at a stir rate of 350 RPM.  
 Preparation of Wax Microspheres: Microspheres containing solid amines were 
prepared following a previously reported procedure
18
 with modifications. Briefly, 10 g paraffin 
wax (mp 58–62 °C)/amine at various ratios (6 g wax + 4 g amine for 40% and 5 g wax +             
5 g amine for 50% spheres) was combined and melted in a capped, 20 mL scintillation vial in an 
80 °C water bath. In a 1000 mL beaker, 225 mL of a PVA solution (25%, 56 mL) in deionized 
water (75%, 169 mL) was mechanically stirring at 1000 RPM in an 80 °C water bath while the 
wax/amine mixture was added. The stirring continued for 1–2 min then 400 mL of an ice water 
mixture (mostly ice) was quickly added to the beaker upon stopping the stirring, and the beaker 
was removed from the bath. The microspheres were filtered and dried under vacuum overnight. 
 Amine Protection Syntheses:
24,25
 2.2 equiv. (Boc)2O and 5 mol% sulfamic acid were 
charged in a 10 mL flask and pre-heated at 30 °C. 1 mL DETA/TETA was added slowly via 
pipette and smoke immediately formed. The Boc-TETA product was filtered, washed with 
deionized water, and dried under vacuum overnight before further analysis. For the amine-salt 
formation,
25
 0.5 mL DETA/TETA (9.16 M) was added to a 20 mL scintillation vial in ethanol 
(3.84 mL for DETA; 1.29 mL for TETA). Concentrated HCl was slowly added via pipette to the 
vial (0.38 mL for DETA; 0.76 mL for TETA). These reactions are extremely exothermic and 
need to be done in a hood. Upon mixing, the vials were capped and stored in the freezer to 
facilitate crystal formation. 
 Pseudo-encapsulation Procedure: 1,4-diazabicyclo[2.2.2]octane (DABCO), tetramethyl 
piperidine (TMP), 1,8-Diazabicyclo[5.4.0]undec-7-ene (DBU), N,N-Dicyclohexylmethylamine 
(MDCA), N,N-diisopropylethylamine (DIPEA), quinoline, 2,4,6-collidine,                                  
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4-dimethylaminopyridine (DMAP), and cyclooctadiene (COD) were all purchased from    
Sigma-Aldrich and used as received. Stock core solutions of 85 μL amine (listed above), 31 μL 
COD (as an internal standard), and 5 mL PhCl solvent were prepared. For each experiment,     
1.2 mL core solution was added to 2 mL deionized water and 0.5 mL of the 2.5 wt% EMA 
solution in 20 mL scintillation vials. The vials were magnetically-stirred at 55 °C for 4 h to 
simulate the UF encapsulation procedure.
17
 Upon cooling, NMRs were taken of each mixture in 
the solvent CDCl3. 
 Instrumentation: Capsule diameters were determined through optical microscopy using 
a Leica DMR Optical Microscope at various magnifications. ImageJ software was used to 
measure the diameters and an average of at least 100 capsules was used to determine the size 
distribution. A Philips XL30 ESEM-FEG instrument was used to image epoxy fracture surfaces 
with a 5 kV electron source after sputter-coating the sample with a gold-palladium source. 
Differential scanning calorimetry (DSC) was performed on a Mettler-Toledo DSC 821
e
 
instrument, calibrated by indium, octane, and zinc standards. Unless otherwise indicated, the 
heating rate was 10 °C/min. For each analysis, the sample (ca. 20 mg) was accurately 
weighed into an aluminum pan, which was hermetically sealed. Routine DSC traces recorded 
heat flow during a heating and cooling cycle over the temperature range 25–300 °C at a rate of 
10 °C/min. The Tg was measured (reported as the midpoint temperature of the transition) on the 
second heating scan after a single cycle from 25–300 °C at a rate of 10 °C/min. Isothermal DSC 
experiments were performed at 25 °C for 120 min. The degree of cure (%, αt) was determined as 
a function of time using the following equation: 
            T
t
t
Q
Q
100
                                         (1) 
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where Qt is the reaction heat during an isothermal scan at various times t, and QT is the total heat 
of polymerization taken from dynamic scans.
27,28
 Thermogravimetric analysis (TGA) was 
performed on a Mettler-Toledo TGA851
e 
instrument, calibrated by indium, aluminum, and zinc 
standards. The mass loss was recorded during a heating cycle over the temperature range of    
25–650 °C at a constant rate of 10 °C/min in an atmosphere of N2. For each experiment, 
approximately 2–5 mg of sample was accurately weighed (± 0.02 mg) into an alumina 
crucible. Mid-IR absorbance spectra were acquired for epoxy/amine mixtures on a Nicolet Nexus 
670 FT-IR spectrometer representing the sum of 64 individual scans at a resolution of 4 cm
-1
 
from 800–4000 cm-1. For Santoflex 6PPD, 6.6 g solid was added to 11.8 g EPON 828, stirred 
and degassed under vacuum for 10 min before putting two drops in between two NaCl plates for 
FTIR analysis and a small amount (10 μL) was used for DSC analysis. For DPG, 3.8 g solid was 
added to 10 g EPON 828 for FTIR and DSC analysis as described above for Santoflex samples. 
Absorption spectra were recorded from 200–800 nm with a background scan of hexyl actetate 
solvent using a Shimadzu UV-Visible Spectrophotometer, model number UV-1601PC. NMR 
experiments were performed on a Varian UNITY INOVA 500NB instrument in CDCl3. 
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6.7 Figures and Tables 
 
 
 
 
Figure 6.1. Chemical structures of solid amines investigated. 
 
(a)  (b)  
Figure 6.2. (a) Optical micrograph of solid Ancamine 2337S particles and (b) SEM image of 
fracture surface of an 828:DETA epoxy matrix containing solid Ancamine 2337S particles     
(6.5 wt%). 
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Figure 6.3. Dynamic DSC thermograms of EPON 862:Epikure 3274 with 5.1 wt% P100 solid 
particles. The first scan is a temperature sweep of the uncured resin and the second heating scan 
is done upon cooling to RT. 
 
(a)  (b)  
 
Figure 6.4. SEM images of healed fracture surfaces of an 862:3274 epoxy matrix containing 
P100 particles (5.1 wt%) with (a) no solvent and (b) EPA injected as a healing agent. 
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(a) (b)  
 
Figure 6.5. Normalized dynamic DSC scans of (a) different sized solid mPDA particles in 
EPON 828 (small mPDA = 75–180 µm) and (large mPDA, > 180 µm), and (b) small mPDA 
particles in 828 (red curve) and 828:DETA epoxy matrix (black dashed curve) compared to the 
828:DETA epoxy matrix only (blue curve). 
 
(a)  (b)  
 
Figure 6.6. SEM images of healed fracture surfaces of an 828:DETA epoxy matrix containing 
small mPDA particles (2.2 wt%) with injected solutions of (a) 13% 828-PhCl and                     
(b) 13% 828-PA. 
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Figure 6.7. SEM image of a healed TDCB fracture surface of an 828:DETA epoxy matrix 
containing small mPDA particles (0.5 wt%) with 3.5 wt% microcapsules. Samples were healed 
at RT for 24 h. 
 
(a) (b)  
 
Figure 6.8. TGA and DSC dynamic scans of (a) DDS and (b) DICY solid particles. 
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(a)  (b)  
 
Figure 6.9. SEM images of healed fracture surfaces of an 828:DETA epoxy matrix containing 
DDS particles (3 wt%) with injected solutions of (a) EPA solvent only and       (b) 13% 828-
EPA. 
 
(a)  (b)  
 
Figure 6.10. SEM images of healed fracture surfaces of a fully-cured 828:DETA epoxy matrix 
containing DICY particles (3.8 wt%) healed at 125 °C for 1 h with injected solutions of            
(a) 13% 828-EPA and (b) 13% 828-PA. 
 
 
 
Figure 6.11. Chemical structures of the components of a high temperature epoxy matrix. 
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Figure 6.12. DSC thermograms of EPON 862:W through different cure stages. The green trace 
is the „full cure cycle.‟ 
 
(a)  (b)  
 
Figure 6.13. SEM images of healed fracture surfaces of a fully-cured 828:DETA epoxy matrix 
containing DICY particles (3.8 wt%) healed at 125 °C for 1 h with injected solutions of (a) 13% 
828-EPA and (b) 13% 828-PA. 
 
 
 
 
Figure 6.14. Chemical structures of amine antioxidants. 
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(a) (b)  
 
Figure 6.15. (a) Dynamic DSC scan of EPON 828 with DPG at a stoichiometric ratio; and        
(b) FTIR spectra of DPG solid only, and EPON 828 combined with DPG at time = zero and    
time = 24 h. 
 
 
 
 
Figure 6.16. Dynamic DSC scans of EPON 828 with Santoflex 6PPD at a stoichiometric 
amount. The second sweep was performed upon cooling the sample back to 25 °C from 300 °C.  
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Figure 6.17. FTIR spectra of Santoflex 6PPD solid only, and EPON 828 combined with 
Santoflex 6PPD at time = zero and time = 24 h. 
 
 
(a) (b)  
 
Figure 6.18. (a) Calibration for absorbance at 475 nm of Santoflex 6PPD in hexyl acetate stock 
solutions at known concentrations. The data point from the capsules contained an initial core 
solution of 0.03 M Santoflex 6PPD in hexyl acetate; (b) UV-visible spectra for stock solution of 
0.03 M (1 wt%) Santoflex 6PPD in hexyl acetate and for crushed microcapsules that contain a 
core solution of a 0.03 M Santoflex 6PPD. 
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(a) (b)  
 
Figure 6.19. (a) TGA thermograph for UF microcapsules containing 0.1 M Santoflex 6PPD in 
HA and (b) dynamic DSC scans of a 0.1 M Santoflex 6PPD in HA solution compared to 
microcapsules containing a solution at the same concentration. 
 
 
(a)  (b)  
 
Figure 6.20. Optical images of prepared wax spheres containing (a) 40% mPDA and                
(b) 6.25% HDA. 
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(a) (b)  
 
Figure 6.21. Normalized dynamic DSC scans of (a) paraffin wax and wax spheres containing 
mPDA at 2 concentrations; and (b) paraffin wax compared to wax spheres containing 10 wt% 
first generation Grubbs‟ catalyst. 
 
 
(a)  (b)  
 
Figure 6.22. SEM images of wax spheres in 828:DETA with: (a) no solvent injected; and        
(b) hexyl acetate injected in fracture plane after healing. 
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(a)  (b)  
 
Figure 6.23. (a) Optical micrograph of capsules containing the N-Boc amine in xylenes;          
(b) Dynamic TGA traces of these capsules compared to pure xylenes capsules. 
 
 
(a) (b)  
 
Figure 6.24. (a) DSC thermograms of N-Boc amine in xylenes (0.22 M), microcapsules 
containing this solution, and pure xylenes microcapsules; (b) IR scans of N-Boc amine in 
xylenes (0.22 M), crushed microcapsules containing this solution, and pure xylenes. 
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(a)  (b)  
 
Figure 6.25. (a) Optical micrograph of N-Boc amine capsules after heat treatment in EPA; (b) 
TGA curves of N-Boc amine capsules before and after heat treatment in EPA.  
 
 
(a) (b)  
Figure 6.26. (a) Dynamic DSC scans of TETA and Boc-protected TETA; and (b) FTIR spectra 
of TETA and Boc-protected TETA. 
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(a)  (b)  
Figure 6.27. SEM images of healed fracture surfaces of (a) a regular cured epoxy sample healed 
with triethylamine and (b) a post-cured epoxy sample healed with triethylamine.  
 
 
 
 
Figure 6.28. Chemical structures of bases screened for encapsulation. 
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Table 6.1. Characteristics and Solubility of Solid Amines. 
 
Solid Amines Ratio to 
Epoxy 
(pph) 
Melting 
Point (°C) 
Solubility 
Meta-phenylene diamine 
(mPDA) 
14.5 64-66 EPA, PA, PhCl, anisole 
Ancamine 2337S 
(aliphatic amine) 
40 63-78 Partially in: xylenes, PhCl, EPA, 
HA 
imidazole - 89-91 Not in: PhCl, EPA, PA, HA, 
xylenes 
P100 Curing Agent - 85-105 PA 
4,4'-diaminodiphenyl 
sulfone (DDS) 
30 175 PA 
Dicyandiamide (DICY)* 25.5 208 Not in: PhCl, EPA, PA 
Curezol 2MZ  33.2 250 Not in: PhCl, EPA, PA, HA, 
xylenes 
* 6 or 8 pph DICY is used as an accelerator in an EPON 828:DETA matrix.  
 
Table 6.2. Curing Behavior of EPON 862:Epikure 3274 at a 2:1 ratio (wt%). 
 
Curing Conditions Residual Heat of 
Rxn (J/g) 
Degree of 
Cure (%) 
Tg 
(°C) 
Baseline 432 100 - 
24 h RT, 24 h 35 °C 110 75 - 
24 h RT, 48 h 35 °C 28.3 93 - 
24 h RT, 24 h 35 °C, 1 h 140 °C 0 100 - 
cured with P100 41.2 90 55 
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Table 6.3. Thermal Reactivity of Epoxy Systems with mPDA. 
 
EPON 828:DETA Residual Heat 
of Rxn (J/g) 
Onset Temp of 
Polymerization 
(°C) 
Degree of 
Cure (%) 
Tg (°C) 
Baseline 540 70 100 130 
 
EPON 828 with  
14.5 wt% mPDA 
Residual Heat 
of Rxn (J/g) 
Onset Temp of 
Polymerization 
(°C) 
Degree of 
Cure (%) 
Tg (°C) 
Baseline 507 123 100 149 
After 12 h at RT 94 - 19 - 
After 24 h at RT 141 - 28 - 
 
 
EPON 828:DETA 
with 14.5 wt% 
mPDA 
Residual Heat 
of Rxn (J/g) 
Onset Temp of 
Polymerization 
(°C) 
Degree of 
Cure (%) 
Tg (°C) 
Baseline 445 58 100 92 
- Compared to 
828:DETA 
- 82 - 
- Compared to 
828:mPDA 
- 88 - 
After 12 h at RT 414 - 93 - 
After 24 h at RT 414 - 93 - 
 
Table 6.4. Self-Healing Results for TDCBs containing mPDA and Epoxy-EPA Capsules. 
 
mPDA 
(wt%) 
Capsule 
(wt%) 
Capsule Core 
Materials 
Healing 
Conditions 
Healing 
Efficiency (%) 
Notes 
10 Injection of 13% 828-EPA RT – 2 days 7.4 ± 1.8 Wet fracture 
surface 
0.5 3.5 50% 828-EPA RT – 1 day 0  
2.3 4.7 50% 828-EPA RT – 2 days 0  
2.3 4.7 50% 828-EPA 35 °C – 2 days 0  
 
Table 6.5. Curing Behavior of EPON 862:W at a 100:26.4 ratio. 
 
Curing Conditions Residual Heat 
of Rxn (J/g) 
Degree of 
Cure (%) 
Tg (°C) 
Baseline 409 100 138 
24 h 70 °C 30.5 92 93 
24 h 70 °C, 1 h 121 °C 141 98 100 
24 h 70 °C, 1 h 121 °C, 2.5 h 177 °C  0 100 142 
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Table 6.6. Properties of Rubber Amine Particles. 
 
Amines Ratio to Epoxy (pph) Melting 
Point (°C) 
Solubility 
Santoflex 
6PPD 
1-3 46-51 EPA, PA, HA, toluene, 
xylenes, PhCl 
Perkacit 
DPG 
0.5-1 144 EPA, PA, PhCl, HA 
 
 
Scheme 6.1. Deprotection of an encapsulated Boc-protected amine. 
 
Scheme 6.2. Boc-Protection of DETA.
24
 
 
 
 
Scheme 6.3. Boc-Protection of TETA.
24
 
 
 
 
Scheme 6.4. Acid-Protection of DETA.
25
 
 
 
154 
 
CHAPTER 7 
 
SOLVENT-BASED SELF-HEALING OF THERMOPLASTIC MATERIALS 
 
 
7.1 Initial Screening of Solvents 
 
7.1.1 Introduction 
 
 Microcracking damage to plastics due to everyday stresses can result in catastrophic 
failure over time. Self-healing polymers containing liquid monomer microcapsules and a solid 
catalyst phase have been developed to arrest crack growth and prevent failure in bulk 
materials.
1,2
 A simpler and more economic epoxy system has been developed in which solvent 
microcapsules are the only component necessary for the self-healing process to occur upon crack 
damage, discussed in Chapters 2 and 4 of this dissertation. Work has yet to be done on 
processing thermoplastics containing solvent-filled microcapsules for self-healing; thus, this 
chapter will present our efforts and progress in achieving this goal. 
 Crack healing in thermoplastic materials has been demonstrated by a number of 
researchers over the past 40 years. At temperatures above that of the materials‟ glass transition 
temperature (Tg), polymer chains can diffuse across a crack plane. This interpenetration and 
chain entanglement makes load transfer possible in healed materials.  Previous work with 
solvent-based crack healing involved this type of chain entanglement.
3-7
 It is reported that the 
healing process is two-fold: first is the wetting of crack surface which is followed by the 
diffusion of solvent, allowing recovery of the mechanical properties of the polymer.
3-7 
Ethanol, 
methanol, and carbon tetrachloride were the solvents chosen to demonstrate crack healing in 
poly(methyl methacrylate) (PMMA) at temperatures above 40 °C.
3,6,7
 One group recently 
reported the self-healing of PMMA with microencapsulated glycidyl methacrylate.
8
 However, 
this approach was not a solvent-based system because it employed a functional acrylate 
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monomer and the samples containing the microcapsules were prepared using living radical 
polymerization reactions, not commercial thermoplastic processing techniques. Thus,       
solvent-based crack healing in processed thermoplastics has not been reported with pure solvent 
microcapsules. Additionally, in some prior work the healing process was non-autonomic; 
researchers manually injected the solvents onto the thermoplastic surfaces and measured 
outcomes of healing performance as a result of polymer diffusion.
3-7 
Our proposed mechanism 
for self-healing thermoplastics based on solvent healing agents would be as follows: the 
thermoplastic material experiences damage, the ruptured microcapsules release solvent into the 
crack plane and by solvent-promoted chain entanglement or plasticization, the crack is healed 
(Figure 7.1). No stimulus such as increased heat or pressure would be needed for the healing 
event to occur. 
 This chapter first demonstrates solvent healing in thermoplastics with a variety of 
common organic solvents. Then, it goes on to describe various attempts at manufacturing 
PMMA with microcapsules using commercial processes. As a method for analyzing 
microcapsule survival in the samples post-processing, x-ray microtomography (microCT) was 
employed as a non-destructive imaging technique. The final phase of this project includes testing 
the healing efficiencies of samples containing solvent microcapsules using mechanical testing. 
The last section in this chapter summarizes efforts towards developing a blended self-healing 
polymer in which thermoplastics were melted or incorporated in solid bead form into a         
fully-cured epoxy matrix. Self-healing of these systems was initiated by solvent release from 
embedded microcapsules – no heat or external intervention was necessary. 
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7.1.2 Lap-shear Testing – PS/PC 
 
 In order to screen the various solvents that can be encapsulated for use with healing 
thermoplastic matrices, a series of lap-shear experiments with commercial polystyrene (PS) and 
polycarbonate (PC) sheets were conducted. PS reported an Mn = 35 kDa and a PDI = 1.6, while 
PC had an Mn = 92 kDa and a PDI = 2.2 measured by gel permeation chromatography (GPC) 
traces. Using a previously reported sample geometry and procedure for lap-shear testing,
9
 
solvents were injected into the overlap region and clipped together (one „foldback clip‟ on each 
side of the overlap region) overnight to heal at room temperature (RT). Initially, the overlap 
region was 15 mm x 25 mm for both the PS and PC samples. However, when testing the PS 
samples, the bond was so strong that they were observed to bend to failure instead of shearing at 
the interface of the solvent bonded region. Consequently, the overlap was reduced                    
(10 mm x 25 mm) and samples did shear at the interface, allowing for an accurate analysis of the 
failing stresses for each solvent. On the other hand, PC is a stiffer polymer and this bending 
phenomenon was not observed. Thus, the peak loads accurately reported the strength of the 
solvent bond formed. A summary of these tests for PS and PC is shown in Figure 7.2. While 
there is not a significant difference between solvent behavior for PS (other than the extremely 
polar and nonpolar solvents used as controls), ethyl phenylacetate (EPA) and chlorobenzene 
(PhCl) did outperform the other solvents for the PC samples. Figure 7.3 shows a representative 
picture of the lap-shear testing setup and a scanning electron microscopy (SEM) image of a 
healed interface for a PC sample indicating cohesive failure. This mode of failure was observed 
for every sample, further confirming the mechanism of polymer chain entanglement or solvent 
welding for these thermoplastics. By appropriately matching a thermoplastic with a good healing 
solvent, a self-healing thermoplastic can be envisioned. 
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7.1.3 Tear Testing – PDMS  
 
 The healing behavior of solvents was also explored in an elastomeric           
poly(dimethyl siloxane) or PDMS matrix. Previous efforts in our laboratory demonstrated a   
self-healing elastomeric system with healing efficiencies of 70-100% measured by recovered tear 
strength.
10
 The mechanism of solvent-based healing in an elastomeric system would be based on 
chain entanglement and mobility in the presence of an optimal solvent. Initial experiments 
probed the ability of selected solvents to sufficiently swell the PDMS matrix to promote chain 
mobility. A number of nonpolar solvents such as xylenes, chlorobenzene, and hexyl acetate 
showed promise for use in an autonomic system as evidenced by their high degree of swelling 
reported after 48 h (Figure 7.4). These results agree with previous findings related to solvent 
compatibility of PDMS.
11 
  
 However, when bulk tear testing was attempted with PDMS and references tests 
conducted with a variety of solvents, minimal healing response was observed. PDMS tear 
specimens
10
 were then prepared with 15 wt% solvent capsules. Little to no healing was observed 
for selected solvents (Table 7.1). These solvents were chosen due to their ability to form robust 
urea-formaldehyde (UF) microcapsules, but the healing results did not match the trend observed 
with the swelling performance of the solvents. A representative SEM image of a tear specimen 
containing EPA capsules after the healing event is shown in Figure 7.5. Xylenes promoted the 
highest degree of swelling with the PDMS matrix, but when xylenes capsules were incorporated 
into the tear specimens, no healing response was observed. It was proposed that the reason for 
limited healing was due to a large damage volume between the tear faces after the initial damage 
event occurred. During this experimental test, exact alignment of the two tear faces to promote 
intimate contact was extremely difficult. Thus, the swelling of the PDMS was not significant 
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enough to promote chain entanglement across such a large area in the specimen. Additionally, 
since the polymer chains in elastomers are part of a three-dimensional (3D) chemically-bound 
cross-linked network, they don‟t have the ability to entangle as well as other bulk polymers. 
Since other thermoplastic materials discussed in this section showed more promise for solvent 
healing, PDMS was no longer considered for further studies. 
7.1.4 Bulk Fracture Testing – PMMA 
 
 PMMA was chosen as a viable thermoplastic to study because of the previous findings 
with regard to solvent healing
3-7 
and availability. Related work on a self-healing bone cement 
utilized a Teflon mold to make tapered double-cantilever beam (TDCB) specimens (Figure 7.6) 
for crack-length independent fracture testing.
9,12
 In the sample preparation, MMA monomer was 
polymerized around commercial, cross-linked PMMA beads by a free-radical mechanism 
initiated by benzoyl peroxide and with dimethylaniline as the tertiary amine activator. This 
mixture was poured into a Teflon mold (Figure 7.6) and tested in the same manner as epoxy 
specimens as previously discussed in this dissertation (with the Instron load frame under load 
displacement).
13
  
 Using these testing protocols, crack healing at RT was demonstrated in polymerized 
PMMA (bone cement mimic) with a variety of solvents (Table 7.2). These solvents were selected 
for this study because their water immiscibility allowed for microencapsulation using the in situ 
UF procedure.
14
 Ethanol and methanol were tested in this study since healing with these solvents 
had been previously reported,
3-7
 even though they cannot be encapsulated with the UF procedure. 
Reference tests (Figure 7.7a) were conducted by manually injecting solvent into the crack plane 
to predict the healing response of an eventual in situ system that contains solvent microcapsules. 
The healing was reported after 24 h and resulted in ductile fracture. Thus, both the healing 
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efficiency based on peak load (η)2 and peak area (η')15,16 was reported for selected solvents in 
Table 7.2. The trend shown here does not tend to correlate to that of solvent healing in an epoxy 
matrix as was previously reported (Chapter 3 of this dissertation).
17 
However, it is evident that 
EPA is the superior solvent for healing the PMMA matrix, followed by PhCl. Both of these 
solvents reported higher healing efficiencies than that of methyl methacrylate (MMA) monomer 
alone, confirming that solvent healing was occurring rather than possible reactions of residual 
material in the bone cement in the presence of solvent. MMA monomer acts like a solvent when 
injected into the crack plane of bone cement samples, but its functionality allows for further 
polymerization to occur; whereas with organic solvents, solvent welding is the most feasible 
mechanism of healing.
9
 The poor healing response in these tests for ethanol and methanol did not 
correspond to previously reported systems,
3-7
 but could be due to the difference in the PMMA 
processing conditions used in each case. Representative SEM images of healed fracture surfaces 
are shown in Figure 7.8 for a control specimen (no solvent injected), methanol which exhibited 
very little healing, and an EPA-healed surface. 
 After the initial demonstration of solvent healing with reference tests, in situ specimens 
(Figure 7.7b) were prepared that contained solvent-filled microcapsules (EPA, phenyl acetate or 
PA, and PhCl). Pictures of these samples are shown in Figure 7.9. As the amount of capsules in 
the PMMA matrix increased, the healing response was non-linear for both EPA and PhCl  
(Figure 7.10a), which was unexpected and different from previous findings with microcapsules 
embedded in an epoxy matrix.
13,18
 The best healing response was observed for the smallest 
amount of capsules (3 vol%) and as the capsule volume increases, the healing efficiencies 
decreased. The exception for this trend was the healing for PA capsules. One explanation for this 
general trend is that the virgin fracture toughness is decreased with the increased amount of 
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solvent capsules embedded (Figure 7.10b). Thus, the healing efficiencies were somewhat 
misleading at higher microcapsule loadings because the virgin peak loads were significantly 
lower than expected. Additionally, with a larger amount of microcapsules, there are fewer 
polymer chains to entangle across the crack plane for healing to occur. Figure 7.11 shows 
representative load-displacement curves for two sets of samples containing capsules. 
Furthermore, the ductile nature and difficulty in preparing void-free samples due to rapid 
polymerization of the MMA monomer by the high amounts of BPO initiator and DMA activator 
in the bone cement preparation complicated the self-healing analysis for these in situ samples. 
When these samples were imaged using SEM, it became evident that a healing event was 
occurring because of the dissolved surfaces and entangled chains apparent on the specimens 
(Figure 7.12).  
7.2 Processing PMMA with Microcapsules 
  
 The preliminary solvent screen presented in the previous section successfully confirmed 
that encapsulated solvents will serve as efficient healing agents for commercial thermoplastics. 
In the design of a self-healing thermoplastic, solvent-filled microcapsules would have to be 
incorporated into the bulk polymer matrix. To our knowledge, there is no record in the literature 
of this task being accomplished. Thus, this section describes multiple attempts to incorporate 
microcapsules containing a solvent healing agent into bulk PMMA using commercial processing 
techniques. Samples were prepared at three different locations depending on equipment 
availability (ranging from the highest to lowest temperatures and pressures) – Illinois State 
University (ISU) for extruding/compounding followed by injection molding into test specimens, 
the Army Research Laboratory (ARL) for compounding and molding on the micro-scale, and the 
University of Illinois at Urbana-Champaign (UIUC) for solvent casting PMMA samples 
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containing microcapsules. This section describes the processing conditions at each location and 
their corresponding outcomes. 
 An optical image of the microcapsules used in this study is shown in Figure 7.13. 
Iodobenzene was selected as the core because it provided more contrast than other solvents for 
the x-ray based imaging (described in the Section 7.2.4) used in determining capsule survival. 
Furthermore, it exhibited a qualitative solvent healing effect when used to weld pieces of 
commercial PMMA together and a healing response of 34.3% in reference tests (Table 7.2). The 
prepared microcapsules have been shown to be thermally stable for temperatures up to 250 °C 
when the shell wall decomposes. A description of capsule stability was given in Chapter 2 of this 
dissertation.
17,19,20
 Based on our preliminary thermal stability studies, it was hypothesized that 
the capsules would survive the high temperatures required by commercial plastics processing.  
7.2.1 Extrusion and Injection Molding 
 
 PMMA was first compounded with dyed iodobenzene microcapsules using standard 
extruding conditions. The temperatures for the various parts of the extruder are listed in       
Table 7.3. Using a vented barrel compounder at ISU, the capsules could be visually identified in 
the compounded strands by the pink color present in the clear PMMA matrix (from the            
co-encapsulated Oil Red O dye). The method of introducing capsules through the small vent was 
not ideal, since a pre-weighed amount was hand-fed into the vent via funnel. Thus, the volume of 
capsules that could be added without clogging the vent opening (inset of Figure 7.14) was 
limited (0.7 wt% or 0.49 vol%). Then the PMMA material that was populated with 
microcapsules in the form of strands was injection molded into rectangular bar specimens to be 
used for eventual compression testing. In an effort to minimize rupture of the embedded capsules 
in the PMMA strands, they were not pelletized but force-fed into the hopper by hand. The 
162 
 
molding parameters used followed the standards given in ASTM D3641-02 for injection molding 
of thermoplastics, and more details are given in the Experimental Section of this chapter  
(Section 7.4). Further analysis of these samples was conducted via microCT (Section 7.2.4) and 
neat PMMA samples were used for compression testing (Section 7.2.5) described later in this 
chapter. 
7.2.2 Micro-scale Processing 
 A smaller type of compounding was next attempted at ARL using micro-scale equipment. 
The optimal settings for compounding had to be established, in terms of screw speed and type of 
extrusion (straight pass, re-circulated, force control). During these experiments, the most 
promising samples would be those that contained the least amount of bubbles and the highest 
amount of microcapsules (determined by microCT). Thus, solid mixtures of PMMA         
(powder form) were prepared with three different amounts of dyed iodobenzene microcapsules 
(2.5, 5, and 7.5 wt%). These mixtures were then fed into a twin-screw compounder in 15 g 
increments at screw speeds ranging from 25–100 RPM to process strands of PMMA containing 
microcapsules. Another variable tested was feeding the material through the compounder in a 
straight shot versus a re-circulated sample. The conditions used for all these experiments are 
given in Table 7.4.  
 Samples were first qualitatively characterized in terms of color and amount of bubbles 
present in the strands since the optimal sample would be void-free. As the amount of capsules 
incorporated increased, the strands turned from a pink color (matching that of the dyed 
iodobenzene microcapsules) to a deep orange color. Upon heat treatment to UF capsules, it has 
been qualitatively observed the shell wall changes color to a yellow-orange hue, indicating 
decomposition of the UF polymer at high temperatures (see Section 6.4.2 of this dissertation for 
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another example). Deeply colored samples could also indicate a high amount of capsule rupture 
during processing, leading to very low percentages of capsule survival. At the different screw 
rates used to prepare these samples, the most void-free samples were produced at the lowest 
screw speed (25 RPM) and when the mixtures were re-circulated through the compounder. The 
strands with microcapsules were then analyzed by microCT to determine a percentage of capsule 
survival and those results are discussed later in Section 7.2.4. 
 In an alternative processing approach at ARL, a powder mixture of PMMA and 
iodobenzene capsules was mechanically mixed and inserted into the transfer line of a          
micro-injection molder that was preheated to 240 °C (Figure 7.15). A caulk gun was added to the 
end of this transfer line and the melt was forced through the line. This method provided adequate 
back-pressure to prevent ejection of the piston as the mixture heated, and allowed for controlled 
ejection of the melt. The melt formed foams upon heating, due to mostly air entrapped when the 
powder was loaded into the transfer line. Characterization of these foams by microCT is given in 
Section 7.2.4 of this chapter. 
7.2.3 Solvent-Casting  
 
 Since the post-processing analysis of samples made at ISU and ARL was not promising 
in terms of high capsule survival, we sought a method of capsule incorporation where they would 
not rupture by shear forces. The mildest procedure undertaken at UIUC was to gently mix 
iodobenzene capsules into a PMMA/solvent mixture and solvent-cast bulk samples. Although 
this type of processing is quite different from commercial endeavors, it was attempted in our 
effort to maximize capsule survival and allow proof of concept testing. Methylene chloride 
(CH2Cl2) was selected as a good solvent for PMMA and a 40 wt% solution (based on the 
concentration of PMMA) was prepared with slight heating. Iodobenzene microcapsules were 
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gently mixed into the solution by shaking the vials and then the solution was poured as thick 
strips onto polytetrafluoroethylene (PTFE) release-ply-covered trays. These samples were heated 
at 50 °C in an oven overnight (12–16 h) for solvent evaporation. The strips containing 
microcapsules (Figure 7.16) were then compression molded using a hot press into rectangular 
specimens for mechanical testing and analyzed by microCT (Section 7.2.4). 
 Throughout these various processing stages, the PMMA matrix was analyzed by 
differential scanning calorimetry (DSC) to determine the Tg of the bulk material and the degree 
of residual solvent trapped in the matrix (Figure 7.17a). The Tg should be close to 105–110 °C 
and a scan of the commercial PMMA powder is shown as a comparison to the other curves in 
Figure 7.17a (dashed line). The initial DSC scan was of the strands before heat treatment and 
shows a depressed Tg at ca. 50 °C. This transition is elevated upon heat treatment to remove 
more solvent from the matrix and finally, after the material was compression molded, the Tg 
returned to the expected temperature range. In an effort to confirm microcapsule stability during 
these processing stages, thermogravimetric analysis (TGA) was performed on capsules exposed 
ex situ to the overnight thermal treatment at 50 °C (Figure 7.17b). The scan (solid line) was 
overlaid with the initial scan of dried microcapsules post-synthesis and drying (long dashed line) 
to show very little deviation in stability. Furthermore, iodobenzene capsules were soaked in 
CH2Cl2 overnight and then filtered before analyzing by TGA. The thermal trace indicates that the 
capsules are just as stable as the previous two traces. This data confirms that the processing 
conditions do not negatively affect the mechanical properties of the PMMA polymer, and that 
the capsules survive the thermal and solvent exposure during processing, showing promise for 
developing a self-healing thermoplastic. 
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7.2.4 Determination of Capsule Survival  
 
 Since different processing conditions were used to mold PMMA with microcapsules, a 
screening method was necessary to determine the degree of capsule survival post-processing.   
X-ray microtomography (microCT)
21
 was used as a non-destructive imaging technique to view 
microcapsules within a bulk sample. This technique has been utilized by one research group to 
show microcapsules in a self-healing system.
22,23
 Its high resolution (down to 8 μm using our   
in-house equipment) allows for effective imaging of small particles with enough contrast inside 
of a bulk polymer sample. Images are taken while the sample rotates in the instrument and cross-
sectional images can then be reconstructed to form 3D depictions of samples.
24
 
  In order to determine the correlation between the amount of capsules initially added into 
the PMMA before processing and the volume of capsules that can be imaged using microCT, a 
calibration plot was constructed using epoxy specimens containing iodobenzene microcapsules at 
known concentrations (Figure 7.18a). A representative 3D image of an epoxy sample with       
1.6 vol% (2.5 wt%) iodobenzene capsules is shown in Figure 7.18b where the capsules appear 
white in the image. During the preparation of these epoxy samples, we assume 100% capsule 
survival since the capsules were gently hand-stirred into the matrix and none visibly ruptured 
during this process. The theoretical and actual amounts of microcapsules appear to correlate 
better with increasing amounts of capsules used, and a best fit line is shown in Figure 7.18a 
which was also used to calculate the volume percent of capsules in the matrix. 
 In order to determine survival rates of samples processed at ISU, small sections of 
cylindrical strands were inserted into the chamber of the Skyscan 1172 microCT machine. 
 Cross-sectional views of three samples are shown in Figure 7.19. Figure 7.19a shows the 
iodobenzene capsules imaged in a model system (epoxy) to give a reference of what the images 
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would look like if 100% of the capsules had survived, and to ensure that the capsules were whole 
and intact (white spheres on the image). Figure 7.19b shows an image of the compounded 
PMMA with capsules, with the insert pointing to three distinct capsules. The compounded 
PMMA strands containing capsules were fed through the hopper of the injection molding 
machine. In order to prove capsule survival after this step, small portions of the molded sample 
(14 mm long x 8 mm in wide x 11 mm thick) were imaged by microCT (Figure 7.19c). As a 
control for these images, processed PMMA with no capsule incorporation was also imaged after 
each processing step and no capsules were visible in any acquired image. It should be noted that 
the rings on the cross-sectional images shown here are ring artifacts of the microCT instrument 
used and were not present in the actual sample.   
 The initial capsule loading was recorded as weight percentages but converted to a volume 
percent based on the theoretical amount of capsules fed into compounders/extruders at all three 
processing locations. A summary of results is given in Table 7.5. In the PMMA samples made at 
ISU, the percent incorporation of capsules by volume (vol%) was determined from dividing the 
volume that the capsules occupied in reconstructed CT image by the total volume of the sample 
imaged. Note that there were very low capsule survival rates as visualized by CT for these 
specific processing conditions (0.02% after compounding alone). The best result for the 
compounded samples prepared at ARL at a screw rate of 50 RPM showed only 0.09% capsule 
survival by CT. Under the different screw speeds and processing conditions outlined previously 
in Section 7.2.2, the volume percent of capsules that could be identified by microCT was even 
lower than this value. However, for samples that were molded as foams using the caulk gun, a 
much higher amount of capsules survived (1.8 vol%). Reconstructed images are shown in   
Figure 7.20 to compare the same amount of capsule loading (7.5 wt% initially) in epoxy and in 
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PMMA foams. During the next processing step of compression molding for these PMMA 
samples, the amount of capsules that survived significantly decreased to 0.3%, which can be 
attributed to the high temperatures and pressures applied during hot-pressing. A similar result 
was observed for solvent-processed samples that were compression molded and a representative 
3D image is shown in Figure 7.21. Larger capsules were used in these samples                       
(38–125 μm diameters), and selected using Amira software by their intensity values and colored 
for better visualization. They appear very spherical in shape and full of liquid; however, by 
calculating the amount of capsules in the matrix by volume (Table 7.5), a significant amount of 
capsules are lost during the compression molding step. For each type of processing, the value 
from the software analysis was plugged into the best-fit line equation and a “calc” value for the 
molded samples is given in the last column of Table 7.5. These values relate the capsules imaged 
by microCT to what the initial volume of capsules in the molded sample was determined to be. 
Ongoing work for this project involves minimizing the amount of pressure applied to these 
samples in order to maximize the amount of capsules that survive this processing step.  
7.2.5 Compression Testing 
 
 Ultimately, the goal was to produce specimens of PMMA with solvent microcapsules for 
double-cleavage drilled compression (DCDC) testing.
25,26
 This method was chosen because the 
geometry was simple enough for molding designs and the mechanical test ensures small crack 
face separations for solvent healing.
25-27
 Initially, samples of neat injection molded PMMA from 
ISU were tested in compression and removed from the load frame before the crack propagated 
through the entire sample. EPA was injected into the crack faces of the intact sample to confirm 
solvent healing in processed PMMA. Then, after 24 h RT healing, the samples were tested 
following the same procedure used for the virgin samples. Crack length was tracked with a 
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camera in real time during the testing and images for both the virgin and healed samples are 
shown in Figure 7.22. Additionally, the stress vs. crack length plot for the virgin and healed 
samples shows the plateau stresses for each. The average plateau stresses and calculated KIC 
values are reported in Table 7.6. When the healed KIC was divided by the virgin KIC, a healing 
efficiency of 63 ± 11% was calculated for EPA as a healing solvent for PMMA. This value is 
close to that reported for PMMA bone cement reference tests in Table 7.2 (Section 7.1.4). In 
addition, SEM was used to analyze the crack face separation of samples after the virgin break 
had occurred (Figure 7.23). The further away from the hole in the sample, the smaller the crack 
face separation becomes. This analysis was important for a solvent-based healing system because 
in epoxy thermosets the threshold separation distance tested was 3 μm.17,28 When void-free 
samples can be successfully prepared with the maximum percentage of capsule survival (using 
the most optimal processing conditions described in the above Sections 7.2.1–7.2.3), they will be 
molded into the DCDC geometry and tested in the same manner as the reference tests outlined in 
this section. With the appropriate amount of capsules incorporated into these specimens, it is 
expected that healing efficiencies close to 63% (result from reference testing) should be 
attainable in an in situ autonomic system. 
7.3 Thermoplastic-Thermoset Blends 
 
 For commercial applications in the aerospace industry, it is imperative that self-healing 
occurs in a fully-cured polymer system, without temperature sensitive catalysts. Hayes et al. 
recognized that the mobility of thermoplastics at elevated temperatures could lead to diffusion 
across a crack plane in response to crack damage.
29,30
 Thus, modified epoxy matrices containing 
the thermoplastic poly(bisphenol-A-co-epichlorohydrin) at varying amounts was assessed for 
healing performance at temperatures of 100–140 °C.29 Instead of using heat as the catalyst to 
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initiate mobility of the blended thermoplastic in the epoxy, we investigated the use of solvent 
released from microcapsules
17,20
 embedded in the polymeric blend. The entanglement of linear 
thermoplastic chains across the crack plane in the presence of a good solvent is expected to lead 
to the recovery of fracture toughness in the self-healing material.  
 Due to the solvent healing effect of thermoplastics studied in this chapter, it was thought 
that these thermoplastics could be blended with a fully-cured epoxy thermoset as an additive to 
promote solvent-based healing. This concept is shown in Figure 7.24 in which the thermoplastic 
polymer chains would be intertwined with the epoxy matrix (A) and when crack damage occurs, 
the chains of both are broken (B). Upon release of solvent from embedded microcapsules (C), 
the thermoplastic chains begin to entangle across the crack plane (D) to heal the blended matrix. 
PMMA and PS were selected as the thermoplastics to use initially in the fully-cured epoxy 
system (EPON 828:DETA), based on the previously noted success of solvent-based healing 
(Section 7.1). The polymer polyetherimide or PEI was used in a higher-temperature epoxy 
system (EPON 862:curing agent W) since it has a higher Tg (219 °C) than PMMA or PS. The Tg 
of the thermoplastic blended into the epoxy was important because in order for this system to 
display solvent-promoted healing it needed to remain a solid during the processing temperatures 
of the epoxy system. 
7.3.1 PMMA/PS Beads 
 
 In a fully-cured epoxy, self-healing was attempted by embedding micron-sized polymer 
beads in the matrix along with solvent-filled microcapsules. When a crack propagates through 
the matrix, solvent no longer swells a fully cross-linked system, but instead solvates the polymer 
beads (PMMA or PS), forming a thermoplastic layer that seals the crack upon solvent 
evaporation. This system would work optimally if the polymer beads were small, incorporated at 
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a high loading percentage, and soluble in various solvents that can be encapsulated. This section 
outlines self-healing results in a fully-cured epoxy system with PMMA and PS beads embedded 
in the matrix with PhCl microcapsules. 
 Thermoplastic beads were synthesized by a previously reported procedure, and had an 
average diameter of 200 μm.31 Since the polymer beads act as fillers in the matrix, they were 
stirred into the degassed resin mixture and poured into TDCB molds. Samples were all          
post-cured after the „standard curing cycle‟ at 100 °C for 4 h to result in a fully-cured matrix. 
The amount of beads was varied between 10–30 wt%, while the best healing results were for 
30% PMMA and 20% PS, in separate systems. Control samples exposed to PhCl as a healing 
agent without thermoplastic beads resulted in zero healing efficiencies. A summary of both 
reference tests (long-groove TDCBs) and in situ tests (short-groove TDCBs) with 300 μm PhCl 
capsules is shown in Table 7.7. As new solvents for self-healing polymers such as phenyl acetate 
were discovered,
20
 they were found to dissolve the thermoplastic beads better than the 
previously-used PhCl. A healed fracture surface is shown in Figure 7.25. Preliminary studies 
were conducted to demonstrate this improvement, but fracture data was not acquired, which 
could be the subject of future studies. 
7.3.2 Polyetherimide 
 
 The addition of thermoplastics to epoxy matrices provides the benefit of toughening 
without compromising the strength, stiffness, and other materials properties of the system.
32,33
 In 
preliminary studies we selected polyetherimide (PEI) as the thermoplastic to demonstrate this 
concept in a matrix composed of EPON 862 and curing agent W. The chemical structure of PEI 
is shown in Figure 7.26. Three different forms of PEI were acquired to use in this study and were 
characterized by GPC (refer to Table 7.8). PEI was first blended into the epoxy
34-37
 by dissolving 
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in CH2Cl2 and added to the epoxy while heating and stirring before adding the curing agent in 
order to prepare a homogeneous material. The curing kinetics of this system has been studied in 
great detail;
35
 thus, we were able to select an appropriate cure cycle for our system by using DSC 
analysis. After 15 h at 90 °C, the matrix was 94% cured with a Tg = 111 °C (Table 7.9). This 
cure cycle was used for the remainder of experiments for the epoxy-PEI blended samples. 
 In order to determine the optimal solvent to use with this blend, a screen was conducted 
with a variety of solvents using lap-shear experiments (as had been previously reported in 
Section 7.1.2). Only chlorobenzene and dichlorobenzene (diPhCl) showed any response of 
solvent healing by welding together PEI sheets. The lap-shear results are shown in Table 7.10 
and were much lower than the response observed for PS and PC in Section 7.1.2. Nevertheless, 
fracture specimens were prepared with the epoxy-PEI blend (using all three forms of PEI) and 
these solvents were injected into the crack plane of these samples. The healing of these reference 
tests is shown in Figure 7.27. The best results were obtained with PhCl as the solvent and the 
healing was slightly higher with increasing molecular weight PEI, while the healing response 
with diPhCl was about the same for all three types of PEI. SEM images provided evidence of 
dissolved PEI material on the surface of the healed fracture planes (Figure 7.28). Accordingly, 
control samples of 862:W with no PEI showed no healing effect nor evidence of healed material 
on fracture surfaces. One last study expanded the solvent healing agent scope to two more 
solvents with similar structures to PEI – anisole and acetophenone – and investigated their 
healing capability through reference tests (Figure 7.29). Acetophenone slightly outperformed the 
healing observed with PhCl, but not to the extent where it warranted further investigation. If 
perhaps a higher concentration of PEI or another thermoplastic were used, then a higher healing 
efficiency could be achieved and this could be the study of future research.         
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7.4 Experimental Section 
 
 Materials: powder PMMA (MW = 120 kDa), benzoyl peroxide powder (BPO),        
N,N'-dimethylaniline (DMA), MMA, all solvents were purchased from Sigma-Aldrich and used 
as received, unless otherwise noted. The BPO was ground with a mortar and pestle before use. 
The PMMA cross-linked beads (MW = 350,000 g/mol) was purchased from Polysciences, Inc. 
(PDI = 2.7, Tg = 105 °C) and used as received. Poly(bisphenol-A-co-4-nitrophthalic anhydride-
co-1,3-phenylene diamine) or PEI pellets (melt indexes, MI of 9 and 18 g/10 min) were acquired 
from Sigma-Aldrich and dissolved before use. Thermoplastic sheets were purchased from 
McMaster-Carr and cut into 75 mm (length) x 25 mm (width) specimens for lap-shear 
experiments – polycarbonate rectangular bar (0.118" Thick, 3" Wide, 4' Length, Clear), 
polystyrene sheet (1/8" Thick, 40" x 72", White), and Ultem 1000 (polyetherimide square sheet, 
1/8" Thick, 12" x 12", Amber). PDMS was purchased as a two-part system from Ellsworth 
Adhesives under the trade name Sylgard 184™.10 Microcapsules were prepared with    
poly(urea-formaldehyde) / polyurethane shell walls and iodobenzene (PhI, used as received from 
Acros Organic) liquid cores following a modified in situ polymerization procedure
19
 with 
average diameters of 40–50 μm. An Oil Red O dye (Sigma-Aldrich) was added at a 0.1 wt% 
concentration with 3 g polyurethane polymer (Desmodur L75, Bayer MaterialScience) to the 
iodobenzene and were completely dissolved before adding to the stirring emulsion to make the 
microcapsules. Release ply (Wrightlease 5900, PTFE) was generously donated by Air Tech. 
Curing Agent W (diethyltoluene diamine) was purchased and used as received from Hexion. 
EPON 828 and EPON 862 were purchased from Miller-Stephenson and used as received. 
Diethylenetriamine (Ancamine DETA) Curing Agent was received from Air Products and used 
as received. 
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 Instrumentation: Gel permeation chromatography (GPC) measurements were 
performed on small pieces of thermoplastics at a concentration of 0.5–1 mg/mL (PMMA, PS, 
PC) in THF and PEI in DMF at 30 °C with a Waters 515 HPLC pump, Viscotek TDA model 300 
triple detector, and a series of 3 Styragel HR 7.8 × 300 mm columns (HR3, HR4, HR5) at a flow 
rate of 1.0 mL/min. The GPC was calibrated with monodisperse polystyrene standards, and all 
molecular weight data are reported as polystyrene equivalents. Scanning electron microscopy 
(SEM, Philips XL30 ESEM-FEG) was used to image capsules and fracture surfaces after sputter-
coating with a gold-palladium source. Thermogravimetric analysis (TGA) was performed on a 
Mettler-Toledo TGA851
e 
instrument, calibrated by indium, aluminum, and zinc standards. The 
mass loss was recorded during a heating cycle over the temperature range of 25–650 °C at a 
constant rate of 10 °C/min in an atmosphere of N2. For each experiment, approximately 2–5 mg 
of sample was accurately weighed (± 0.02 mg) into an alumina crucible. Differential scanning 
calorimetry (DSC) was performed on a Mettler-Toledo DSC 821
e
 instrument, calibrated by 
indium, octane, and zinc standards. Unless otherwise indicated, the heating rate was                  
10 °C/min. For each analysis, the sample (ca. 20 mg) was accurately weighed into an aluminum 
pan, which was hermetically sealed. Routine DSC traces recorded heat flow during a heating and 
cooling cycle over the temperature range 25–300 °C at a rate of 10 °C/min. The Tg was measured 
(reported as the midpoint temperature of the transition) on the second heating scan after a single 
cycle from 25–300 °C at a rate of 10 °C/min. 
 PMMA Fracture Testing: The bone cement samples were prepared from two parts and 
were based on the composition of Surgical Simplex® P.
9
 The solid part was comprised of a total 
of 40 g of powder of which 1.7 wt% was BPO (0.68 g) and the remainder was cross-linked 
PMMA beads. The liquid part (20 mL) was comprised of DMA (2.6 vol%, 520 μL) and the 
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remainder was MMA. The two parts were mixed together and the mixture was quickly 
transferred to long-groove TDCB molds (manufactured Teflon® molds were used). The samples 
were allowed to cure at RT for 24 h after which they were pin-loaded to failure at 5 μm/s under 
displacement control. For reference tests, each solvent (25 μL) was injected into the crack plane. 
For in situ tests, solvent capsules (average diameters = 150 μm) were stirred into the solid 
mixture of PMMA beads and BPO before the liquid part was added. No additional solvent was 
injected into the crack plane of these samples; they were left to heal at RT with no intervention 
before retesting to failure. 
 Lap-shear Experiments: Samples were machined into the desired geometry                
(75 mm x 25 mm) and the area of overlap (10 mm for PS, 15 mm for PC and PEI) was carefully 
drawn with a Sharpie marker and ruler on each sample. The appropriate healing agent mixture 
(30 μL for PS, 50 μL for PC and PEI) was carefully injected into the space in the overlap. The 
two halves of the sample were then held in place by binder clips for 48 h at RT. PS and PEI 
samples were tested at the Army Research Laboratory in Aberdeen, MD on an Instron 4505 load 
frame (equipped with a 20 kN load cell) with the sample placed between two wedge grips. The 
sample was then sheared by tension loading under displacement control at a rate of 50 µm/s. PC 
samples were tested at the Composites Manufacturing Laboratory at the University of Illinois 
(Urbana, IL) on an Instron 8500 load frame (equipped with a 10 kN load cell) with the sample 
placed between two wedge grips. The sample was then sheared by tension loading under 
displacement control at a rate of 50 µm/s.  
 PDMS Swelling and Tear Testing (15 wt% caps): PDMS samples were prepared by 
mixing a commercially available two-part system (10:1 of resin:initiator) under the trade name 
Sylgard 184™ and curing for 48 h at RT. The PDMS was cut with a razor blade into small pieces 
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(0.062 ± 0.01 g) and placed into separate 10 mL scintillation vials after weighing. Exactly 1 mL 
of each solvent was delivered to each vial using a volumetric pipette to completely immerse the 
sample in the solvent. The vials were capped and left at RT for 48 h. Each sample was then 
wiped dry and re-weighed.  The mass (in g) gained from swelling is reported. Tear testing was 
performed on rectangular PDMS samples (25 mm wide x 75 mm long x 1–2 mm thick) prepared 
the same way as stated in the literature
10
 and as described above for the swelling experiment. For 
samples containing solvent microcapsules, the PDMS resin was mixed and allowed to gel at RT 
for 4 h before stirring in 15 wt% capsules and pouring the resin in aluminum molds. After 
curing, a 50 mm precut was made in each sample with a razor blade and samples were loaded in 
tension until the tear reached the end of each specimen. Samples healed at RT for 48 h before 
retesting to measure healing efficiency. 
 PMMA Processing (ISU): PMMA pellets were purchased from Maine Plastics   
(Acrylic, # 131181, ROHM & HAAS V826 1.5MLT). The pellets were dried for 8 h at 225 °F 
(107 °C) in a tray dryer before extruding/molding. Processing was done in the Technology 
Department at ISU. The compounding of the PMMA with the microcapsules was achieved with 
an 18 mm two-stage single screw extruder in a vented barrel running at 40 RPM. Iodobenzene 
microcapsules were weighed and inserted into the barrel of the extruder through a vent port 
under the conditions given in Table 7.3. Compounded strands containing microcapsules were 
weighed and then molded into rectangular bar shapes using an Engel 60 TL injection molder 
with a 35 mm screw. A specially-designed four-cavity aluminum mold was built to produce four 
sample bars per injection molding cycle. Each bar was 56 mm in length x 8 mm in width x        
11 mm in thickness with each containing approximately 12 g of material. The process conditions 
of the injection molding are summarized in Table 7.11. 
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 PMMA Processing (ARL): A DSM Xplore Microcompounder/Extruder was used to 
extrude small batches of PMMA mixtures with 2.5–7.5 wt% iodobenzene microcapsules, in 25 g 
total sample sizes. Powder mixtures were prepared with powdered PMMA                        
(Sigma-Aldrich, 120 kDa). The indicated quantity of microcapsule and powdered PMMA were 
combined in a 40 mL vial and then gently agitated to form a macroscopically homogeneous 
mixture.  Mixing techniques included gentle shaking, vial inversion, and the use of a roller table 
for ca. 5 min (ca. 30–40 RPM) to permit homogenization with minimal damage to 
microcapsules.  
 The DSM Xplore 12cc Injection Moulder transfer line was preheated to 240 °C. A 
macroscopically homogeneous, mechanically dispersed mixture of iodobenzene capsules and 
PMMA powder was dropped into the transfer line (with a blockage at the die). After filling the 
transfer line with the powder the piston was added to the back end, and the transfer line was 
loaded into a caulk gun. After ca. 4 min, the piston was actuated and a polymer melt was ejected 
from the front of the transfer line.   
 PMMA Processing (UIUC): PMMA powder was dissolved in CH2Cl2 at a 40 wt% 
concentration (40 g in 100 mL) in a 200 mL round-bottom flask and heated at 45 °C for 45 min 
until all the solid had dissolved. Then 15 mL aliquots of this solution were poured into individual 
20 mL scintillation vials and 0.6 g dyed iodobenzene microcapsules (10 wt%) were added and 
stirred by gentle shaking. Solutions were poured onto release-ply covered trays and heated at    
50 °C in an oven overnight (12–16 h). Small sections were then compression molded using a hot 
press in the Composites Manufacturing Laboratory at UIUC (Carver, Inc., Model AutoFour/15 
with a maximum force of 15 tons and maximum temperature of 650 °F) at 105 °C for 5 min with 
700 lbs. pressure in rectangular DCDC specimens (25 mm long x 10 mm wide x 2 mm thick).  
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 MicroCT Imaging: X-ray imaging was performed on cylindrical stands, about            
15–16 mm in length x 5.2 mm in diameter, made at ISU. The imaging was done at the Beckman 
Institute, (ITG facilities, UIUC) using a SkyScan 1172 MicroCT at 80 kV with a 10 Megapixel, 
12-bit digital cooled CCD; medium resolution scan at 8.5 μm resolution and 0.2° rotation 
intervals for a complete 360° scan. An Xradia BioCT (MicroXCT-400) was used to image 
samples prepared at ARL and UIUC at 40 keV (8 W power and 200 μA current) at a 10X 
objective for 10 s exposure times. Rotation intervals were 0.5° for a complete 360° scan. Images 
were reconstructed using Xradia software and visualized in 3D with Amira
®
 software. A 
complete description of the data/image analysis and use of Amira
®
 software to reconstruct 
images is given in Appendix A of this dissertation. 
 Compression Testing: Double-cleavage drilled compression (DCDC) experiments
25,26
 
were performed on plain PMMA rectangular bar specimens prepared at ISU                             
(56 mm long x 8 mm wide x 11 mm thick). A hole with a diameter of 4 mm was drilled by 
machine in the center of the specimen and 4 precracks (one on each side of the specimen in the 
vertical direction) were introduced into the samples with a razor blade before testing. Each 
PMMA sample was individually tested in compression at the Composites Manufacturing 
Laboratory at the University of Illinois (Urbana, IL) on an Instron 8500 load frame        
(equipped with a 12 kN load cell) at a rate of 2 μm/s. The crack length was monitored by a    
fast-speed camera taking images every 2 s. Testing halted before complete failure of the 
specimens for reference tests and 5 μL EPA was injected via syringe on each side of the sample 
(2.5 μL aliquots to ensure complete coverage of the crack plane). Samples were re-tested in 
compression after healing at RT for 24 h. The data curves were analyzed according to previously 
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reported procedures
25,26,38-40
 to determine a virgin and healed plateau stress and the average and 
one standard deviation is reported for 3 samples.  
 Thermoplastic Beads: Poly(methylmethacrylate) beads were used as received from 
Polysciences, Inc., MW 350,000 (GPC); polystyrene pellets were obtained from Aldrich,       
MW 280,000 (GPC), Tg = 100 °C; and polycarbonate pellets were obtained from Bayer        
(Makrolon 2658-550115), Tg = 150 °C. Following a literature procedure,
19
 both PS and PC were 
dissolved in CH2Cl2 (8 g in 50 mL) and added to a stirring solution of 10–15 mL 1% PVA 
solution and 85–90 mL deionized water. Three-four drops of 1-octanol were added to prevent 
foaming. The solution is heated uncovered at 45 °C for 2 h at 950 RPM and solid beads were 
filtered (yield = 90%). 
 Epoxy/PEI Blends: Short-groove TDCB samples were poured at a 100:12 pph ratio of 
EPON 828:DETA and cured at RT for 4 h. The inserts were composed of the following mixture: 
3.36 g PEI (powder or pellet form) were dissolved in 20 mL CH2Cl2 with stirring and gentle heat 
(40 °C). This mixture was added to 20 g EPON 862 in a round-bottom flask and heated from  
75–120 °C until all the solvent had boiled off (3–4 h with stirring). Then a stoichiometric amount 
of curing agent W (26.4 pph relative to the amount of epoxy) was added to the blend and heated 
at 100 °C under vacuum for 10–15 min until it was bubble-free and quickly poured into the insert 
section of TDCB molds. The amounts given here made 6 samples and the insert areas of the 
PDMS molds had to be sprayed with PTFE before adding the blended mixture to keep the 
samples from sticking to the molds. TDCB fracture testing was conducted as described in 
previous chapters of this dissertation and following published procedures.
14,28
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7.6 Figures and Tables 
 
 
 
Figure 7.1. In the process of solvent-based self-healing, chain entanglement of the thermoplastic 
matrix (beige) results from encapsulated solvent (green) penetrating the network after capsules 
are ruptured: (a) the capsule's components are released into the crack plane upon crack damage, 
(b) the solvent goes into the matrix and locally depresses the Tg, and (c) as the solvent facilitates 
mobility of chains across the crack plane, the crack is healed. [Image courtesy – Eric Shoemaker 
(ITG)] 
 
(b) (a) (c) 
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(a) (b)  
 
Figure 7.2. Lap-shear results for (a) polystyrene and (b) polycarbonate sheets tested 24 h after 
solvent introduction into the overlap region of the sample. Error bars represent one standard 
deviation based on 4 samples per solvent tested. 
 
 
(a)  (b)  
 
Figure 7.3. (a) Photograph of lap-shear experiment with polycarbonate sheets being loaded to 
failure under tension; (b) SEM of a PC surface healed with EPA. 
 
 
 
182 
 
 
 
Figure 7.4. Mass gained for PDMS samples after 48 h of solvent exposure. Error bars represent 
one standard deviation based on 2 samples. 
 
 
 
Figure 7.5. SEM of a healed PDMS tear specimen surface containing 15 wt% EPA 
microcapsules. 
 
 
 
Figure 7.6. Bone cement long-groove TDCB fracture specimen Teflon mold used for 
processing.  
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(a) (b)  
 
Figure 7.7. Diagrams of two specimens used to conduct fracture experiments to monitor solvent 
healing in PMMA. The reference test (a) involves manually injecting the solvent (25 μL) into the 
crack plane of a fractured sample, while the in situ specimen (b) contains the solvent-filled 
microcapsules that release upon crack damage and no further intervention is required for healing. 
 
 
(a)  (b)  
 
(c)  
 
Figure 7.8. SEM images of healed reference TDCB specimens with (a) no solvent, (b) methanol, 
and (c) EPA. 
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Figure 7.9. Bone cement specimens containing solvent microcapsules with the closed Teflon 
mold in the center of the picture. 
 
(a) (b)  
 
Figure 7.10. (a) In situ test summary for PMMA bone cement TDCB specimens with varying 
amounts of solvent capsules. The error bars represent one standard deviation based on 3–4 
samples for each solvent. Healing efficiencies were determined by peak loads (η), not peak areas 
(η'). (b) Fracture toughness (KIC) of virgin PMMA bone cement samples as a function of solvent 
capsule loading (vol%) for EPA and PhCl. 
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(a)  (b)  
 
Figure 7.11. Representative load-displacement curves for in situ PMMA bone cement specimens 
containing (a) 3 vol% PhCl capsules and (b) 3 vol% EPA capsules. The healing was tested 24 h 
after the initial fracture event. 
 
 
(a)  (b)  
 
Figure 7.12. SEM images of healed in situ TDCB specimens for (a) 6 vol% PhCl capsules and 
(b) 3 vol% EPA capsules. 
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Figure 7.13. Optical micrograph of iodobenzene-filled microcapsules with Oil Red O dye. 
 
 
 
Figure 7.14. Compounder with vent where dyed iodobenzene microcapsules were inserted into 
the melted PMMA. Pellets of PMMA were introduced via the hopper on the right and melted to 
flow down the barrel in the direction indicated by the arrow in the photo. 
 
 
 
Figure 7.15. Micro-scale injection molder used for processing a dry PMMA 
powder/microcapsule mixture at ARL. The transfer line was replaced with a caulk gun and the 
heated mixture (240 °C) was forced through the gun. [Image courtesy – DSM Xplore] 
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Figure 7.16. Photograph of solvent-casted PMMA strips after heat treatment containing dyed 
iodobenzene microcapsules. 
 
 
(a) (b)  
 
Figure 7.17. Thermal analysis by (a) DSC of solvent-casted PMMA after each processing step; 
and (b) TGA scans of iodobenzene microcapsules before and after heat and solvent treatment. 
Capsules were exposed to 50 °C for 24 h for the heat treatment and methylene chloride solvent 
for 24 h, then filtered before the TGA was acquired. 
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(a) (b)  
Figure 7.18. (a) Calibration plot for microCT imaging results showing the relationship of initial 
amount of microcapsules incorporated into a model epoxy sample and amount of capsule imaged 
by microCT (both in volume percent); (b) 3D reconstructed image of an epoxy sample 
containing 1.6 vol% capsules. 
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(a)  (b)  
 
(c)  
 
Figure 7.19. Cross-sectional microCT image of iodobenzene microcapsules in (a) an epoxy 
sample (at a 2 wt% loading); (b) a compounded PMMA sample with inset showing zoomed in 
region with intact microcapsules; and (c) in a molded PMMA sample with inset showing three 
microcapsules. 
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(a)  (b)  
 
Figure 7.20. 3D reconstructed images of (a) an epoxy sample and (b) a foam PMMA sample 
processed at ARL containing 4.8 vol% (7.5 wt%) iodobenzene capsules initially. The capsules 
have been colored yellow and blue using Amira software. 
 
 
 
 
Figure 7.21. 3D reconstructed image of a solvent-casted PMMA sample after compression 
molding at UIUC containing 6 vol% (10 wt%) iodobenzene capsules initially. The capsules have 
been colored green using Amira software. 
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Figure 7.22. Representative stress vs. crack length data for injection molded PMMA. The virgin 
curve shows crack growth and the healed curve is for the same sample after EPA was injected 
into the crack plane and healed at RT for 24 h. Images corresponding to initial samples tested 
(a,c) and when crack length = 2l/R (b,d) are shown on the perimeter. 
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(a)  
 
(b)  
 
Figure 7.23. SEM images showing crack face separation in processed PMMA after the virgin 
break has occurred. The images are numbered according to their placement on the sample 
diagram in the center of the image. Those shown in (a) were from the top part of the sample 
while (b) is the bottom half of the sample. 
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Figure 7.24. Thermoset/thermoplastic blend solvent-based healing concept. 
 
 
 
Figure 7.25. SEM of healed fracture surface of an epoxy-PS matrix healed with phenyl acetate. 
 
 
 
 
Figure 7.26. Chemical structure of PEI (Ultem 1000). 
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Figure 7.27. Summary of short-groove TDCB reference tests performed on 862:W with different 
forms of 15 wt% PEI. 5 μL of diPhCl or PhCl was injected into the crack plane and healing was 
tested at RT 24 h after the initial virgin fracture event. Error bars indicate one standard deviation 
based on 3–5 samples per solvent. 
 
 
(a)  (b)  
 
Figure 7.28. SEM images of healed fracture surface when (a) PhCl or (b) diPhCl were injected 
into 862:W with PEI (15 wt%) and the crack faces were realigned and allowed to heal for 24 h at 
RT. 
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Figure 7.29. Summary of short-groove TDCB reference tests performed on 862:W with 15 wt% 
PEI. 5 μL of each solvent was injected into the crack plane and healing was tested at RT 24 h 
after the initial virgin fracture event. Error bars indicate one standard deviation based on 3–5 
samples per solvent. 
 
 
Table 7.1. In situ test summary for PDMS tear specimens with 15 wt% solvent capsules. The 
error represent one standard deviation based on 3–4 samples for each solvent. 
 
Solvent η (Peak Load, %) 
EPA 8.9 ± 2.4 
Chlorobenzene 10.3 ± 2.5 
PA 12.5 ± 3.4 
Xylenes 0 
 
Table 7.2. Reference test summary for PMMA fracture specimens. The error represents one 
standard deviation based on 3–5 samples for each solvent. 
 
Solvent η (Peak Load, %) η' (Peak Area, %) 
Phenyl Acetate 18.7 ± 1.1 32.3 ± 8.1 
Chlorobenzene 56.2 ± 9.9 52.2 ± 1.3 
Ethyl Phenylacetate 71 ±15.5 86.3 ± 10 
Iodobenzene 34.3 ± 0.3 13 ± 0 
Hexyl Acetate 7.0 ± 4.0 2 ± 0 
Toluene 40.3 ± 9.6 32.5 ± 13.4 
Xylenes 26.8 ± 1.1 11 ± 1.4 
Ethanol 9.4 ± 6.6 3.7 ± 1.5 
Methanol 5.6 ± 0.1 3.4 ± 2.2 
MMA (monomer)9 47 ± 6 – 
Hexanes 0 0 
No Solvent (control) 0 0 
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Table 7.3. Single-screw compounding parameters (ISU). 
 
Barrel Temperatures for Extruding 
Zone Temp °F( °C ) 
Feed 340 (171) 
Compression 390 (199) 
Metering 400 (204) 
Die 460 (238) 
 
 
Table 7.4. Twin-screw compounding parameters (ARL).   
 
DSM Xplore Conditions for 
Compounding 
Zone Temp (°C ) 
1 200 
2 220 
3 220 
Screw Speed 25, 50, 100 RPM (varied) 
 
 
Table 7.5. Summary of microcapsule survival/percentage incorporated in the PMMA samples 
determined experimentally.  
 
Capsules Initial Loading Compounded* Molded (raw)* Molded (calc)†
PhI (at ISU) 0.74 wt% (0.49 vol%) 0.02 vol% 0.003 vol% 0.39%
PhI (at ARL, compounded) 2.5 wt% (1.6 vol%) 0.09 vol% - -
PhI (at ARL, foam) 7.5 wt% (4.5 vol%) 1.8 vol% 0.30% 0.66%
PhI (at UIUC) 10 wt% (6 vol%) 6 vol% 1.8% 2.0%
none (control) 0% 0% 0% 0%  
*These percentages are determined from microCT imaging cross-sections of the bulk sample. 
† 
These values were calculated from the calibration plot as the initial volume of capsules imaged. 
 
 
Table 7.6. Summary for DCDC reference testing with EPA as the healing solvent. The error 
represent one standard deviation based on 3 samples. 
 
Sample Stress (MPa) KIC (MPa·√m) 
Virgin 30 ± 0.6 0.82 ± 0.02 
Healed 19 ± 3.1 0.51 ± 0.08 
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Table 7.7. Self-healing performance of thermoplastic-thermoset TDCBs. Reference tests were 
conducted by injecting 20 μL solvent, and healing is reported 24 h after the virgin fracture. 
 
Beads 
 
Solvent  
Healed Peak 
Load (N) 
Healing 
Efficiency 
No. of 
Samples 
30 wt% 
PMMA 
injected PhCl 
25.1 ± 1.6 22.4 ± 2.8 3 
30 wt% 
PMMA 
15 wt% PhCl 
capsules 22.1 ± 3.1 16.4 ± 3.1 5 
20 wt% 
PS 
injected PhCl 
21.0 ± 3.6 20 ± 1.8 4 
20 wt% 
PS 
15 wt% PhCl 
capsules 22.8 ± 8.5 16.4 ± 1.8 4 
 
 
Table 7.8. GPC Data for different forms of PEI. 
 
PEI Form Mn (kDa) Mw (kDa) PDI 
powder 30.6 46.4 1.5 
MI 9 20.9 82.4 3.9 
MI 18 31.6 78.7 2.5 
 
 
Table 7.9. Thermal Reactivity of Epoxy Matrix with PEI. 
 
EPON 862:W with  
15 wt% PEI 
Residual Heat of Rxn (J/g) Degree of 
Cure (%) 
Tg (°C) 
Baseline 374 100 102 
15 h at 90 °C 20.5 94 111 
Control (no PEI) 
after 15 h at 90 °C 
- 100 115 
 
 
Table 7.10. Lap-shear results for polyetherimide (Ultem 1000) sheets tested 24 h after solvent 
introduction into the overlap region of the sample. Error represents one standard deviation based 
on 4 samples per solvent tested. 
 
Solvent Failing Stress (MPa) 
Chlorobenzene 1.0 ± 0.48 
o-dichlorobenzene 0.56 ± 0.16 
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Table 7.11. Injection molding process parameters (ISU). 
 
Molding 
Parameters   
Temperatures °F °C 
Feed Zone 460 238 
Compression Zone 480 249 
Metering Zone 480 249 
Nozzle 440 227 
Mold Temperature 160 71 
Melt Temperature 450 232 
Pressures and Dose Psi MPa 
Back Pressure 100 0.7 
Hold Pressure 1,000 7 
Dose, Speeds, Times   
Feed Stroke 2.2 in 55.8 mm 
Injection Speed 5 in/s 127 mm/s 
Screw Plastication  120 RPM 
Injection Time  1.2 s 
Hold Pressure 
Time  15 s 
Cooling Time  40 s 
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CHAPTER 8 
 
SELF-HEALING BONE CEMENTS AND DENTAL RESINS 
‡
 
 
 
8.1 Introduction 
 
 In the United States, there are on average 234,000 total hip replacements and 478,000 
knee replacement surgeries performed annually, and these numbers are expected to more than 
double within the next 20 years.
1
 Not only do these surgeries affect a large population, but 
patients must also undergo revision surgeries about every ten years, mainly due to dislocation 
and loosening of the initial prosthesis from the bone.
2
 The polymeric material used to anchor 
metal prostheses to contiguous bone is an acrylic resin-based bone cement formulation.
3
 This 
two-part poly(methyl methacrylate) (PMMA) bone cement has emerged as one of the most 
widely used biomaterials in revision surgeries and knee/hip replacements since its development 
by Charnley in 1960.
4
 The components of this formulation include cross-linked poly(methyl 
methacrylate) (PMMA) bead, a liquid methyl methacrylate (MMA) monomer polymerized under 
free-radical polymerization conditions with a peroxide initiator and a tertiary amine activator.
5,6
 
The liquid and solid components are mixed together just before use to form a grouting which 
quickly sets as the polymerization of the MMA monomer is initiated.
2
  
 However, the long-term stability of using bone cement has been a major concern because 
of the brittleness and poor wear resistance of the polymeric matrix, requiring additional fillers 
such as carbon nanotubes,
7
 silver,
8
 or by using alternative polymers such as polyethylene.
3
 It is 
well-recognized that bone cement has a number of additional drawbacks ranging from toxicity of 
residual reactants, which leads to chemical necrosis; the high polymerization exotherm, which 
leads to thermal necrosis; weak-link zones in the cement construct (bone-cement interface and 
                                                          
‡
 Some of the content presented in this chapter was published in Wilson, G. O. et al. J. Polym. Sci. Part A.: Polym. 
Chem. 2010, 48, 2698-2708, Copyright 2010, Wiley InterScience. 
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cement-prosthesis interface); and aseptic loosening.
9
 These drawbacks often result in 
complications during and/or after surgery and often lead to revision surgery. The development of 
self-healing polymers in the past decade
10-12
 presents an opportunity for research on extending 
the lifetime of bone cements. The development of biocompatible self-healing bone cement
13
 
could lead to opportunities for application of the self-healing polymer technology to other 
biomaterials such as dental resins.
14
 New chemistries designed for these applications could also 
be used in other non-biomedical applications such as self-healing reinforced vinyl ester 
composites, coatings, and adhesives.  
 The development of solvent-based self-healing systems in both thermoset epoxies and 
thermoplastic materials have been discussed in previous chapters of this dissertation. The ability 
to microencapsulate solvents has expanded the toolbox of new chemistries that can be 
compartmentalized for use in self-healing materials. For example, given that peroxides and 
tertiary amine activators typically used in free-radical polymerization reactions are solid 
materials, appropriate solvents could be selected to prepare solutions for microencapsulation. 
Free-radical initiated polymerization stands out as the most attractive chemistry for designing a 
self-healing system for biomaterials because the acrylates monomers possess similar structures 
and curing chemistries to the monomers used in bone cements and dental composites. A 
proposed concept for the compartmentalization of this chemistry in a self-healing system is 
shown in Figure 8.1. In this dual-capsule concept, damage propagating through the cement in the 
form of a crack would rupture the microcapsules containing the free-radical initiator as well as 
those containing the mixture of monomers and accelerator. The contents of the capsules would 
then be released into the crack plane, where they would react, initiating a free-radical 
polymerization that would repair the damage, and restore structural continuity to the cement. 
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This chapter outlines the preparation and characterization of both types of capsules used in this 
system. Evaluations of various monomers, initiators, and activators were conducted until an 
optimal self-healing system was achieved. The objectives of this work were to attain maximum 
healing efficiencies by forming a polymer with strong mechanical properties and good adhesion 
to the matrix at a kinetically favorable rate at ambient and in vivo temperatures. 
8.2 Encapsulation of Peroxide Initiators 
 
 The suitability of five peroxide initiators for a free-radical polymerization-based self-
healing system was previously evaluated in our laboratory and it was reported that benzoyl 
peroxide (BPO) and lauroyl peroxide (LPO) had the lowest onset polymerization temperatures 
for an epoxy vinyl ester resin.
13
 While BPO and LPO are well-studied peroxide initiators for 
free-radical polymerization,
15,16
 BPO emerged as the best performing initiator across the range of 
evaluation criteria (thermal stability and polymerization performance). Both initiators were 
successfully encapsulated with urea-formaldehyde (UF) shell walls using previously reported 
procedures at a stir rate of 450 RPM.
17,18
 The resulting capsules are shown in Figures 8.2a and 
8.2b and had average diameters of 106 ± 24 μm and 125 ± 32 μm, respectively. To facilitate 
encapsulation and delivery of free-radical initiators, a maximum of 9.9 wt% of BPO and 4.3 wt% 
of LPO were dissolved into the solvents phenyl acetate (PA) and hexyl acetate (HA), 
respectively. These solvents were chosen because of their similarity in chemical structure and 
they demonstrated the highest degree of solubility when a number of solvents were screened. 
Fracture samples of simulated bone cement were prepared containing both varieties of capsules 
at 10 vol%. These samples were then fractured on a load frame to ascertain the ability of the 
capsules to rupture due to crack propagation. The fracture planes for samples prepared with 
capsules containing BPO (Figure 8.2c) and LPO (Figure 8.2d) show that both capsules ruptured 
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during the fracture event. For the remainder of this chapter, only the BPO in PA microcapsules 
are referred to as the ‘initiator capsules’ since they contained the maximum amount of initiator 
present in the core solution, making them the preferred capsules for use in a free-radical         
self-healing system. 
 Characterization of initiator-containing microcapsules needed to be further investigated 
to prove that the BPO was encapsulated and that the capsules were stable over time at RT. These 
capsules, prepared by saturating the solvent with the initiator were stored at RT to avoid 
crystallization at lower temperatures (< 21 °C). Encapsulation of higher concentrations of the 
initiators was possible if the initiators were initially dissolved into the appropriate solvent at an 
elevated temperature (> 50 °C) before adding to the emulsion. However, when capsules 
containing these solutions were allowed to cool to temperatures lower than RT for storage, the 
initiators precipitated from solution destroying the capsule shell wall. Nevertheless, storage at 
RT for a time period of at least 3 months showed no significant mass loss when compared to an 
initial scan, as measured by TGA (Figure 8.3a). Further characterization included                 
cross-examination of UV-visible scans from the core solution of ruptured microcapsules to core 
solution samples taken before encapsulation (Figure 8.3b). Maximum absorbances at similar 
wavelengths confirmed the presence of BPO in the capsule cores. This method had been 
previously reported as a valid technique for verifying UV-active core materials in 
microcapsules.
19
 Thus, having obtained optimized initiator capsules, the next challenge was to 
encapsulate the monomer and activator components of the free-radical polymerization system.  
8.3 Microcapsules Containing Tertiary Amine Activators 
 Although free-radical polymerizations of acrylates can be initiated solely by peroxide 
initiators, elevated temperatures (65–125 °C) are required for these reactions to occur.16 For 
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biomedical applications, the temperature of reactions permitted is 37 °C or below. Additionally, 
the highest maximum temperature reported at the bone-implant interface was 70 °C.
20,21
 Thus, 
tertiary amine have been used to activate the decomposition of peroxides and generation of 
radicals for a polymerization to occur at room temperature (RT).
16,20,22,23
 The reaction scheme for 
this process between BPO and dimethylaniline (DMA) is shown in Scheme 8.1.
22
 Since this is 
the central reaction for the polymerization of vinyl monomers, they must be kept in separate 
microcapsules until the self-healing reaction is desired to take place (at the event of crack 
damage to a polymer matrix). Optimization of the activator:initiator ratios are discussed later in 
this chapter (Section 8.4), emphasizing the importance of stoichiometry for this reaction. 
 For the activator component of a self-healing free-radical system, the encapsulation of the 
liquid amine DMA was attempted with an interfacial polymerization reaction to make 
polyurethane-walled capsules.
24
 Although the initial stability of these capsules was reasonable, it 
was found that the core liquid permeated the shell wall over time. Thus, an alternative tertiary 
amine, 4,4′-Methylenebis(N,N-dimethylaniline) or MBDMA, was selected as the activator to use 
in this self-healing system. This solid activator also demonstrated a lower onset temperature of 
polymerization than DMA when used as 0.1% of an epoxy vinyl ester (EVE) resin mixture.
13
 In 
order to determine the threshold of how much MBDMA could be encapsulated, the amount was 
varied in separate batches [from 0.2–1 g in a total volume of 60 mL ethyl phenylacetate (EPA) 
solvent (Figure 8.4)]. EPA was selected as the solvent for these capsules due to the high degree 
of MBDMA and monomer(s) solubility. As the amount of amine increased per batch of capsules, 
the capsules became less free-flowing in nature. When encapsulations were attempted with 
solutions > 1 g MBDMA in 60 mL EPA, no capsules formed because the amount of amine was 
great enough to react with the urea-formaldehyde shell wall reaction. 
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8.4 Vinyl Monomer/Activator Microcapsules 
 
 Since the range and maximum amount of MBDMA that was stable in the core solution of 
microcapsules without reacting with the shell wall materials had been determined in the previous 
section, microcapsules with monomer(s) and MBDMA activator in EPA could be synthesized. If 
all three components would have been separately encapsulated (initiator, activator, and monomer 
capsules), it would have led to a three-capsule self-healing system. This would have greatly 
increased the complexity of the system because it would be difficult to ensure that adequate 
mixing of all three components would occur to promote polymerization. The stoichiometry 
would have to be optimized with three different capsules – a significant challenge to overcome. 
Due to the unreactivity between vinyl monomers and a tertiary amine activator, these 
components were able to be compartmentalized together in one microcapsule, effectively 
decreasing the complexity of the system. This was achieved by first dissolving the solid 
MBDMA activator into EPA and then sonicating this mixture with a ratio of multifunctional 
vinyl monomers [trimethylolpropane triacrylate (TMPTA) or trimethylolpropane ethoxylate 
triacrylate (TMPET), and bisphenol A ethoxylate diacrylate (Bis-EMA)], a solution was 
generated that could be successfully encapsulated at a stir rate of 400 RPM. Optical images of 
these monomer/activator (M/A) capsules are shown in Figure 8.5 and the average diameters were 
130 ± 30 μm. As previously stated, only the peroxide initiator and tertiary amine activator 
needed to be kept in separate microcapsules since the peroxide will decompose and react in the 
presence of amines.
25
 
 These M/A capsules were characterized by TGA and UV-visible spectroscopy to confirm 
the core components in the same manner as the initiator capsules (Figure 8.6). Only MBDMA 
and Bis-EMA were UV-active and appeared on the spectra while the other components did not. 
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With these capsules produced, an optimal ratio of M/A to BPO capsules had to be determined. 
An initial range of activator/initiator ratios had been reported
13
 and established a starting point 
for these studies. Qualitative experiments were conducted in which known amounts of capsules 
were weighed between the ratios of 2:1 and 50:1 M/A capsules:BPO capsules and ruptured 
between two glass slides. After 24 h, the polymers formed were characterized in terms of 
qualitative mechanical strength, color, and adhesion to the glass slides. At a lower amount of 
M/A capsules, the polymers were very brittle. When an excess of M/A capsules was used    
(20:1–50:1 ratios), the polymers formed were very mechanically weak with an excess of 
unreacted monomers and solvent present. This observation agrees with previous reports where an 
excess of amine activator inhibits acrylates polymerization.
23
 The optimal ratio from this 
screening was found to be 5:1 M/A capsules to BPO in PA capsules and all of the following 
experiments in this chapter used this ratio of two capsules when testing the healing. 
 For a two-capsule system with three different components, there were a number of 
variables to consider while preparing optimized capsules. The chemical structures of these 
components are shown in Figure 8.7. The first variable explored was the amount of MBDMA 
needed for rapid polymerization. Numerous batches of capsules were prepared with a constant 
amount of solvent (12 mL) and monomers (48 g of 3:1 TMPET:Bis-EMA), and increasing 
amounts of MBDMA activator (0–1 g). By conducting dynamic differential scanning calorimetry 
(DSC) experiments of these M/A capsules (ex situ) when crushed with BPO in PA capsules at a 
5:1 ratio (based on weight), the polymerization reaction was monitored as the temperature 
increased from 25–300 °C. As shown in Figure 8.8, the onset temperature of polymerization and 
peak of the exothermic curve decreased as the amount of activator present in the capsules 
206 
 
increased, demonstrating that more activator released from the capsules generated a higher 
amount of free radicals to polymerize the vinyl monomers.  
 Epoxy vinyl ester (EVE) resin was chosen as the matrix for the self-healing experiments 
due to its use in dental composites
24
 as a free-radical cured matrix, as well as serving at the 
matrix for other demonstrated self-healing systems in our laboratory.
26,27
 Short-groove     
tapered-double-cantilever beam (TDCB) samples
28
 were prepared by mixing 1 wt% BPO and 
 0.1 wt% DMA in EVE and cured for 24 h at RT (chemical structures of the EVE resin are 
shown in Figure 8.9). The central, insert region of the sample was composed of the same resin 
mixture starting at a 10 wt% capsule loading and cured at RT for another 24 h. Two different 
trifunctional monomers (TMPTA and TMPET)
29
 were analyzed for healing performance. When 
M/A capsules prepared with varying amounts of MBDMA and TMPTA/TMPET separately with 
Bis-EMA were combined with BPO capsules at the 5:1 ratio, an optimal amount of amine to be 
used was determined. The in situ healing results are shown in Figure 8.10a. When TMPTA was 
used with Bis-EMA, the highest reported healing efficiency was 46% an amount of               
0.7% MBDMA in the M/A capsule cores. TMPET had a higher molecular weight than TMPTA 
and thus, was able to produce a more robust polymer which was evidenced by higher healing 
efficiencies. When this monomer was used with Bis-EMA, the highest healing efficiency was 
69% at a concentration of 0.5% MBDMA in M/A capsules. Since TMPET consistently reported 
higher healing efficiencies, it was used instead of TMPTA in further studies. 
 After determining the optimal amount of amine to be 0.5% in the M/A capsule cores, the 
amount of solvent had to now be determined. By keeping the total volume of core material      
(60 mL), the monomers ratio (3:1 TMPET:Bis-EMA) and the amount of amine (0.3 g MBDMA) 
constant, the amount of solvent was varied from 2–20 mL or 3–33% of the core solutions  
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(Figure 8.10b). The highest healing efficiencies were reported when capsules containing        
20% (12 mL) EPA solvent were used (η = 0.63), while a lower healing performance was 
observed with less or more solvent (3% EPA, η = 0.15 and 33% EPA, η = 0.28). 
8.4.1 Evaluation of Monomers 
 
 In order to determine the optimal ratio between the two selected monomers, a screen was 
performed at different ratios of TMPET:Bis-EMA cured with 1 wt% BPO and 0.1 wt% DMA in 
order to compare with previously reported experiments.
24
 The polymerization was monitored 
over during 2 h RT isothermal DSC experiments for each ratio of monomers by comparing the 
exothermic transitions to the total heat of reaction from dynamic experiments of the same ratios. 
Overlaid curves for the isotherms are shown in Figure 8.11. The onset temperature of 
polymerization and monomer conversion results are shown in Table 8.1. The hypothesis was that 
a higher level of monomer conversion observed by DSC should correlate to high healing 
efficiencies when the solutions were used in self-healing experiments. TMPET is a trifunctional 
acrylate and Bis-EMA is bifunctional; thus, as the amount of TMPET is increased, the overall 
monomer conversion of the mixtures increased. The highest percent conversion for all ratios was 
reported as 79% for the 8:2 TMPET:Bis-EMA mixture. The kinetics of the reaction can be 
observed from the inset of Figure 8.11. This 8:2 (or referred to as the 4:1) ratio also reported the 
lowest onset temperature (46 °C) during dynamic DSC experiments, indicating that this should 
be the optimal ratio to use for RT polymerization. 
 The monomer conversion results were also plotted in Figure 8.12a where the highest 
percentages ranged from 3:1 to 9:1 TMPET:Bis-EMA. A similar trend in healing performance 
was observed through reference tests of different monomer mixtures (Figure 8.12b). For these 
experiments, M/A solutions were prepared with constant amounts of amine and solvent – 0.5% 
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MBDMA and 20% EPA – and added to a 9.9 wt% BPO in PA solution at a 5:1 ratio. These 
mixtures were then injected into the crack plane of samples composed of plain EVE                 
(no capsules), clamped together, and allowed to heal at RT for 24 h. The healing results are 
shown in Figure 8.12b and the best ratio was 4:1 TMPET:Bis-EMA. In contrast, the lowest 
response was observed for pure Bis-EMA (no TMPET) M/A mixtures, which corresponded to 
the lowest observed monomer conversion by DSC. This solution was an efficient control system 
used in further studies. 
8.4.2 Temperature Studies 
 To this point, all reported healing was after a 24 h RT exposure. Free-radical 
polymerization conversion normally increases at higher temperatures and previous studies had 
confirmed this phenomenon by thermal evaluation of EVE systems.
13
 In order to predict the 
healing efficiencies at higher temperatures, reference tests were performed for four monomer 
ratios at 37 °C (to predict behavior at body temperature) and 50 °C (to observe the effect at 
higher temperatures). The results from these reference experiments are shown in Figure 8.13. At 
ambient conditions, it had been observed that the best healing occurred with the 4:1 monomer 
ratio where the reaction kinetics dominated the healing behavior. However, the healing observed 
from the reference tests at higher temperatures did not follow the same trend. Both the pure    
Bis-EMA and the 3:1 mixtures showed an increase in healing as a function of temperature, but 
the healing for the 4:1 and pure TMPET mixtures decreased at 37 °C. At 50 °C, the degree of 
healing was comparable for all the mixtures except for 4:1, which had a much lower healing 
response. These unexpected trends can be explained by studying the viscosities of the M/A 
mixtures at higher temperatures. 
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 All solutions tested contained a constant amount of MBDMA activator and EPA solvent, 
only amounts of monomers were varied. Three separate rheometry experiments were performed: 
(1) temperature sweep from 25–200 °C; (2) time sweep at 50 °C for 3 h; and (3) shear rate sweep 
from 0.1 sec
-1
 to 100 sec
-1
 and the results are summarized in Table 8.2. Further experimental 
details and data analysis are given in the Experimental Section of this chapter (Section 8.6). 
From the temperature sweep, the onset temperatures of polymerization (based on viscosity 
increase) for each solution were observed to correspond to the healing trend at RT (Figure 8.13) 
where the 4:1 mixture polymerized at the lowest temperature. Additionally, one can see that the 
viscosity of 4:1 at 50 °C is much lower than the other three solutions in both the temperature and 
time sweeps, which corresponded to the lowest healing efficiencies observed for this mixture at 
50 °C in Figure 8.13. From the time sweep at 50 °C, the 3:1 mixture had the highest viscosity 
and this mixture is what was used for the optimal in situ healing experiments. Thus, 
polymerization conversion did not correlate exactly to healing performance. The difference in 
viscosities at higher temperatures indicated that the reaction kinetics do not dominate in the 
healing mechanism for this specific system. 
8.5 Self-Healing Performance in an EVE Matrix 
 
 Reference testing discussed in the previous section was an empirical way of predicting 
healing efficiencies of an eventual self-healing system, but the highest healing efficiencies were 
acquired through in situ fracture testing where both sets of capsules are embedded in the matrix 
and no external intervention is required for the healing event to occur. From optimizing all of the 
necessary components for a free-radical polymerization, the fully in situ system consisted of 
M/A capsules containing a mixture of 3:1 TMPET:Bis-EMA with 0.3 g MBDMA and 12 mL 
EPA and BPO in PA capsules (at a 5:1 ratio). Figure 8.14 shows a summary of healing 
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performance for all the control systems and the best in situ results for two different amounts of 
capsules (5 and 10 wt% of the surrounding matrix). Healing efficiencies at RT were reported for 
samples tested after 24 h from initial fracture event. Very little healing response was observed 
for the initiator capsules only samples whereas about 20% healing was noted for M/A capsules 
only. This result can be explained by reactions of the M/A solution from the capsules with the 
residual/trapped BPO solid within the EVE matrix. Since the BPO initiator is a solid and 
mechanically mixed into the EVE resin during sample preparation, it does not always dissolve 
completely and thus is available for further reaction. When compared to all the control systems, 
the in situ system at both capsule loadings is significantly larger in reported healing efficiencies 
and the corresponding SEM images of healed polymer on the specimen surfaces are shown in 
Figure 8.15. The healed surfaces for BPO capsules only and M/A capsules only did not show any 
polymer film, whereas the in situ result produces a jagged polymer film when the contents of 
both capsules react. The newly healed polymer forms on top of the voids created from empty 
ruptured capsules to create a distinguishing feature on the surface (Figure 8.15c). 
 Although much of the initial healing experiments were conducted at a 10 wt% capsule 
loading, it was later found that this was not the optimal amount of capsules needed for the in situ 
system. Thus, the relationship between capsule loading and healing efficiency was explicitly 
explored and the best result was observed from healing with a 5 wt% capsule loading        
(Figure 8.16). When a large amount of capsules were incorporated into an EVE matrix, a 
significant decrease in healing was observed, as previous self-healing chemistries have 
demonstrated.
28,30,31
 The time scale of healing for this optimized system was also explored since 
the healing performance depends on the healing time (Figure 8.17).
11,32,33
 Within 14 min of the 
initial virgin fracture event, about 20% of fracture toughness recovery was observed for samples 
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containing 5 wt% capsules. The healing also tends to reach steady-state levels 24 h from the 
initial virgin fracture event. SEM images for healed samples (Figure 8.18) after 14 min healing 
show very minimal film formation, while after 24 h of healing, the surface displays a thicker 
film. 
 The ultimate test for this new self-healing chemistry was to analyze the healing behavior 
in a simulated body fluid (SBF) environment
34
 to predict its feasibility as a biomaterial. SBF was 
prepared following previously reported procedures at a pH 7.25 (Table 8.3)
34
 and equilibrated at 
37 °C in an environmental chamber. One set of the optimized in situ EVE short-groove TDCB 
samples containing 5 wt% capsules was prepared and immersed in the SBF immediately 
following the virgin fracture event. Another set of identical samples were prepared and exposed 
to the same temperature and humidity conditions but not immersed in the SBF to serve as a 
control. Figure 8.19 shows a picture of the samples healing in the environmental chamber. After 
24 h, the samples were dried and tested for healing at RT. The results are shown in Table 8.4. 
Within error, the samples in and out of the SBF were comparable in their healing performance 
with those exposed to the SBF being slightly higher in value. By examining the fracture surfaces 
of healing specimens for each set, more polymer film was present on the samples immersed in 
the SBF (Figure 8.20). The film rippling appears to indicate that a thicker polymer film formed 
on the surface in the SBF than on the control surface. Thus, the simulated body conditions did 
not affect the free-radical self-healing chemistry and shows great promise for use in                
bio-environments. The possible applications for this system have not been fully explored, and 
could be expanded for use in dental resins, as the chemistry used is based on polymerization of 
acrylate-containing monomers. Future studies can also examine the fatigue performance of this 
system, since the rapid polymerization observed should lead to a robust, self-healing system. 
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8.6 Experimental Section 
 
 Materials: Benzoyl peroxide (BPO, Sigma-Aldrich), lauroyl peroxide (LPO,         
Sigma-Aldrich) 4,4'-methylene bis(N,N-dimethyl aniline) (MBDMA, Acros Chemical) were 
ground into a fine powder before use. The PMMA cross-linked beads (MW = 350,000 g/mol) 
were purchased from Polysciences, Inc. (PDI = 2.7, Tg = 105 °C) and used as received. Ethyl 
phenylacetate (EPA), phenyl acetate (PA), hexyl acetate (HA), dichloromethane (DCM), 
dimethylaniline (DMA), trimethylolpropane triacrylate (TMPTA), trimethylolpropane ethoxylate 
triacrylate (TMPET), bisphenol A ethoxylate diacrylate (Bis-EMA), urea, ammonium chloride 
(NH4Cl), resorcinol, and formaldehyde solution (formalin, 37 wt/vol%) were purchased from 
Sigma-Aldrich and used as received. Ethylene-maleic anhydride (EMA) copolymer      
(Zemac®-400) powder with an average molecular weight of 400 kDa was graciously donated by 
Vertellus and used as a 2.5 wt% aqueous solution. The Derakane 510A-40 Epoxy Vinyl Ester 
(EVE) resin was generously donated by Ashland Chemicals and used as received.  
 Instrumentation: Absorption spectra were recorded from 200–800 nm with a 
background scan of PA and EPA using a Shimadzu UV-Visible Spectrophotometer, model 
number UV-1601PC. Approximately 25 mg DCM-washed microcapsules were ruptured in a 
mortar and pestle, and 2.5 mL solvent (either PA or EPA) was added. The capsule/solvent 
mixture was added to a 5 mL syringe then filtered through a 0.45 μm syringe filter into a quartz 
cuvette for UV analysis. 
 Microencapsulation of Solutions containing Initiators: The maximum 
solubility/saturation limit of BPO and LPO initiators at RT was determined in PA and HA, 
respectively, as follows:  a constant amount of solvent in a covered, stirring jar was used while 
the amount of initiator added was increased until no more solid would dissolve. The resulting 
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solubility values are expressed as percentages by weight of solid initiator that dissolved in the 
respective solvents.  Urea-formaldehyde (UF) microcapsules
18
 were prepared at 450 RPM with a 
slight modification to the original procedure. The amount of wall-forming materials was halved, 
while the 60 mL of core material remained constant.
17
 Bone cement TDCB fracture specimens
30
 
that contained 10 vol% of microcapsules were prepared and the fracture surfaces were imaged by 
scanning electron microscopy (SEM, Philips XL30 ESEM-FEG instrument with a 5 kV electron 
source) after sputter-coating with a gold-palladium source. 
 Microencapsulation of Solutions containing Monomers/Activators (M/A): When 
working with these solutions, it was important to keep them in a dark environment (foil-covered 
vials) as much as possible to prevent light-induced polymerization. A large amount of capsules 
were prepared by varying the amounts of activator, monomer, and solvent in the core solutions, 
using the same procedure. For this reason, only the amounts for the optimized system are given 
here. In foil-covered 100 mL glass containers, 0.3 g MBDMA (0.5 wt% of total solution) was 
first weighed and dissolved in 12.1 g EPA (20 wt% of total solution), then 36 g TMPET and     
12 g Bis-EMA were weighed and added to the container in this order. The solutions were 
sonicated for 40 min prior to encapsulation using a Fisher Scientific Mechanical Ultrasonic 
Cleaner at 40 Hz. Stock solutions of M/A were also prepared in smaller volumes at a variety of 
monomer ratios and used for DSC and reference testing, as described below. UF microcapsules
18
 
were prepared at 400 RPM with a slight modification to the original procedure. The amount of 
wall-forming materials was halved, while the 60 mL of core material remained constant.
17
 
Additionally, the reaction vessel (600 mL beaker) needed to be covered entirely in foil during the 
encapsulation. 
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 Thermal Analysis: Dynamic and isothermal DSC experiments were performed on a 
Mettler-Toledo DSC821
e
. All DSC experiments were performed in 40 μL aluminum crucibles. 
Average sample sizes were 5–10 mg. Dynamic experiments were performed under nitrogen 
atmosphere from 25–300 °C at a rate of 10 °C/min. For experiments with capsule mixtures, 
samples of 25 mg total were ruptured between glass slides and were transferred quickly to DSC 
pans, crimped, and loaded into the instrument. Isothermal DSC experiments were performed at 
25 °C for 120 min. Samples tested contained monomer mixtures of TMPET:Bis-EMA at various 
ratios, with BPO (1 wt %) and DMA (0.1 wt %).  In foil-covered 20 mL scintillation vials, BPO 
was first added to the monomer mixtures and vortexed for 1 min. DMA was then added to this 
solution via pipette immediately prior to loading the sample into the DSC. The degree of 
monomer conversion (αt) was determined from isothermal experiments as a function of time 
using the following equation: 
     
T
t
t
Q
Q
100                                            (1) 
where Qt is the reaction heat at time t, and QT is the total heat of polymerization (calculated from 
dynamic experiments).
13,27,35
 To determine the thermal stability of the microcapsules, TGA was 
performed on a Mettler-Toledo TGA851
e 
instrument calibrated by indium, aluminum, and zinc 
standards. The mass loss was recorded during a heating cycle over the temperature range of    
25–650 °C at a constant rate of 10 °C/min in an atmosphere of N2. For each experiment, 
approximately 2–5 mg of sample was accurately weighed (± 0.02 mg) into an alumina crucible.  
 Sample Preparation and Testing: PMMA simulated bone cement samples were 
prepared from two parts and were based on the composition of Surgical Simplex
®
 P.
3
 The solid 
portion was comprised of a total of 40 g of powder of which 1.7 wt% was BPO (0.68 g) and     
10 wt% of initiator capsules (9.9 wt% BPO in PA). The remainder was PMMA beads (40 g). The 
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liquid portion (20 mL) was comprised of DMA (2.6 vol%, 520 μL) and the remainder was 
MMA. The two portions were mixed together and the mixture was quickly transferred to the 
Teflon
®
 long-groove TDCB mold. The samples were allowed to cure at RT for 24 h after which 
they were removed from the molds and pin-loaded to failure at 5 μm/s under displacement 
control on an Instron load frame. The fracture surfaces were then analyzed by SEM.  
 Epoxy vinyl ester (EVE) long-groove TDCB samples for reference tests were prepared 
by stirring 1 wt% BPO into the Derakane 510A-40 resin at 1,500 RPM for 5 min, followed by 
the addition of 0.1 wt% DMA.
24,27
 The mixture was then poured into silicone molds and allowed 
to cure at RT for 24 h. After fracturing the specimens on a load frame under displacement control 
at a rate of 5 μm/s, solutions that had been encapsulated containing monomer mixtures of 
TMPET:Bis-EMA and BPO in PA at a 5:1 ratio (by weight) were injected into the crack plane 
via micropipette (25 μL for each TDCB sample). Due to the rapid rate of polymerization 
between these two solutions (10-15 s at RT), one mixture per sample was prepared in small 
amounts via pipette (0.24 g M/A + 0.048 g BPO in PA). The samples were clamped together and 
allowed to heal at various temperatures (RT, 37 °C, 50 °C) in a MicroClimate
®
 Environmental 
Chamber (Cincinnati Sub-Zero Products) at 40% relative humidity for 24 h before retesting to 
failure.  Four to six samples were tested for each data entry. 
 For short-groove in situ EVE samples, the central insert section of the sample was 
prepared with the same matrix materials and procedure as above (EVE, BPO, and DMA) and the 
appropriate amount of microcapsules (0–15 wt%) were mixed in the resin and poured into PDMS 
molds. The samples were allowed to cure at RT for an additional 24 h after which they were 
precracked and pin-loaded at a rate of 5 μm/s under displacement control on an Instron load 
frame, and loaded until the crack propagated to the end of the 25 mm groove. The samples were 
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removed from the load frame and allowed to heal at RT for 24 h. For the time study experiments, 
samples were left at RT for the following time periods: 14 min, 30 min, 2, 4, 9, 18, 24, and 48 h.  
The samples were then re-tested and healing efficiencies were measured to compare the virgin 
peak loads to the healed peak loads. 
Viscosity Measurements: The viscosities (η) of M/A solutions were determined using a 
TA Instruments AR-G2 rheometer with 25 mm diameter aluminum parallel plates using a 
frequency of 1 Hz at 25 °C and 50 °C with 1 min equilibration time, a shear rate ramp of          
0.1 sec
-1
 to 100 sec
-1
. Each test was run for 30 min and data sampled at 10 points per decade with 
constant gap size during entire test. Viscosities reported in Table 8.2 were extracted as the slope 
of the best-fit line when the shear stress vs. shear rate was graphed. Complex viscosities (η*) 
were determined from two additional oscillation experiments on each M/A solution – a 
temperature sweep from 25–200 °C at a rate of 5 °C/min and a time sweep at 50 °C for 3 h. The 
onset temperature of polymerization for each solution was determined from the temperature 
sweep. The complex viscosity from the temperature sweep was determined by the following data 
analysis: a best-fit line was plotted on a graph of complex viscosity vs. temperature, and the 
calculated η* at 50 °C using this equation was reported in the table. For the time sweep at 50 °C, 
a best-fit line was plotted on a graph of complex viscosity vs. time, and the y-intercept using this 
equation was reported in the table.   
 Simulated Body Fluid (SBF) Experiments: Using published procedures,
34
 1 L of 
simulated body fluid was prepared in a 2 L flask that was charged with all the dry salts and large 
stir bar. The amounts and concentrations of the salts used are reported in Table 8.3. Then, 1 L 
MilliQ water was added to the flask, and the solution was covered and stirred overnight with 
slight heat (35 °C) until the solids had dissolved. Concentrated HCl was added via pipette until 
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the pH of the solution was 7.25 (2–3 drops). Then, 500 mL were added to an empty plastic 
pipette tip container and equilibrated at 37 °C, 40% relative humidity in the MicroClimate
®
 
environmental chamber for 5 h before adding the fracture specimens. Five in situ short-groove 
TDCB EVE samples with 5 wt% capsules (M/A and BPO at a 5:1 ratio by mass) were prepared 
as described above and fractured with a razor blade, clipped at the top of the samples, and 
immediately submerged into the SBF in the environmental chamber. The pipette tip box cover 
was slid into place to prevent evaporation of the SBF. An identical set of five in situ TDCB 
samples were prepared, fractured, and placed to heal in the environmental chamber at 37 °C   
(not in the SBF) to serve as the control specimens for this experiment. 
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8.8 Figures and Tables  
 
 
 
Figure 8.1. Proposed concept for a self-healing bone cement showing the compartmentalization 
of reactants in microcapsules that would be mixed into the bone cement formulation prior to 
application between the prosthesis and the contiguous bone. 
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Figure 8.2. Urea-formaldehyde microcapsules containing (a) BPO encapsulated in phenyl 
acetate and (b) LPO encapsulated in hexyl acetate. Fracture planes of simulated bone cement 
samples containing (c) BPO/phenyl acetate capsules and (d) LPO/hexyl acetate capsules, 
respectively. Reprinted with permission from Reference 13. Copyright 2010, Wiley InterScience. 
 
(a)  (b)   
 
Figure 8.3. (a) TGA scans of the BPO in PA microcapsules at different time intervals after RT 
exposure; (b) UV-visible traces for BPO capsules and their core components (PA was used for 
the background). 
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(a)   (b)   
  
(c)  
 
Figure 8.4. Optical micrographs of UF EPA capsules containing increasing amounts of 
MBDMA activator: (a) 0.2 g; (b) 0.3 g; and (c) 0.4 g per batch. 
 
 
 
Figure 8.5. Optical micrograph of capsules containing a core solution of the monomer mixture 
with amine activator in EPA. 
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(a)  (b)   
 
Figure 8.6. (a) Initial TGA scan of the M/A microcapsules; (b) UV-visible traces of M/A 
capsules and their core components (EPA was used as the background).  
 
 
 
Figure 8.7. Chemical structures of components in the core mixture of monomer/activator 
microcapsules.  
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Figure 8.8. Onset and exothermic peak temperatures vs. amount of MBDMA activator in the 
monomer/activator capsule cores recorded from dynamic DSC experiments on the core materials 
of BPO and monomer/activator microcapsules. Error bars represent one standard deviation of 3 
runs.  
 
 
 
Figure 8.9. Chemical structures of epoxy vinyl ester matrix components.   
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(a)  (b)  
 
Figure 8.10. Self-healing performance as a function of (a) MBDMA activator and (b) solvent in 
the microcapsule core material (relative % to other core components). The error bars represent 
one standard deviation based on 4–5 samples. 
 
 
 
Figure 8.11. Polymerization conversion of monomer mixtures at varying ratios during a 2 h 
isotherm at 25 °C. The inset shows the reactivity during the first 30 min. 
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(a) (b)  
 
Figure 8.12. (a) Monomer conversion (%) for various TMPET:Bis-EMA monomer mixtures as 
measured by DSC. (b) Summary of healing results at RT (25 °C) from reference tests of 25 μL 
injected solutions into each long-groove TDCB sample. Healing response was tested 24 h after 
samples were clamped back together. Error bars represent one standard deviation for 4–6 
samples of each system. 
 
 
 
Figure 8.13. Summary of reference tests for monomer ratios (TMPET:Bis-EMA) with BPO in 
PA solutions (5:1 molar ratio). Healing was conducted at the three different temperatures for    
24 h and then tested at RT. Error bars represent one standard deviation based on 4–5 samples. 
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(a)  (b)  
 
Figure 8.14. Summary of healing performance for various systems and the appropriate controls 
at (a) 5 wt% and (b) 10 wt% capsules. The error bars represent one standard deviation based on 
4–5 samples. 
 
(a)  (b)  
 
(c)  
 
Figure 8.15. SEM images of healed fracture planes for (a) BPO in PA capsules only (5 wt%),   
(b) M/A capsules only (5 wt%), and (c) in situ two capsule system (10 wt% capsule loading). 
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Figure 8.16. Healing performance for 3:1 TMPET:Bis-EMA capsules with BPO in PA capsules 
at a 5:1 ratio. The error bars represent one standard deviation based on 3–5 samples and healing 
was reported at RT 24 h after the initial virgin fracture event. 
 
 
 
 
Figure 8.17. Study of healing efficiency over a 48 h time period after initial virgin fracture 
occurs. The samples are fully in situ specimens with 5 wt% capsule loading.  
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(a)  (b)  
 
Figure 8.18. SEM images of healed fracture surfaces after (a) 14 min healing and (b) 24 h 
healing at RT. 
 
 
 
 
Figure 8.19. EVE in situ self-healing samples in the environmental chamber at 37 °C           
(40% relative humidity) for 24 h. Five samples were clipped and submerged in the simulated 
body fluid (center clear plastic container), while another set of five identical samples were 
exposed to the same temperature and humidity conditions.  
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(a)  (b)  
 
Figure 8.20. SEM images of healed fracture surfaces after healing at 37 °C in the environmental 
chamber (a) not immersed and (b) immersed in the SBF at 40% relative humidity. 
 
 
Table 8.1. Summary from DSC Experiments of TMPET:Bis-EMA at Different Ratios.* 
 
[TMPET] by weight Conversion (%) Onset T (°C)
0 62.8 52 ± 2.7
1 63.1 49 ± 7.2
2 64.0 54 ± 11
3 65.1 52 ± 3.6
5 64.9 48 ± 2.1
7 74.7 48 ± 4.5
8 79.3 46 ± 0.2
9 77.0 48 ± 1.9
10 64.2 49 ± 3.8  
* averages and standard deviations are based on 3 runs for each data entry 
 
 
Table 8.2. Summary of Viscosities (at 50 °C) for M/A Solutions.
†
 
 
Monomer 
Mixtures 
(TMPET:Bis-
EMA) 
 
Onset T of 
Polymerization 
(°C) 
η* from 
temperature 
sweep (Pa·s) 
η* from 
time sweep 
(Pa·s) 
 
η from shear 
rate sweep 
(Pa·s) 
pure Bis-EMA 178 1.2 0.41 4.8 x 10
-2
 
3:1 148 0.78 0.72 2.2 x 10
-2
 
4:1 122 0.40 0.28 1.8 x 10
-2
 
pure TMPET 139 0.70 0.36 1.7 x 10
-2
 
† The temperature sweep was from 25–200 °C; and time sweep (isotherm at 50 °C for 3 h). A best-fit line 
was plotted and complex viscosity at 50 °C was calculated (third column) and the y-intercept of the best-
fit line was reported (fourth column). 
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Table 8.3. Simulated Body Fluid Components. 
 
Salts Mass Used (g) Concentration (mM) 
NaCl 8.1 58 
NaHCO3 0.35 84 
KCl 0.22 75 
K2HPO4 0.17 174 
CaCl2 0.28 111 
MgCl2 0.14 94 
 
 
Table 8.4. In Situ Self-Healing Summary of Optimized System. 
 
Healing 
Temperature 
(°C) 
Healed Peak 
Load (N) 
Healing Efficiency 
(%) 
# of 
Samples 
25 91.7 ± 10.3 75.7 ± 10.3 5 
37 70 ± 6.4 58.9 ± 6.4 5 
37 (in SBF)* 76.8 ± 15.7 64.4 ± 13.2 10 
* SBF = simulated body fluid solution at pH 7.25 
 
 
Scheme 8.1. Mechanism for Free-Radical Generation between BPO and DMA. 
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CHAPTER 9 
 
MICROCAPSULES FOR ELECTRONIC APPLICATIONS 
†
 
 
 
9.1 Background/Motivation 
 
 To date, self-healing materials systems have largely focused on restoring functions such 
as mechanical properties of structural composites
1
 and barrier properties of protective coatings.
2
 
The self-healing concept based on release of liquid content from microcapsules is a general one 
that may potentially apply to other functionalities such as the restoration of electrical 
conductivity in damaged electronic materials. For example, in order to overcome the limited life 
cycles and safety issues inherent to current lithium-ion battery technology, new approaches are 
needed that can stabilize the electrode-electrolyte interface and repair both anode and cathode 
components. The expansion and contraction of electrode materials during charge-discharge 
cycling cause cracking and loss of electrical conductivity.
3
 With the goal of “electrical 
restoration” in mind, two new types of polymer nanocomposites have been characterized in 
which suspensions of single-walled carbon nanotubes (CNTs) and precursor solutions to a 
conductive charge-transfer salt were incorporated within polymer-based microcapsules. 
Microcapsules containing CNT suspensions release these conductive particles upon mechanical 
rupture of the microcapsules; this system is the focus of the first part of this chapter. The second 
part of this chapter will discuss the encapsulation of two separate components that form the 
conductive charge-transfer salt upon mixing of the liquid released from the microcapsules. 
                                                          
†
 Some of the content presented in this chapter was published in Caruso, M. M. et al. J. Mater. Chem. 2009, 19, 
6093-6096, Copyright 2009, Royal Society of Chemistry and Odom, S. A.; Caruso, M. M. et al. Adv. Funct. Mater. 
2010, 20, 1721-1727, Copyright 2010, Wiley InterScience. 
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9.2 Capsules containing Carbon Nanotube Suspensions 
 
9.2.1 Introduction 
 
Carbon nanotubes have proven to be valuable particulate additions to composites due to 
their exceptional mechanical and electronic properties.
4
 CNTs have been incorporated into 
polymer composites in order to produce materials with unique optical and electronic properties 
not present in the polymer alone.
5
 Structural composites have been made stiffer
6
 and tougher
7
 by 
the incorporation of CNTs. Their application has also been explored in the field of self-healing 
systems, wherein the embedded CNTs serve as electronically-responsive damage sensors.
8,9
 In 
an approach for electrical self-healing, Bielawski and coworkers employed N-heterocyclic 
carbenes coordinated to transition metals for the restoration of electrical conductivity in a      
self-healing system.
10
 These results provided the inspiration for encapsulation of suspensions of 
conductive CNTs aimed at the restoration of electrical conductivity upon microcapsule rupture, 
which had not previously been investigated. In the following section, the preparation of 
microcapsules containing a suspension of CNTs in organic solvents is demonstrated, and the 
conductive behavior of their core liquids upon rupture is reported. These healing agents could be 
used in a system where upon mechanical damage to the microcapsules results in the release of 
CNTs, and thus, restores electrical conductivity. 
 CNTs have been “encapsulated” with solid polymers at the molecular level in an effort to 
enhance dispersion in composites
11,12
 and with peptide amphiphiles for use in bioactive 
nanomaterials.
13,14
 We were the first group to report the preparation of microcapsules with robust 
shell walls containing core suspensions of CNTs.
15
 Due to the hydrophobic character of 
unfunctionalized CNTs, we hypothesized that the CNTs would remain suspended in the organic 
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phase of an oil-in-water emulsion and therefore can be encapsulated using an in situ 
polymerization method employed for the microencapsulation of nonpolar phases.
16
    
9.2.2 Preparation and Characterization of Microcapsules 
 
The dispersion of commercially available CNTs in various solvents was first qualitatively 
studied.  Although surfactants are often used to disperse the CNTs in liquids,
17
 these stabilizers 
could adversely affect capsule synthesis. Therefore, unfunctionalized CNTs were screened in a 
number of nonpolar solvents to maximize dispersability without modifying the CNTs 
themselves. CNT suspensions were reasonably stable in chlorobenzene (PhCl) and ethyl 
phenylacetate (EPA), which was consistent with our expectations given the aromatic character of 
these solvents. Solutions of unfunctionalized single-walled nanotubes (CNTs) in both PhCl and 
EPA were prepared at a concentration of 0.5 mg/mL (0.05 wt%) and were then sonicated for    
30 min to achieve maximum dispersion. Figure 9.1 shows images acquired by transmission 
electron microscopy (TEM) of the unmodified CNTs before encapsulation. Minor impurities 
(most likely the iron catalyst used to make the CNT from graphite) apparent in the CNT 
suspension were also present in the as-received CNTs. 
Whereas neat solvents EPA and PhCl are routinely encapsulated as mentioned in Chapter 
3 of this dissertation,
18-20
 secondary nucleation of the poly(urea-formaldehyde) particles became 
problematic when encapsulating CNTs dispersed in these solvents as shown by images of the 
capsules prepared by this procedure
16
 (Figure 9.2). Therefore, the quantity of shell wall 
components was reduced in order to minimize particle agglomeration on the outer walls of the 
capsules.
18
 Representative scanning electron microscopy (SEM) images of the resulting capsules 
containing CNTs are shown in Figure 9.3. Optical micrographs also show the formation of 
spherical capsules. The capsules were imaged in an index-matched fluid. This fluid was selected 
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based on the respective core solvent (e.g. CNT-EPA capsules were imaged in EPA). From the 
optical microscopy images, it was evident that the microcapsule interiors contained bundles of 
CNTs (Figure 9.3b and 9.3d). The thermal stability of the microcapsules containing suspensions 
of CNTs was compared to pure solvent capsules by thermogravimetric analysis (TGA), shown in 
Figure 9.4. 
Using a stir rate of 300 RPM during encapsulation resulted in microcapsule diameters 
ranging from 280–350 μm. First, the capsule diameter is highly dependent on the stir rate used in 
the encapsulation procedure and thus, can be modified as desired for specific applications. When 
capsules were prepared at stir rates above 300 RPM (e.g., 400–600 RPM), capsules continued to 
form, but their small size (40–90 μm in diameter) made characterization of the core material and 
release of the CNTs more challenging. As a result, the larger capsules prepared at 300 RPM were 
used in the subsequent studies.  
When dried capsules were crushed between glass slides, optical micrographs showed that 
all microcapsules released the suspended CNT bundles (Figure 9.5). The release of CNTs from 
these capsules was monitored after being crushed onto a silicon wafer mounted on top of a 
carbon tape-coated stage, which was examined by SEM (Figure 9.6). The nanotubes appeared to 
contain particulate impurities (inset), consistent with the observation by TEM in Figure 9.1 of the 
CNT-EPA suspension. 
9.2.3 Conductivity Measurements 
CNT encapsulation was indirectly shown using conductivity measurements and the 
experimental setup shown in Figures 9.7 and 9.8a. Encapsulated CNTs suspended in EPA and 
PhCl were first ruptured with a destructive method of mixing (under magnetic stirring for         
30 min). The core materials were then analyzed at room temperature and the voltage was swept 
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from -50 V to +50 V. When the voltage was applied and cycled in this range, bundles of CNTs 
migrated towards the probe tips (separated by a distance of 100–150 μm) until enough material 
had collected to form a bridge spanning between probe tips (Figure 9.8). This migration of CNTs 
in an organic solvent in the presence of an external electrical field is consistent with previous 
reports.
17,21-23
 In our case, the abundant release of CNT core suspensions into the stirred solution 
resulted in a measurable current, a summary of which is given in Table 9.1. The observed current 
for these solutions indeed resulted from only a fraction of CNTs bridging the probe tips based on 
the result that non-encapsulated CNT suspensions showed a current of 20 μA at 50 V.24 A series 
of controls were also performed to check the validity of the conductivity measurements. First, 
solvent capsules without CNTs were destructively mixed, and showed no measurable current, 
demonstrating that the solvent-only core solution contained no conductive species. Next, CNT 
capsules were mixed in a non-destructive manner (without rupturing the capsules) by vortexing 
for 30 min. Conductivity measurements of the suspended non-ruptured capsules showed that the 
previous current response reported in Table 9.1 required microcapsule rupture, thus 
demonstrating that the CNTs were incorporated into the microcapsule cores and absorbed to the 
exterior of the capsules.  
Increasing amounts of CNTs in the core of the microcapsules was expected to result in an 
increase in the measured current. Due to the volatility and lower dispersability of CNTs in the 
solvent PhCl, it was not possible to obtain reliable conductivity measurements for the studies of 
varying CNT loading in these microcapsule core dispersions. The lower vapor pressure of EPA 
allowed longer experiments to be conducted with greater reliability than with PhCl. As a result, 
only EPA-CNT capsules were tested for their resistance as a function of CNT weight fraction. In 
order to analyze the effect of CNT weight fraction in the core material of the microcapsules on 
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resulting current, microcapsules were prepared containing core suspensions of CNTs in EPA that 
varied from 0.025–0.1 wt% CNTs. The current carrying capabilities of core suspensions with 
different concentrations of CNTs were then studied. For solutions with a smaller concentration of 
CNTs, the voltage was swept 5 times before a significant current was observed (multiple sweeps 
were necessary in order for a sufficient concentration of CNTs to build a seamless bridge 
between the probe tips). Representative plots at each concentration are shown in Figure 9.8b. As 
expected, the current increased as a larger amount of CNTs was released from the microcapsules. 
The thermal behavior of this set of capsules was also characterized by TGA (Figure 9.9). 
9.2.4 Capsules containing P3HT:CNT Suspensions 
 Single-walled CNTs are promising materials for electrodes in batteries and the 
microcapsules containing the CNT suspensions show great promise for this type of application. 
However, since current synthetic methods yield polydisperse mixtures of aggregating CNTs, the 
performance of CNT electrodes and use of CNTs in commercial applications has previously been 
hindered by the presence of semiconducting species.
25
 Recent work by Hersam et al. has shown 
that monodisperse samples of predominantly metallic CNTs can be prepared through the use of 
stabilizers by density gradient ultracentrifugation (DGU).
25-27
 Compared to unstabilized 
materials, films enriched in metallic CNTs can enhance conductivity by as much as a factor of 
10.
27
 We hypothesize that preparing capsules that contain suspensions of monodisperse CNTs 
 (in diameter, length, chiral handedness, and electronic type) should increase the conductive 
behavior from the measured response of commercial, unpurified CNTs.
15
 
 In collaboration with the Hersam group at Northwestern University, we obtained a 
suspension of a 1:1 ratio of regioregular poly(3-hexylthiophene) (P3HT) to CNTs in the solvent 
o-dichlorobenzene (o-DCB). Microcapsules were prepared with this suspension as the core 
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material at a stir rate of 900 RPM. Figure 9.10 shows optical and SEM images of the resulting 
microcapsules produced with an average diameter of 67 ± 15 μm. Larger capsules were also 
prepared at a lower stir rate (500 RPM) to form capsules for bulk conductivity measurements. 
The thermal stability of the microcapsules was analyzed by TGA, and this curve is overlaid with 
that of microcapsules containing a core of only o-DCB (Figure 9.11). The CNT suspension does 
not appear to have an adverse affect on the temperature at which the microcapsules rupture     
(ca. 260 °C). In order to further confirm the presence of the CNT suspension in the core of the 
microcapsules, UV-visible absorption spectra of the initial suspension were acquired, which was 
overlaid with a spectrum of the CNT capsules in the same solvent, o-DCB (Figure 9.12). The 
capsules were observed to suspend in the solvent, allowing for core material to be index-matched 
within unruptured capsules. The absorbance between 400-500 nm is due to the P3HT, and peak 
around 600 nm is due to the metallic CNT; both sets of peaks are present in the capsules 
suspended in o-DCB. As a control, solvent-only microcapsules were also suspended in o-DCB 
and do not show peaks for the P3HT or CNT absorptions. 
 Using the 1:1 P3HT:CNT suspension, microcapsules were prepared with an average 
diameter of 165 ± 50 μm for use in bulk conductivity experiments. A new testing protocol was 
adopted where fabricated gold lines on a glass substrate down to 5 μm gaps were present in the 
center (Figure 9.13).
28
 A suspension of ruptured capsules containing CNTs was placed in the 
central region of the gold line on the gap, and probe tips were placed on the outer edges of the 
gold line. The voltage was continuously swept from -10 V to +10 V. The resulting            
current-voltage results obtained from these experiments are reported in Table 9.2. Due to the 
increase in dispersion of P3HT-stabilized CNTs in the o-DCB, we initially expected higher 
conductivity values than when compared to results with the commercial CNT capsules. 
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However, these results are on the same order of magnitude. Representative I-V traces from these 
experiments are shown in Figure 9.14. It was empirically determined that by continually 
sweeping the voltage between the probe tips on the gold line, an increase in measured current 
was achieved (Figure 9.14). This behavior was attributed to the alignment of the CNTs in 
solution from the released capsules to form a bridged network across the 5 μm gap. In order to 
maximize the amount of current measured from these types of experiments, future experiments 
could include encapsulating graphene particles and other carbon-containing materials, then 
monitoring their electronic behavior upon microcapsule rupture. 
9.3 Restoration of Conductivity with TTF-TCNQ Charge-Transfer Salts 
9.3.1 Introduction 
 Another plausible method for restoration of conductivity is the conductive 
tetrathiafulvalene–tetracyanoquinodimethane (TTF-TCNQ) charge transfer salt29,30 that can be 
generated from solutions of its precursors. This system would be more complex from the       
one-component CNT capsules, in that two liquid-filled microcapsules would be required to mix 
upon capsule rupture and form a conductive compound. The major advantage of this approach is 
the greater mobility of the precursor solutions; here it is possible that both core solutions may 
travel by capillary action to the relevant damage site before forming the conductive salt. 
Individually, TTF and TCNQ are soluble in a variety of organic solvents, commercially available 
in bulk quantity, and are non-conductive. The formation of the relatively insoluble charge 
transfer salt (Scheme 9.1) occurs rapidly at room temperature, and preferentially forms the   
TTF-TCNQ salt in a 1:1 molar ratio, even when TTF and TCNQ are not combined in equal 
amounts.
30
 Rapid and spontaneous generation of conductive TTF-TCNQ via microcapsule 
delivery of solutions of its constituents could enable autonomous conductivity restoration.  
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 Single crystal TTF-TCNQ shows a high conductivity of 400–500 S/cm,31-33 making it a 
useful material for electronic devices.
34-36
 The conductivity of polycrystalline TTF-TCNQ has 
been studied by fabrication through chemical vapor deposition,
37
 thermal evaporation,
38
 and 
from crystals grown from combined solutions of TTF (the electron donor) and TCNQ             
(the electron acceptor).
39
 These films generally have conductivities of 5–30 S/cm.34,37,40 In a 
recent example of solution–based salt formation, conductive films and circuits were deposited 
onto substrates using ink-jet printing of the donor and acceptor solutions, forming the charge 
transfer salt (in ca. 10 s) before complete solvent (dimethylsulfoxide) evaporation.
39
  Without 
post-process annealing, this method produced films with conductivities of 5–10 S/cm, 
comparable to that of vacuum-deposited films.
34,37,40
 This section reports on the encapsulation of 
individual solutions of TTF and TCNQ, as well as characterization of the core materials. The 
formation of the TTF-TCNQ charge transfer salt from the rupture of a mixture of TTF- and 
TCNQ-containing microcapsules is also demonstrated through conductivity measurements using 
newly fabricated substrate.
28
 
9.3.2 Microcapsule Characterization 
 Unlike the straightforward encapsulation of CNTs,
15
 a suspension of the TTF-TCNQ 
charge transfer salt was not easily encapsulated using the in situ polymerization procedure.
18
 In a 
preliminary attempt to encapsulate polycrystalline TTF-TCNQ in the solvent phenyl acetate 
(PA),
19
 it was observed that the salt crystals, regardless of size, did not remain in the core of the 
produced microcapsules but instead adhered to the shell wall or were in partial contact with the 
microcapsule exterior (Figure 9.15A).  As a result, the poor quality capsules were observed to 
collapse upon drying and sieving.  In an alternative approach, encapsulation of ground, powdered 
TTF-TCNQ salt with smaller particle sizes than the microcapsule diameters was attempted 
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(Figure 9.15B). However, when these microcapsules were ruptured by manual crushing – which, 
in all cases was accomplished using a mortar and pestle – they did not release the salt from the 
interior of the capsules (Figure 9.15B, inset).  Due to the apparent difficulty of encapsulating the 
TTF-TCNQ salt directly, the encapsulation of individual solutions of each compound was 
investigated. 
 TTF and TCNQ were qualitatively screened in various solvents that have been shown to 
form high quality microcapsules and promote self-healing in epoxy polymers.
18,19
 While TTF 
displayed good solubility in most solvents, the solubility of TCNQ was much lower and proved 
to be the limiting factor in solvent choice for encapsulation. Of the solvents investigated, PhCl, 
EPA, and PA dissolved TCNQ significantly more than other encapsulatable solvents               
(see Chapter 3 of this dissertation for a list of solvents). The solubility of each compound and the 
minimum solution concentrations required for precipitation of the charge transfer salt from 
solutions of equal volumes and concentrations were determined for each solvent (Table 9.3). The 
minimum concentration required for salt precipitation for all solvents was one-half to one-third 
of the maximum solubility of TCNQ. For this test, the minimum concentration required for 
precipitation is reported for precipitation of the salt within 5 min after mixing room temperature 
solutions. The salt formed in all tested solvents.   
 TTF and TCNQ were individually incorporated into microcapsule cores as solutions in 
the three selected solvents at the maximum solution concentrations following our reported 
encapsulation procedure using a stir rate of 400 RPM (Table 9.4).
18
 Spherical, free-flowing 
microcapsules were produced using each solvent; optical images of the produced capsules are 
shown in Figures 9.16–9.19. Table 9.5 shows the average capsule diameters for each batch of 
capsules produced at a stir rate of 400 RPM. Despite the relatively minor difference in 
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solubilities of TTF and TCNQ in the three core solvents, the amounts of each compound 
incorporated into the microcapsule cores were ca. 3 times higher and 10 times higher (by wt%), 
respectively, for PA microcapsules than for PhCl and EPA microcapsules. In PA, the amount of 
TCNQ encapsulated was ca. 50% that of TTF. Due to the increased amount of solubility in PA, 
these capsules were used in subsequent studies. When mixtures of TTF-PA and TCNQ-PA 
microcapsules were ruptured, a dark brown color was immediately observed, indicative of the 
TTF-TCNQ charge-transfer salt formation (Figure 9.20a). When a mixture of these ruptured 
microcapsules was dispersed in mineral oil immediately after, optical micrographs revealed 
small particles that are not present in ruptured TTF-PA or TCNQ-PA microcapsules alone 
(Figures 9.20b). Salt formation was also confirmed by powder x-ray diffraction and FTIR studies 
(not shown).
28
 
 Attempts to increase the concentration of TCNQ in the core solvent by preparing 
supersaturated core solutions led to poor quality capsules that leached core content rapidly when 
stored at RT. Higher concentrations of TTF and TCNQ were encapsulated in the solvent PA only 
when a more robust encapsulation procedure was used involving dissolution of a commercial 
polyurethane prepolymer to the core solution prior to its addition to the emulsion.
41
 The modified 
capsules (marked with „*‟) showed increased thermally stability compared to the TTF-PA 
microcapsules as measured by TGA (Figure 9.21), but also showed significant leaching of core 
content after 2 weeks. The TTF-PA microcapsules showed mass loss at an onset temperature    
ca. 130 °C. The TTF-PA* microcapsules exhibit mass loss at elevated temperatures (ca. 200 °C), 
demonstrating the increased thermal stability of the modified capsules. The TCNQ-PA capsules 
were stable past the boiling point of phenyl acetate (196 °C).  
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9.3.3 Conductivity Analysis of Ruptured Microcapsules 
 After verifying the charge transfer salt formation upon rupture of TTF-PA and TCNQ-PA 
microcapsules, electrical properties of the ruptured microcapsules were examined by        
current-voltage (I-V) measurements. Before analyzing ruptured microcapsules, comparative 
solutions of TTF in PA, TCNQ in PA, and a suspension of TTF-TCNQ salt in PA were analyzed 
by a previously-published procedure for collecting I-V data similar to that used for the analysis 
of microcapsules containing CNT suspensions.
15
 For each case, two tungsten probe tips spaced 
approximately 100 m apart were immersed in suspension deposited on glass slides. The 
potential was varied from -10 V to +10 V, and the resulting current was recorded. TTF in PA 
alone showed little measurable response to applied voltage, while TCNQ in PA and TTF-TCNQ 
in PA showed linear I-V responses, with the I-V ratio of TTF-TCNQ being more intense than 
that of TCNQ (not shown).
28
 It is possible that TCNQ in PA showed an I-V response due to 
partial reduction to the radical anion form upon interaction with PA. Observation by optical 
microscopy during these experiments revealed that the TTF-TCNQ crystals aligned between the 
probe tips, similar to the behavior observed for CNT suspensions.
15 
 The same measurements were performed for suspensions of crushed TTF-PA and  
TCNQ-PA microcapsules in a 1:1 ratio (wt%) at multiple concentrations in PA (Figure 9.22a). 
The I-V response was also linear for these cases and dependent on microcapsule loading (wt%). 
I-V measurements were also obtained for neat ruptured TTF-PA and TCNQ-PA microcapsules, 
both individually and combined (Figure 9.22b). In these measurements, the current reached a 
maximum value for the combination of TTF-PA and TCNQ-PA microcapsules after 5–7 scans, 
potentially due to increased alignment of the charge transfer salt in subsequent scans. The data 
presented in Figure 9.22 represents the final scan. Without dilution, the neat ruptured 
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microcapsule samples were too opaque to see individual crystals/particles, and prevented optical 
confirmation of this effect. However, this phenomenon was previously observed in related work 
when suspensions of ruptured microcapsules containing CNTs were analyzed.
15
  
 The optimal ratio of TTF-PA:TCNQ-PA microcapsules for the restoration of conductivity 
was determined from I-V measurements performed on substrates containing model damage of an 
electrical circuit. Well-defined gap distances (less than 100 m) in conductive lines were 
fabricated using standard photolithography techniques and patterned masks as described in 
Section 9.2.4. To ensure that the gaps were bridged with enough material, an excess of ruptured 
microcapsules was deposited onto the substrate over the gaps in the gold lines.  Tungsten probe 
tips were used to make contact with the gold lines, and the I-V response was measured in the 
subsequent studies. Initially, gold lines with a 50 m gap were used to compare neat crushed 
microcapsules. The ratios of TTF-PA:TCNQ-PA microcapsules were varied to determine which 
combination of microcapsules gave the largest I-V response (Figure 9.23a). The TTF-PA and 
TCNQ-PA microcapsules alone were also analyzed using the gold line substrate and showed no 
measurable current. Out of the ratios of TTF-PA:TCNQ-PA microcapsules analyzed, the largest 
current response occurred with a 1:2 ratio. This ratio of capsules is consistent with delivering the 
optimal 1:1 ratio (by mass and molarity) of TTF:TCNQ, which is expected to yield the highest 
concentration of charge transfer salt. Once the ideal ratio of microcapsules was determined, this 
optimized ratio was used to examine the change in I-V response over multiple gap sizes to 
determine the potential for conductivity restoration for various damage states. In these 
experiments, a 1:2 ratio of neat crushed TTF-PA:TCNQ-PA microcapsules was applied to 
substrates over the 30, 50, and 100 m gaps. As expected for a polycrystalline material, the I-V 
responses were larger for shorter gaps (Figure 9.23b). All gap sizes showed conductivity 
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restoration, indicating that the TTF-TCNQ charge-transfer salt bridges at least 100 m distances 
upon microcapsule rupture. Future work for this project includes the fabrication of substrates 
with smaller gap distances (< 30 μm) and a layered, composite structure for four-point bend 
experiments to yield more representative conductivity measurements of those used in industrial 
settings. 
9.4 Experimental Section 
 
Materials: PhCl, o-DCB, EPA, PA, acetonitrile, single-walled carbon nanotubes (CNTs), 
urea, ammonium chloride, formaldehyde solution, and resorcinol were purchased and used as 
received from Sigma-Aldrich. TCNQ was purchased from Sigma-Aldrich and was purified by 
recrystallization from acetonitrile,
42
 and TTF was recrystallized from hexanes as previously 
described.
43
 ZeMac® ethylene-maleic anhydride (EMA) copolymer was donated by Vertellus 
(formerly Zeeland Chemicals), and mixed with deionized water to produce a 2.5 wt% surfactant 
solution. Silicon wafers (2" in diameter, 228–330 nm thick, resistivity: 0.001–100, P/Boron type 
<100> orientation) were purchased from Montco Silicon Technologies. The commercial 
polyurethane prepolymer, Desmodur L 75, was purchased from Bayer MaterialScience and was 
used as received. 
Preparation of CNT Capsules: The in situ polymerization method for encapsulation of 
hydrophobic solutions was modified to encapsulate CNTs.
16,18-20
 Briefly, a core solution 
consisting of 60 mL solvent (PhCl or EPA) and 30 mg CNTs was sonicated for 30 min using a 
Fisher Scientific Mechanical Ultrasonic Cleaner (FS20, without heater) that operated at 40 Hz. 
This solution was added to a stirring mixture (at a stir rate of 300 RPM) of 100 mL deionized 
H2O, 25 mL EMA, 2.5 g urea, 0.25 g ammonium chloride, 0.25 g resorcinol at a pH of 3.5 in a 
600 mL beaker (these amounts have been designated as the “half recipe” as described previously 
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in Chapter 3 of this dissertation). The concentration of CNTs was changed in the core solution by 
adding 15, 45, or 60 mg to 60 mL EPA (0.025, 0.075, 0.1 wt%) in place of 0.5 mg/mL CNTs in 
EPA (0.05 wt%). After the emulsion stabilized for 10 min, 6.33 g formalin (37 wt/vol% 
formaldehyde) was added to the beaker and the reaction stirred for 4 h at 55 °C. The resulting 
capsules were rinsed with water and dried by vacuum filtration for 2 days. The capsules prepared 
that contained a 1:1 P3HT:CNT suspension in o-DCB at 2 stir rates (500 RPM and 900 RPM) for 
two different batches of capsules using the “full recipe” procedure.16  
Preparation of TTF/TCNQ Capsules: For the encapsulation of crystalline TTF-TCNQ, 
the charge transfer salt was formed from the combination of TTF in acetonitrile with TCNQ in 
acetonitrile, and then was recrystallized again from acetonitrile. The crystals were ground with a 
mortar and pestle such that the length of the longest axis of the majority of the crystals was     
100 m or less. During the encapsulation, the TTF-TCNQ salt was suspended in PA, and used as 
the core material following our previously described procedure for encapsulation.
18
 In the case of 
the encapsulation of powdered TTF-TCNQ, the TTF-TCNQ salt was generated in situ by 
pouring individual solutions of TTF and TCNQ (0.3 g TTF in 30 mL PA, 0.3 g TCNQ in 30 mL 
PA, each sonicated at 40 °C for 30 min prior to encapsulation using a Fisher Scientific 
Mechanical Ultrasonic Cleaner at 40 Hz) directly into the emulsification polymerization reaction 
vessel. For the TTF-PA* and TCNQ-PA* microcapsules, 3.0 g of polyurethane prepolymer 
(Desmodur L75) was added to the core solutions before sonicating and the encapsulation 
procedure to produce PU/UF capsules was employed.
41
 
Capsule Characterization: Capsule diameters were determined through optical 
microscopy using a Leica DMR Optical Microscope at various magnifications. ImageJ software 
was used to measure the diameters and an average of 100 capsules was used to determine the 
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size distribution. Capsules were also imaged using an environmental scanning electron 
microscope (ESEM) by mounting on a carbon-tape covered stage. A Philips XL30 ESEM-FEG 
instrument was used with a 5 kV electron source after sputter-coating the sample with a        
gold-palladium source. The released CNT suspensions were prepared by rupturing the 
microcapsules on a silicon wafer mounted on top of a carbon tape-coated stage, sputter-coated, 
and then imaged. TEM was performed using a Philips CM200 instrument with an operating 
voltage of 120 kV. The solutions containing CNTs were mounted onto carbon-coated copper 
grids (Ted Pella, Inc.). To determine the thermal stability of the microcapsules, TGA was 
performed on a Mettler-Toledo TGA851
e 
instrument calibrated by indium, aluminum, and zinc 
standards. The mass loss was recorded during a heating cycle over the temperature range of    
25–650 °C at a constant rate of 10 °C/min in an atmosphere of N2. For each experiment, 
approximately 2–5 mg of sample was accurately weighed (± 0.02 mg) into an alumina 
crucible. For the P3HT:CNT capsules, absorption spectra were recorded from 200–800 nm with 
a background scan of o-DCB solvent using a Shimadzu UV-Visible Spectrophotometer, model 
number UV-1601PC. Approximately 25 mg P3HT:CNT and o-DCB microcapsules were added 
to 1 mL o-DCB solvent in a quartz cuvette.  
Conductivity Measurements: To prepare the solutions for conductivity measurements, 
0.1 g of CNT microcapsules were added to 1 mL of the respective core solvent (EPA or PhCl) in 
a 20 mL scintillation vial. For the “destructive” method of mixing, the vials were stirred with a 
magnetic stir bar for 30 min. For the “non-destructive” method of mixing, the vials were agitated 
with a vortex mixer for 30 min. To demonstrate the conductivity of CNTs in solution, 2 drops of 
each suspension were pipetted onto a glass slide from the vials and the current was measured 
using a two-point measurement technique at a Signatone table-top probe station customized with 
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a standard S725 manipulator (see Figure 9.7). The voltage was swept from -50 V to +50 V 
continuously 5–7 times for each solution using an Agilent 4155C Semiconductor Parameter 
Analyzer. For the TTF-TCNQ capsule system, the voltage was swept from -10 V to +10 V 
continuously 5–7 times for each sample. Substrates for conductivity measurements were 
prepared as follows. Glass slides were cleaned using Piranha solution (3:1 vol/vol conc. H2SO4 : 
30% H2O2) for 1 h and then rinsed with Milli-Q water (> 18 M ·cm) and dried under a stream of 
N2. Shipley 1805 was spin-coated onto the cleaned glass wafers at 3000 RPM for 30 s. The 
photoresist was patterned through a transparency mask using a Karl Suss mask aligner           
(~16 mW/cm
2
) for 10 s.  After development of the photoresist using AZ 351 developer, a 10 nm 
chromium adhesion layer followed by a 50 nm gold layer was deposited by electron beam 
evaporation.  Sonication of the substrates in acetone removed any remaining photoresist and gold 
overlayer. The dimensions of gaps in the gold lines were confirmed by optical microscopy. 
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9.6 Figures and Tables 
 
 
 
Figure 9.1. TEM images of CNTs deposited from an EPA suspension. Reprinted with 
permission from Reference 15. Copyright 2009, Royal Society of Chemistry. 
 
 
 
Figure 9.2. SEM image of microcapsules containing CNTs in PhCl prepared with the in situ 
polymerization method
16
 showing excess urea-formaldehyde wall material. 
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Figure 9.3. Representative SEM images and optical micrographs of microcapsules containing 
CNTs (0.05 wt%) suspended in (a, b) EPA and (c, d) PhCl. Capsules were prepared at a stir rate 
of 300 RPM. Reprinted with permission from Reference 15. Copyright 2009, Royal Society of 
Chemistry. 
 
(a)  (b)  
 
Figure 9.4. TGA scans of microcapsules containing 0.05 wt% single-walled CNTs in (a) EPA 
and pure EPA (no CNTs) and (b) 0.05 wt % CNTs in PhCl and pure PhCl. 
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Figure 9.5. Optical micrograph of ruptured capsule containing a CNT-EPA suspension         
(0.05 wt%) on a glass slide showing the released liquid and CNT bundles. 
 
 
 
Figure 9.6. SEM image showing bundles of CNTs released from a ruptured microcapsule. 
Remnants of the microcapsule are visible on the right hand side and lower edge of large image. 
Reprinted with permission from Reference 15. Copyright 2009, Royal Society of Chemistry. 
 
 
Figure 9.7. Experimental setup for conductivity measurements at a table-top probe station. 
251 
 
 
 
 
Figure 9.8. (a) Experimental setup showing probe tips submerged into the solution droplet 
containing CNTs; (b) Representative current-voltage plots (with a DC electric field) showing 
conductivity measurements of solutions from capsules containing CNT in EPA at various 
concentrations (inset: optical micrograph of CNT bundles bridging the probe tips). Reprinted 
with permission from Reference 15. Copyright 2009, Royal Society of Chemistry. 
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Figure 9.9. TGA scans of microcapsules containing various weight fractions of CNTs in EPA. 
 
 
(a)  (b)  
 
(c)  
 
Figure 9.10. Optical micrographs of microcapsules containing 1:1 P3HT:CNT suspension 
imaged in (a) mineral oil and (b) the solvent o-DCB; (c) SEM image of microcapsules. 
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Figure 9.11. Dynamic TGA curves for pure o-DCB microcapsules and the 1:1 P3HT:CNT 
suspension in o-DCB. 
 
 
 
 
Figure 9.12. UV-Visible spectra of P3HT:CNT suspension in o-DCB (red), unruptured pure     
o-DCB capsules (blue), and P3HT:CNT capsules in o-DCB (orange). All spectra were collected 
in the solvent o-DCB. 
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(a)  (b)  
 
Figure 9.13. (a) Photograph of experimental setup for probe station measurements (Reprinted 
with permission from Reference 28. Copyright 2010, Wiley InterScience); (b) Optical image of 
gold line with a 5 μm gap (scalebar = 100 μm). 
 
 
Figure 9.14. I-V traces for ruptured P3HT:CNT capsules using gold lines with 5 μm gaps on a 
glass substrate with continuous voltage sweeping from -10 V to +10 V.  
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Figure 9.15. Optical microscope images from (A) an attempt to encapsulate crystalline         
TTF-TCNQ salt in PA, (B) microcapsules containing powdered TTF-TCNQ salt suspended in 
PA; inset: ruptured capsules containing powdered TTF-TCNQ salt in PA. All scale bars are 200 
μm. Reprinted with permission from Reference 28. Copyright 2010, Wiley InterScience. 
 
 
(a)  (b)  
 
Figure 9.16. Optical micrographs of (a) TTF-PhCl and (b) TCNQ-PhCl microcapsules. 
 
 
(a)  (b)  
 
Figure 9.17. Optical micrographs of (a) TTF-EPA and (b) TCNQ-EPA microcapsules. 
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(a)  (b)  
 
Figure 9.18. Optical micrographs of (a) TTF-PA and (b) TCNQ-PA microcapsules. 
 
 
(a) (b)  
 
Figure 9.19. Optical micrographs of (a) TTF-PA* and (b) TCNQ-PA* microcapsules. 
 
 
(a)  (b)  
 
Figure 9.20. (a) Microcapsules (MCs) crushed between two glass slides: A) 50 mg PA-MCs; B) 
50 mg TTF-PA MCs; C) 50 mg TCNQ-PA MCs; D) 50 mg each TTF-PA and TCNQ-PA MCs; 
(b) Optical micrograph of 1:1 ratio (wt%) of crushed of TTF-PA:TCNQ-PA microcapsules 
dispersed in mineral oil. Reprinted with permission from Reference 28. Copyright 2010, Wiley 
InterScience.       
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Figure 9.21.  TGA scans of TTF-PA MCs (solid green line), TTF-PA* MCs (dotted green line), 
TCNQ-PA MCs (solid red line), and TCNQ-PA* MCs (dotted red line). The vertical line drawn 
is for the boiling point of phenyl acetate (196 °C). 
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Figure 9.22. I-V measurements of capsules on glass slides measured between two tungsten 
probe tips spaced approximately 100 m apart for (a) PA and suspensions of ruptured TTF-PA 
and TCNQ-PA MCs in a 1:1 ratio (wt%) in PA; and (b) neat ruptured TTF-PA MCs, TCNQ-PA 
MCs, and TTF-PA:TCNQ-PA in a 1:1 ratio (wt%) MCs. Reprinted with permission from 
Reference 28. Copyright 2010, Wiley InterScience.  
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Figure 9.23. (a) I-V measurements for neat ruptured microcapsules on gold line on glass with 50 
m gap, with ratios of microcapsules noted; (b) I-V measurements for neat ruptured 
1:2::TTF:TCNQ MCs deposited onto gold lines on glass with 30, 50, and 100 m gaps.   
 
 
Table 9.1. Average conductivity measurements for microcapsules. Reprinted with permission 
from Reference 15. Copyright 2009, Royal Society of Chemistry.   
 
Capsule Core Contents Method of Mixing
a 
Average Current (μA)b 
0.05 wt% CNT in PhCl destructive
c 
87.9 ± 5.95
d 
0.05 wt% CNT in EPA destructive
 
67.0 ± 2.34
d 
PhCl only (no CNT) destructive 0 
EPA only (no CNT) destructive 0 
0.05 wt% CNT in PhCl non-destructive
e 
0 
0.05 wt% CNT in EPA non-destructive 0 
a 
solutions were mixed for 30 minutes; 
b 
measurements taken at +50V; 
c 
the destructive method consisted 
of mixing with a stir bar; 
d 
the standard deviation is based on 4-10 measurements for each sample; 
e  
the 
non-destructive method consisted of mixing with a vortex shaker and capsules did not break open to 
release core material  
 
 
Table 9.2. Summary of CNT conductivity results across a 5 μm gap. 
 
 
 
 
 
 
 
Microcapsule  
Core Contents Current (μA) Conductivity (S/cm) 
0.05 wt% CNT in EPA 390 7.7  x 10
-2
 
1:1 P3HT:CNT in o-DCB 200 4.0  x 10
-2
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Table 9.3. Solubility of TTF and TCNQ in various solvents, and minimum concentration of 
1:1::TTF:TCNQ required for precipitation of the salt at room temperature (with both solutions of 
equal molarities). 
 
 
Solvent 
 
Solubility of TTF (M) 
 
Solubility of TCNQ (M) 
Amount for  
Precipitation (M) 
PhCl 2.8 x 10
-2 
1.9 x 10
-3
 1.2 x 10
-3 
EPA 2.7 x 10
-2
 1.2 x 10
-3
 4.9 x 10
-3 
PA 1.2 x 10
-1
 6.8 x 10
-3
 1.5 x 10
-3 
 
 
Table 9.4. Concentration of TTF and TCNQ used in each core solvent for encapsulation. 
 
Solvent Core TTF (wt%) TCNQ (wt%) 
PhCl 0.20 0.20 
EPA 0.21 0.21 
PA 0.53 0.53 
PA* 1.2 1.2 
* with polyurethane prepolymer (Desmodur ® L75) added to the core solvent 
 
 
Table 9.5. Average sizes of sieved microcapsules. 
 
Microcapsule Type Diameter  1 Std. Dev. ( m) 
TTF-PhCl 119 ± 37 
TTF-EPA 156 ± 27 
TTF-PA 113 ± 28 
TTF-PA* 130 ± 30 
TCNQ-PhCl 96 ± 24 
TCNQ-EPA 142 ± 24 
TCNQ-PA 132 ± 27 
TCNQ-PA* 156 ± 28 
* with polyurethane prepolymer (Desmodur ® L75) added to the core solvent 
 
Scheme 9.1. Formation of TTF/TCNQ charge transfer salt.  
 
NC CN
NC CN
S S
SS
NC CN
NC CN
S S
SS
TTF/TCNQ
charge transfer salt
+
solvent
rt
TTF
TCNQ
 
260 
 
CHAPTER 10 
 
CONCLUSIONS 
 
 
 This dissertation has presented a solvent-based approach to self-healing polymeric 
materials. It begins by providing an overview of self-healing polymers, a relatively new field that 
has generated international interest and greatly expanded in the past decade (Chapter 1). New, 
commercially-viable chemistries for self-healing motivated the development of solvent-based 
healing agents. Although previous researchers have demonstrated solvent healing, our new 
concept is based on incorporating solvent-filled carriers or microcapsules into bulk polymers for 
self-healing functionality. The mechanism of solvent healing in our specific epoxy thermoset 
(EPON 828:DETA) was first probed using thermal analysis and spectroscopic techniques 
(Chapter 2). Different encapsulation procedures were utilized to prepare solvent microcapsules 
(Chapter 3). The most robust solvent capsules possessed double-wall morphology and the core 
solvent ethyl phenylacetate (EPA).  
 A variety of common organic solvents were screened for their healing behavior in 
epoxies (Chapter 4) and the most important properties governing this result were boiling point 
and solvent polarity. Chlorobenzene (PhCl) was first used as the model solvent for a room 
temperature self-healing system. An improved system where epoxy-solvent mixtures were 
delivered as healing agents led to 100% healing efficiencies and full recovery of epoxy fracture 
toughness. The best performing epoxy-solvent solutions were comprised of PhCl, EPA, and 
phenyl acetate (PA). From conducting aging and temperature studies, the healing efficiencies for 
these systems slightly decreased after 1 month at room temperature and then a more dramatic 
exponential decline occurred when the healing was monitored over the course of a year. The 
fatigue performance of the best solvent-based self-healing systems (EPA and epoxy-EPA) 
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demonstrated complete crack arrest at low stress intensity levels (Chapter 5). The epoxy-EPA 
system persisted with the highest degree of fatigue life extension as the stress intensity levels 
increased when compared to control systems. This behavior shows great promise for use in 
epoxy systems cured at low temperatures. 
 For fully-reacted epoxy networks, a secondary embedded phase was incorporated for 
additional functionality to promote healing in commercial epoxy systems (Chapter 6). Various 
solid amines and protection strategies were employed to mask the reactivity of latent amines. An 
autonomic healing system was not developed from these studies, but a large body of data was 
generated that will aid in further investigation to select the appropriate chemistry for this 
concept.   
 Solvent healing was then extended to use in thermoplastic materials (Chapter 7). Various 
commercial processing conditions were attempted to incorporate solvent-filled microcapsules 
into bulk thermoplastics. Determination of capsule presence within the polymers was performed 
by x-ray microtomography with control samples utilized to produce a calibration curve. The 
highest degree of capsule survival post-processing was observed for poly(methyl methacrylate) 
samples that were solvent-casted and then compression molded into rectangular samples for 
mechanical testing. The next step is to demonstrate autonomic healing in this system at a variety 
of capsule loadings and testing parameters. 
 A free-radical based self-healing chemistry was discussed in Chapter 8 with          
solvent-based healing agents. Since some components of free-radical polymerizations were solid 
compounds, they had to be dissolved in selected solvents (PA and EPA) before encapsulation. 
Evaluations of various peroxide initiators, amine activators, and acrylates monomers were 
performed until the self-healing performance was maximized. The optimal two-capsule system 
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achieved up to 75% healing efficiencies at room temperature in an acrylate-based resin. This 
system also reported equivalent healed peak loads when immersed in a simulated body fluid 
environment. Further studies are needed to apply this two-capsule system to bone cements and to 
demonstrate biocompatibility of the capsule core components. 
 The last chapter of this dissertation (Chapter 9) reported the initial steps to developing 
self-healing electronics. Microcapsules filled with carbon nanotube suspensions were prepared 
by in situ emulsion polymerization processes and characterized with conductivity measurements. 
Another scheme examined was a two-capsule system used to form a conductive salt, which was 
shown to restore conductivity on fabricated gold line specimens. These initial projects paved the 
way for ongoing research in the area of conductive materials with the goal to develop a          
self-healing battery. 
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APPENDIX A 
 
DATA ANALYSIS FROM MICRO-CT IMAGING 
 
A.1 Instrument Set-up 
 
 When using the Xradia MicroCT located in the basement of the Beckman Institute 
(UIUC), the XMController program needs to read a temperature of -60 °C before the x-ray can 
be turned on. After clamping the sample in a holder, it is placed on the stage and the x-ray is 
turned on until reaching 40 keV, 8 W power, and a current of 200 μA (note: if the instrument has 
not been in use, the x-ray undergoes an “aging” period of about 20-30 min before it reaches the 
desired energy). Through continuous imaging at exposure times of 1 s and binning at 2, the 
sample must then be centered on the screen. Ensuring that the appropriate objective (10X was 
used in this dissertation) has been selected to view the edges of the sample, two vertical lines 
were drawn on either side of the sample and then the theta value was changed to -15 degrees. 
Using the arrows to move the sample in the z-direction, the sample is moved to fit between the 
two lines. After moving the sample back to 0° rotation, it was then adjusted in the x-direction to 
fit in between the two drawn lines. The angle was changed to +15 degrees and the z-direction 
adjusted again. This same procedure was repeated for angles of +/- 45 and +/- 90°. When the 
adjustments were made, the detector and source were moved so there was a 3:1 ratio of the 
distance between them (36 mm:12 mm used in this work). The viewing area was added to the set 
by clicking the symbol “◙”. Within the “recipe” chosen for the scan, the tomographic location is 
added to the current list based on the dimensions selected during the set-up process. The images 
taken in this dissertation ranged from -93 to +93°, so 373 images were taken = (93+93) x 2 + 1 at 
the beginning. An exposure time of 10 s was used, and the reconstruction commenced following 
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the scan with a binning of 1. The image can then be opened using the Xradia software to convert 
the file to .txm-exm and .txm-exm-occ formats.          
A.2 Data Processing using Amira Software 
 All processing was performed in the Imaging Technology Group Visualization 
Laboratory (Beckman Institute, UIUC) on either a Mac or PC computer that had Amira software. 
When the software is opened, first go to „Preferences‟ and increase the amount of memory in the 
„Main Memory Account‟ and „Video Memory Account‟ under the „LDA‟ tab by dragging the bar 
all the way to the right. This maximized the storage since the microCT images were quite large. 
In order to prevent the software from overloading, the .txm-exm file was opened and then a 
lattice created from this data by selecting „Compute:CastLattice‟ and choosing an output 
database of „signed short (16 bit).‟ When this setting was applied, a new object (Object3*) 
appeared in the workspace. By selecting the “stacks” tool at the top of the workspace, the object 
can be labeled. The „Display and Masking‟ histogram was manually narrowed to view the 
sample only on the right part of the screen. The selected area appeared shaded and then this was 
added to the selected voxels. At the bottom of the left side of the screen, the „threshold‟ tab must 
be selected, and then „select‟ all slices to apply the shading to all of the slices on the screen. A 
duplicate object (Object 5*) was created from Object3 and a new label was also created for the 
embedded capsules only, which appeared as white spheres in the image. Usually, the voxel 
intensity of the capsules only was very high values on the histogram. The labeling as described 
above for the capsules as well. 
 In order to determine the volumes that the capsules occupy in the surrounding matrix 
through Amira, one must return back to the main workspace and select the „labels‟ tabs for 
Objects 3 and 5. Then, go to „Measure:MaterialStatistics‟ and apply this to the data. A new 
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object is created that is a spreadsheet. The data for both the matrix calculation and the capsules 
calculations appear as separate sheets in a column labeled „volume‟ where the units are μm3. The 
volume percentage of capsules imaged through microCT were calculated by dividing the volume 
of the capsules by the volume of the matrix and a summary of these are given in Table A.1 and 
were reported in Chapter 5 of this dissertation. 
 Three-dimensional (3D) reconstructed images were created from the labeled objects in 
the main workspace. By right clicking this label, one can then “Compute:SurfaceGen” and hit 
„apply‟ to run the processing. A new object has been created and from there, go to 
“Display:SurfaceView” to show the image on the right of the screen. A scalebar was created for 
the graphics and snapshot taken of the image. 
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A.3 Tables  
Table A. 1. Summary of microCT results for samples processed at ARL and UIUC. 
Polymer Capsules (wt%) Capsules (vol%) Processing Conditions Cylinder (μm
3
) Capsules (μm
3
) Volume %
epoxy 0.7 0.445 model system 4.23E+09 1.13E+07 0.27
epoxy 2.5 1.59 model system 4.24E+09 3.55E+07 0.84
epoxy 5 3.2 model system 4.16E+09 1.53E+08 3.69
epoxy 7.5 4.8 model system 4.03E+09 1.93E+08 4.80
PMMA 2.5 1.59 straight pass 4.47E+09 1.31E+05 2.93E-03
PMMA 2.5 1.59 recirculated 2.37E+09 1.91E+05 8.05E-03
PMMA 2.5 1.59 straight pass 4.53E+09 7.11E+05 1.57E-02
PMMA 2.5 1.59 straight pass 1.33E+08 1.26E+05 9.46E-02
PMMA 2.5 1.59 recirculated 4.03E+09 3.05E+05 7.56E-03
PMMA 5 3.2 straight pass 4.81E+09 3.10E+05 6.44E-03
PMMA 5 3.2 recirculated 4.81E+09 2.77E+05 5.76E-03
PMMA 7.5 4.8 straight pass n/a n/a n/a
PMMA 7.5 4.8 molded sample 5.80E+09 1.07E+05 1.84E-03
PMMA 7.5 4.8 force control 6.86E+09 1.10E+05 1.61E-03
PMMA 0 0 straight pass n/a n/a n/a
PMMA 2.5 1.59 straight pass 4.14E+09 3.30E+04 7.96E-04
PMMA 5 3.2 straight pass 4.41E+09 n/a n/a
PMMA 7.5 4.8 straight pass 4.44E+09 3.71E+04 8.34E-04
PMMA 2.5 1.59 mechanically mixed 4.82E+09 3.67E+05 7.62E-03
PMMA 2.5 1.59 coprecipitated 4.84E+09 2.60E+05 5.36E-03
PMMA 2.5 1.5 caulk gun, melted 4.65E+09 1.47E+07 0.32
PMMA 5 3 caulk gun, melted 4.32E+09 3.53E+07 0.82
PMMA 7.5 4.5 caulk gun, melted 5.10E+09 9.44E+07 1.85
PMMA 5 3 molded from foam pieces 5.29E+09 1.04E+06 0.02
PMMA 7.5 4.5 molded from foam pieces 5.22E+09 1.58E+07 0.30
PMMA 10 6 molded from solvent casting 5.22E+09 4.53E+07 0.87
PMMA 10 6 molded from solvent casting 5.22E+09 4.27E+07 0.82
PMMA 10 6 molded from solvent casting 4.87E+09 8.56E+07 1.76  
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